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13CHAPTER 1
Renal Cell Carcinoma (RCC) is the most common malignancy arising in the kidney. In the 
US alone, each year 39,000 people are diagnosed with RCC and 13,000 people die from 
the disease 1. The classic triad (flank pain, hematuria and a palpable abdominal mass) is 
only seen in approximately 9% of newly diagnosed patients 2. This considerably compli-
cates the diagnosis, since the disease can present with a broad array of (paraneoplastic) 
symptoms 3, 4. As a consequence, 30% of patients will present with metastatic disease, 
whereas of the other 70% treated by nephrectomy, 30-40% will eventually relapse 1. The 
5-year survival rate for small (less than 7 cm) tumors limited to the kidney (pT1 tumor) 
is more than 90%5, but prognosis for metastatic disease is bleak, with a median survival 
of only 10 months when untreated6. RCC is known as a chemotherapy and radiation re-
sistant tumor7, 8. Therefore, therapeutic strategies focus on immunotherapy, neoangioge-
nis inhibitors and other targeted approaches. 
Monoclonal antibodies
Since the first description of Ehrlich to specifically guide cytotoxic agents to cancer tis-
sue 9, the feasibility of this approach has been debated. Development of the hybridoma 
technique 10 allowed isolation of large quantities of antibodies with predefined specifi-
city. With the identification of the tumor-associated target antigens, real progress was 
made on developing treatment and/or diagnostic strategies using mAbs. 
Tumor-associated antigens (TAA) have been identified for a series of human tumor types 
11-15. These are either differentiation antigens, (transiently) expressed during organoge-
nesis, aberrantly expressed antigens, or (transiently) expressed elsewhere in nonrelated 
normal tissue(s). Expression of antigens on the primary tumor or metastases is generally 
heterogeneous. For tumor targeting with mAbs this is a suboptimal feature, since not 
all cells can be targeted by the mAb. Heterogeneous expression between different tu-
mor sites, varying degrees of expression in tumor cells of the same tumor and temporal 
modulation of TAA-expression are considered major limitations of effective targeting of 
tumors with mAbs. 
In addition to intratumoral heterogeneity of antigen expression, other parameters have 
been defined that may affect tumor targeting with mAbs. These are size of the tumor 
mass, antigen density, the fate of antigen-antibody immune complex, presence of cir-
culating antigen, mAb format, mAb dose, route of administration and mAb circulatory 
half-life 16. These parameters can differ from one tumor type to another. Also, tumor 
physiology is an important factor in antigen targeting by mAbs. MAb targeting of tumors 
is complicated by large tumor blood vessels as well as impaired blood flow in the tumor, 
elevated interstitial fluid pressure (IFP) and large transport distances in the tumor 17. 
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High vascular density is not equivalent to high perfusion rates in the tumor, which are 
required for optimal mAb delivery. RCC has always been considered a highly vascularized 
tumor by morphologic standards. However, in comparison with normal kidney tissue RCC 
is poorly perfused 17, thereby impeding adequate mAb delivery to the tumor cells. These 
limitations of delivering the mAb to tumor tissue have to be overcome in order to deve-
lop a suitable mAb-based treatment strategy. 
Several mechanisms to eradicate tumor cells by mAbs are available: either via effec-
tor cells or complement dependent cytotoxicity or through conjugation of the mAb to 
toxins, drugs or radionuclides. Since antigen expression within tumors is heterogeneous, 
antigen-negative tumor cells may evade tumor cell lysis by effector cell- or complement-
mediated cytotoxicity, which may eventually lead to tumor recurrence. The same applies 
to mAbs conjugated to toxins or drugs, since internalization of a mAb conjugated to a 
toxin or drug is required to mediate cell killing 16. 
Radiolabeling of antibodies was pioneered in 1950, when Eisen observed that proteins 
could be labeled with 131I without altering their immunological specificity 18. Besides 
131I, other radionuclides (90y, 177Lu, 186Re, 188Re and 67Cu) have since been investigated to 
induce tumor cell death (Table 1). The advantage of the use of radiolabeled antibodies 
is that the mAb does not have to bind to every tumor cell to induce cytotoxicity, since 
these radionuclides emit β-particles, which can be effective to up to 50 or more cell 
diameters. This so-called crossfire effect can thus overcome heterogeneity of antigen 
Radio-
nuclide
 
Half-life
 
β-average 
(keV)
 
γ 
(keV) 
Maximum 
range 
β-particles in 
tissue (mm) Advantages Disadvantages 
131I
 
8.0 days 192 362 3.0 Easy labeling
Inexpensive 
High radiation burden 
to personnel/relatives
Hospital admittance 
required
186Re
 
90.7 hr
 
362
 
137
 
5.1 Out-patient  
treatment possible
Ideal gamma for 
imaging 
Laborious labeling
90y 64 hr
 
935
 
none 12
 
High-energy beta-
emission
Prolonged tumor 
retention
Out-patient treat-
ment possible 
No imaging possible
177Lu
 
6.7 days
 
149
 
208
 
2.5
 
Prolonged tumor 
retention 
Table 1. Radionuclides used in radioimmunotherapy of clear cell renal cell carcinoma.
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expression, as the radiation destroys the antigen-negative cells as well (Figure 1). 
Limitation of this approach is the sensitivity of normal organs to radiation, particularly 
the bone marrow. The dose limiting toxicity of delivering high dose radioimmunotherapy 
(RIT), using radiolabeled antibodies, is therefore generally hematological.
Reference 
Radiophar-
maceutical
 
Target antigen MAb type No. of patients
 
Responses 
Special 
features
Divgi et al. 46
 
131I-G250 G250
 
Murine G250 33 17 SD 
Steffens et 
al. 57  
131I-G250 G250
 
Chimeric 
G250 
12 1 PR; 1 SD 
Divgi et al. 59
 
131I-cG250 G250 Chimeric 
G250
 
15 7 SD Fractionated 
RIT
Brouwers et 
al. 61 
131I-cG250 G250 Chimeric 
G250 
27 5 SD 2 high-dose 
treatment
Table 2. Phase I/II radioimmunotherapy trials in clear cell renal cell carcinoma.
Naked antibody Radiolabeled antibody
Figure 1. Cross-fire effect of radioimmunotherapy: Not all tumor cells are targeted by the IgG 
mAb, but the radiation delivered by the mAb kills all tumor cells in the vicinity of the targeted 
cell (adapted from Fink-Bennett et. Al, J Nucl Med Technol 2003).
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Using the previously mentioned hybridoma technique a wide array of mAbs against TAAs 
has been produced, e.g. mAbs against carcinoembryonic antigen (CEA) (mainly expressed 
in colorectal and medullary thyroid cancer), MUC-1 (ovarian, breast cancer, a.o.), TAG72 
(ovarian cancer, colorectal cancer, a.o.), CD20 (Non-Hodgkin’s Lymphoma (NHL)) and 
carbonic anhydrase IX (CAIX) in RCC. In various clinical trials safety and efficacy of these 
newly developed mAbs labeled with various radionuclides have been investigated 11. 
RIT with mAbs targeting NHL have shown exciting results. These tumors are relatively 
radiosensitive and mAbs have good access to the tumor. The effector cell, complement 
and apoptosis inducing cytotoxicity of the mAb give high intrinsic anti-tumor activity as 
well. Extensive research has resulted in the first registered treatment with radiolabeled 
mAbs directed against the surface antigen CD20 expressed on B-cell NHL (90y-labeled 
anti-CD20 mAb Ibritumomab Tiuxetan (Zevalin®) and 131I-labeled anti-CD20 mAb tosi-
tumomab (Bexxar®).
In patients with solid tumors therapeutic strategies with radiolabeled mAbs have been 
less successful than in patients with hematological malignancies. This is partly due to 
the lower radiation sensitivity of solid tumors. However, as mentioned previously, tumor-
related factors also play an important role. The most common types of solid malignancies 
targeted in clinical trials with RIT have been epithelial cancers, e.g. colorectal cancer, 
ovarian cancer, medullary thyroid cancer, breast cancer, prostate cancer and RCC. Results 
of these trials did not result in registration of radiolabeled mAb preparations for regular 
treatment of these cancer types. However, patients entered in these trials often had 
bulky metastatic disease and had been heavily pretreated with chemotherapy and/or 
radiotherapy in most cases. Complete responses to RIT have incidentally been reported. 
Partial responses and stabilizations of previously progressive disease have been seen in 
few patients in most of these trials 19. 
Monoclonal antibodies in renal cell carcinoma
In RCC, several mAbs have been defined that are reactive with RCC-associated antigens 
20-29. Most of these recognize kidney differentiation antigens expressed by subsets of RCC. 
Cross-reactivity with non-kidney tissue was seen in some of these mAbs, whereas others 
were only expressed in the kidney. 
One of the mAbs, that showed relative high tumor-to-blood ratios in mice with RCC 
xenografts is mAb A6H 30, 31. This mAb recognizes an antigen common to RCC, some lung 
and colon carcinomas, the proximal renal tubules but no other normal tissues in vivo 32. 
In a clinical study, the imaging and RIT potential of this mAb was examined 31. Positive 
images were obtained in only 5 of 15 patients. This low sensitivity was attributed to 
soluble antigen binding by the mAb and the localization of the antibody in normal tis-
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sue, thereby not allowing the mAb to bind to tumor tissue. This clinical finding of loca-
lization of the antibody in normal tissue was not in line with the previous findings on 
antigen expression. After modification of the dosing regimen, the detection rate of me-
tastatic lesions increased, but the number of detected lesions remained unsatisfactory. 
As a result, the use of mAb A6H for diagnosis and treatment of RCC was discontinued.
Discovery and use of G250; from mG250 to cG250
G250, a mAb against a RCC-associated antigen has been investigated extensively, be-
cause the antigen that this mAb recognizes showed remarkable tissue distribution and 
expression. The mAb G250 was obtained after fusion of spleen cells from a mouse im-
munized with fresh RCC homogenates. The antigen that mAb G250 targets has been de-
signated in literature as MN, CAIX and G250. The term CAIX will be used in this chapter. 
Of the 47 primary RCC specimen initially analyzed, 42 (89%) showed homogeneous CAIX 
expression, whereas 4 tumors showed heterogeneous expression and 1 tumor was CAIX-
negative. Of the 8 metastases examined, CAIX expression was homogeneous in 5 (62%), 
heterogeneous in 2, while 1 did not express the CAIX 25. Expression in normal tissues has 
been evaluated extensively and it has shown to be restricted to the (upper) gastrointes-
tinal mucosa (stomach, ileum, proximal and middle colon) and gastrointestinal related 
structures (intra- and extrahepatic biliary system, pancreas), with much lower expression 
levels than in RCC 25, 33, 34.
Later studies showed an almost ubiquitous expression (>90%) of CAIX in clear cell RCC 
(ccRCC), being the most prominent form of RCC (80% of cases) 35. CAIX expression in 
the different histological subtypes of RCC was determined by RT-PCR and immunohis-
tochemistry. All the clear cell tumors displayed CAIX mRNA, but expression of CAIX by 
oncocytomas, chromophobe or papillary RCC was low or absent 35-37. Various animal and 
ex vivo experiments have shown the potential of the G250 mAb as a targeting modality 
of RCC 38-43. Since CAIX is high and homogeneously expressed in RCC tissue, is expressed 
in only a few normal tissues, mAb G250 seemed a suitable candidate for further inves-
tigation in clinical studies. 
Two clinical studies with radiolabeled murine G250 (mG250) have been completed. Ima-
ging and biodistribution were studied in 16 patients receiving 370 MBq 131I-labeled 
mG250 at escalating protein dose levels one week prior to nephrectomy. After 3 to 4 
days clear delineation of tumors was seen in 12 patients, imaged with a gamma camera. 
Ten of these tumors proved to be G250-positive, whereas the other two showed less 
than 5% CAIX expression. The four tumors that were not visualized were non-clear cell 
RCC. After nephrectomy, tumor samples were shown to have high and focal uptake of 
13054 Alexander proefschrift_01.indd   17 09-01-14   20:33
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G250, up to 0.21 % injected dose/gram (%ID/g). Tumor targeting was not the result of 
blood pooling, as the blood volume marker 99mTc-labeled human serum albumin showed 
significantly lower tumor uptake than 131I-mG250 that had been administered earlier. 
Therefore, this was indicative of true antibody targeting of the tumor by mG250 44. As 
good targeting of ccRCC by mG250 was seen in this study, a phase I/II radioimmuno-
therapy (RIT) dose escalation study was performed by Divgi et al. Patients in this study 
were treated with one high-activity-dose injection of 131I-mG250. After reaching the 
maximum tolerated dose (MTD), another fifteen patients were enrolled and treated at the 
MTD to monitor any possible therapeutic effects. In the phase I dose-escalation study, MTD 
was defined at 3330 MBq/m2, with hematological toxicity being dose limiting. Transient 
hepatic toxicity occurred at dose levels of 1665 MBq/m2 and higher, but was not dose 
limiting. Fourteen patients had grade 3 hepatic toxicity, that did not last for more than 
2 weeks. A total of 33 patients was treated, 18 in the dose-escalating part of the study 
and another 15 patients at the MTD (3330 MBq/m2), to evaluate therapeutic efficacy. Of 
these 33 patients, 17 stabilized for three months, after which patients received other 
treatments, preventing further follow-up. Three patients showed regression of some of 
their lesions, but no partial or complete responses were noted 45. 
The formation of human anti-mouse antibodies (HAMA) in all patients receiving mG250 
prohibited retreatment. Formation of immune complexes with rapid clearance of the 
radiolabeled mAb to liver and spleen would have occurred in the case of repeated admi-
nistration, thereby limiting targeting of the mAb to the tumor 45. This, in combination 
with the high potential of G250 as a targeting agent in the treatment of metastasized 
RCC, led to the development of a chimeric form of G250 (cG250) 46. This mAb is com-
posed of murine antigen-binding variable domains, that recognize the TAA and human 
constant domains of heavy and light chains derived from the human IgG1 isotype 47, 48. 
Rationale behind this construction was the decrease in immunogenicity of the antibody, 
potentially allowing multiple administrations.
Use of unlabeled antibody cG250
Unlabeled G250 antibody facilitates antibody-dependent cellular cytotoxicity (ADCC) of 
CAIX expressing cells, which leads to induction of lysis of these cells 47. This finding led 
to a study where 36 patients with metastatic ccRCC received 50 mg cG250 weekly for 
12 weeks. No drug-related grade 3-4 toxicity occurred during this trial 49. Development 
of human anti-chimeric antibody (HACA) was low and not clinically significant. Before 
treatment, 80% of patients were progressive. After treatment, 11 patients had stable 
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disease and during follow-up one complete and one partial response were seen. The 
median survival of 15 months suggested that G250 may be able to immunomodulate the 
natural course of metastatic RCC 50. Based on these results, an adjuvant phase III trial 
has been completed in high-risk ccRCC patients who were nephrectomised and had no 
known metastases, using this treatment regimen. Results of this trial are awaited.
Since the 1990’s, high-dose bolus interleukin-2 (IL-2) has been used as a first-line 
therapy for metastatic RCC, although in the present era of targeted agents it is not com-
monly used. IL-2 is a T-cell growth factor that is thought to play a critical role in T-cell 
dependent immune responses. High-dose bolus IL-2 as therapy in metastatic RCC has 
had varying success, with responses in up to 15% of patients 51. It was hypothesized that 
the immunological specificity of lymphokine-activated killer cells of patients receiving 
IL-2 therapy may be enhanced through the co-administration of cG250 47. Vice versa, 
co-administration of IL-2 can enhance the therapeutic efficacy by stimulating G250-
mediated ADCC 52-54. 
In a phase II trial 35 patients with progressive ccRCC received weekly i.v. infusions of 50 
mg G250 and daily sc low-dose IL-2, for 11 weeks. When patients responded or disease 
stabilized, therapy was continued for another 6 weeks. Treatment was safe and well 
tolerated. After 16 weeks, 1 partial response was noted and 11 patients had stabilized. 
These 12 patients continued treatment. This resulted in 1 partial response and 7 patients 
retained stable disease. Mean survival was 24 months in this trial, compared to 16.3 
months median survival with high-dose IL-2 therapy 51, while side effects were mild. 
The authors considered it unlikely that the increased survival was due to the low-dose 
IL-2, using a 6-fold decrease of normal IL-2 dose used to induce clinical efficacy. They 
considered it rather a synergic effect of G250 and IL-2 55. 
Studies with radiolabeled cG250
After cG250 became available, the pharmacokinetics, biodistribution, imaging characte-
ristics and dosimetry of this new radiolabeled targeting vehicle was studied in a protein 
dose escalation study as was done with murine G250. Sixteen presurgical RCC patients 
were entered, receiving increasing doses of cG250 between 2 and 50 mg labeled with 
131I, given i.v. a week before patients underwent nephrectomy. Highest tumor uptake 
was observed in particular in the patients that received 5 and 10 mg 131I-mG250, with 
focal tumor uptake as high as 0.52% ID/g. At higher protein doses, focal tumor uptake 
did not exceed 0.017% ID/g. This suggested that antigen-saturation could have occur-
red at protein doses exceeding 10 mg. Excellent images of CAIX positive tumors were 
obtained, with visualization of tumor lesions and metastases, seen earlier on CT or X-
ray. No previously unknown lesions were visualized. Dosimetric analysis showed a high 
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radiation-absorbed dose to primary tumors as well as metastases (up to 1.9 cGy/MBq 
to the primary tumor). Up to 20 weeks post injection, Human anti-chimeric antibody 
(HACA) responses were seen in 2 patients, but titers were considered low and clinically 
irrelevant 56. Reducing the immunogenic properties of the antibody opened the possi-
bility to multiple treatments. These results justified further investigation on the use of 
cG250 as a radioimmunotherapeutic agent. 
The MTD of 131I-cG250 in metastatic RCC was determined in a phase I radioactivity dose 
escalation trial in patients with progressive metastatic RCC at study entry. Twelve pa-
tients received 5 mg cG250 labeled with 185 MBq 131I (scout dose). When accumulation 
of antibody was seen in any tumor site, patients received escalating radioactivity doses 
of 131I-cG250 one week later. In contrast to the trials performed with murine G250, no 
hepatic toxicity was seen. This was believed to be the result of saturation of the hepatic 
compartment by the diagnostic scout dose 131I-cG250. Besides mild nausea without vo-
miting and transient fatigue (both grade 1 CTC) no other non-hematological side effects 
occurred. The MTD was observed to be 2220 MBq/m2, with hematological toxicity as the 
dose-limiting factor. Of the 8 patients receiving treatment, one patient showed stable 
disease and one had a partial response 57.  
In subsequent studies two strategies were tested to optimize targeting of metastatic ccRCC 
with RIT. These were fractionation of the dose and two sequential high-dose treatments.
Fractionation of the dose was done in a phase I study by Divgi et al 58. In this study, 
patients received 1110 MBq 131I-cG250 and whole-body activity was measured after 2-3 
days. Then, another administration of 131I-cG250 was given to again ‘top up’ the ra-
dioactivity in the body to 1110 MBq. This was continued until a whole-body absorbed 
dose of 0.50 Gy was reached. Patients without disease progression were retreated after 
recovery from hematological toxicity. In subsequent cohorts, the whole-body absorbed 
dose was increased by 0.25 Gy. A total of 15 Patients were included in the trial. HACA 
development was measured in 2 patients, altering pharmacokinetics and excluding them 
from further treatment. Dose-limiting toxicity was again hematologic, with the MTD at 0.75 
Gy as whole-body absorbed dose. Four patients received multiple fractionated doses. Seven 
patients stabilized, but no major clinical responses were seen. This trial therefore provided no 
evidence on a potential benefit of fractionation of RIT doses in treating ccRCC.
The MTD found in the activity dose-escalation study by Steffens et al. 
(2220 MBq/m2), combined with the properties of cG250 allowing multiple administrati-
ons led to a study where two sequential high doses of 131I-cG250 treatment were given. 
Patients had progressive metastatic ccRCC at study entry. Patients received 2220 MBq/m2 
131I-cG250. Three months later, rapid clearance of the mAb by HACA development was 
excluded by imaging of a scout dose of 185 MBq 131I-cG250. When tumor targeting was 
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seen again, the second high-dose injection 131I-cG250 was given. MTD of the 2nd RIT 
proved to be again due to hematological toxicity and was set at 1665 MBq/m2, being 
75% of the MTD of the first infusion. Subsequently, 15 patients were treated at this dose 
level to evaluate tumor response. In total, 29 patients entered the study, 11 were exclu-
ded due to grade 4 hematological toxicity after the first RIT (n=3), palliative treatment 
(n=2), rapid progressive disease (n=2) or HACA development (n=4). Of the 18 patients 
evaluated (3 did not receive the 2nd RIT at MTD), 5 patients had stabilization of their 
disease, lasting 3-12 months. No partial or complete responses were seen. There proved 
to be an inverse correlation between the size of metastases and radiation absorbed dose. 
Therapeutic radiation doses (more than 50 Gy) 59 were only guided to the lesions smaller 
than 5 grams. The authors concluded that RIT in RCC patients could best be given in the 
setting of small volume disease or as adjuvant therapy 60.
Various radionuclides in targeting ccRCC with cG250 have been under investigation. 
First, the targeting capabilities of 111In-cG250 have been compared to those of 131I-
cG250. In nude mice with human tumor xenografts, superior targeting of 111In-cG250 
over 131I-cG250 was shown 61, 62. As part of the cG250 antibody-antigen complex is inter-
nalized, intracellular 131I-cG250 is metabolized and rapidly excreted by the tumor cell. 
Metallic radionuclides, such as 111In, 90y and 177Lu, are trapped in the lysosomes and residua-
lize intracellularily after internalization of the mAb-antigen complex by the target cells 63-66. 
To investigate whether this phenomenon may also occur in humans, 5 patients with me-
tastatic RCC were i.v. injected with 185 MBq 111In-DTPA-cG250 on day 0 and 185 MBq 
131I-cG250 on day 4. Gamma images were made directly and on day 4 after both injections 
and compared. 111In-DTPA-cG250 images (Fig. 2) revealed more lesions than 131I-cG250 
(47 vs. 30) and quantitative analysis showed higher accumulation of 111In-DTPA-cG250 
in 20 of 25 lesions measured in terms of %ID/g 34. 
The therapeutic properties of cG250 labeled with 4 radionuclides were tested in nude 
mice with human RCC xenografts. The 4 radionuclides under investigation were 90y and 
177Lu (both residualizing), and 131I and 186Re (both non-residualizing). After determining 
the MTD for each radionuclide conjugated to cG250 in mice, a RIT experiment was done 
comparing tumor growth and survival after treatment with each radiolabeled cG250 pre-
paration. Tumor growth was delayed most effectively by 177Lu, followed by 90y and 186Re 
and least by 131I (185, 125, 90 and 25 days, respectively). The best median survival was 
observed for 177Lu (300 days), with the control group having a median survival of less 
than 150 days. The residualizing radionuclides 177Lu and 90y administered higher radia-
tion doses to the tumor. These radionuclides should be considered better candidates for 
RIT with cG250 than 131I 67.
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Figure 2a. 111In-cG250 immunoscintigram of a patient with metastatic ccRCC, acquired 6 days 
after injection of 185 MBq 111In-cG250. Black arrows mark the RCC lesions. Green arrows mark a 
lesion not seen on the FDG-PET-CT images shown in Figure 2b. Red arrows indicate the injection 
standard. The anterior image is shown in the left panel, the posterior image is shown in the 
right panel.
Figure 2b. PET-CT scan of the same patient acquired after injection of 250 MBq 18F-FDG. 
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Positron emission tomography
18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) has been widely inves-
tigated and is now an established molecular imaging modality for various malignancies. 
In RCC, the diagnostic accuracy depends on the tumor grade, the FDG uptake being 
higher in dedifferentiated tumors which is also observed in other tumor types. One of 
the major drawbacks for detection renal cell carcinoma with FDG-PET is the excretion of 
FDG via the kidneys, resulting in relatively high background activity. This can only partly 
be reduced by hyperhydration or administration of diuretics. Another disadvantage of 
imaging renal masses with FDG-PET is the reported false-positive signal in patients with 
angiomyolipoma, pericytoma, and pheochromocytoma 68. Wang et al. recently performed 
a meta-analysis of 14 articles on the role of FDG-PET and FDG-PET/CT in both primary 
renal tumors as extra-renal lesions 69. For primary renal tumors the pooled sensitivity and 
specificity of FDG-PET was 62% and 88%, respectively. The use of FDG-PET/CT improved 
the accuracy of detecting metastases, as the pooled sensitivity and specificity increased 
to 91% and 88%, respectively. The authors conclude that combining FDG-PET and CT is 
mainly helpful for detecting extra-renal metastasis rather than renal lesions. However, 
the total number of studies assessing the role of FDG-PET/CT evaluated in this meta-
analysis is limited and further studies are warranted.
A few investigations have studied the capabilities of cG250-based immunoPET, i.e. com-
bining the favorable characteristics of PET (high spatial resolution, three-dimensional 
(3D) imaging and accurate quantification of tumour uptake) with the high and specific 
targeting of cG250 to CAIX-expressing cells 70-72. The relatively slow pharmacokinetics of 
i.v. injected radiolabeled mAbs (optimal tumour uptake after several days) prevents the 
use of the most commonly used positron emitters (11C and 18F) because their half-life is 
too short to be used in immunoPET. The half-lives of the positron emitters 89Zr and 124I 
(78 and 100 h, respectively) do match the relatively slow kinetics of antibodies. In a 
prospective study by Divgi et. al. 25 patients with suspect renal lesions scheduled for 
nephrectomy were studied with 124I-cG250. Of sixteen patients with pathologically con-
firmed ccRCC after surgery, 15 had a positive scan (tumour-to-normal kidney ratio ≥ 3:1). 
The failure in one patient was attributed to technical problems with the labeled mate-
rial. The study showed that 124I-cG250 could aid in the preoperative characterization of 
suspect renal masses and might guide crucial aspects of surgical RCC management 70. A 
large multicenter trial comparing conventional diagnostic CT to 124I-cG250 immunoPET/
CT for the detection of ccRCC in 226 patients scheduled for nephrectomy showed a signi-
ficantly higher rate of ccRCC detection with 124I-cG250 immunoPET/CT over conventional 
CT (p=0.016) 73.
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Current treatment of metastatic RCC
Immunotherapy was the standard systemic treatment of metastatic RCC in 
the 1980s and 1990s, when it was the only treatment that offered a chance 
of achieving a durable complete response (IL-2 approximately 5% and interferon-
α(IFN-α) approximately 2.5%). However, the development of tyrosine kinase inhibitors 
(TKI) targeting neo-angiogenesis pathways such as sunitinib, pazopanib and temsi-
rolimus has resulted in signifi cant clinical benefi t for patients with metastatic RCC 74. 
Response rates to treatment with these substances are relatively high (70-80% disease 
control). These agents mainly cause disease stabilisations, while side-effects are com-
mon and may be severe in nature 75, 76. In a randomized phase 3 study comparing suniti-
nib with IFN-α in previously untreated mRCC patients, the progression free survival (PFS) 
was signifi cantly longer in the sunitinib group compared to the IFN-α group (11 vs. 5 
months). In this study, the high-response rate was confi rmed with 37% of the patients 
achieving a partial response by RECIST criteria versus 9% for IFN. 75 Pazopanib, another 
multiple tyrosine kinase inhibitor showed prolonged PFS compared to placebo (9.2 vs. 
4.2  months) in treatment-naïve or cytokine-pretreated metastatic RCC patients. 77 Be-
vacizumab in combination with IFN-α was compared to IFN-α with placebo in a phase 3 
trial. This study reported a signifi cantly improved PFS for bevacizumab with IFN-α (PFS 
10.2 vs. 5.4 months). Overall survival (OS) was also higher for bevacizumab with IFN-α 
(OS 23.3 vs. 21.3 months), but this was not statistically signifi cant. 78, 79 Temsirolimus, 
targeting the mammalian target of rapamycine (mTOR) in the neo-angiogenesis pathway, 
also showed a treatment benefi t over IFN-α (PFS 5.5 vs. 3.1 months, OS 10.9 vs. 7.3 
RCC type  MSKCC risk group 1st-line therapy 2nd-line therapy 3rd-line therapy
Clear cell  Good or 
intermediate
- Sunitinib
- Bevacizumab + 
 IFN-α 
- Pazopanib
- In selected patients 
 (good prognosis, 
 only pulmonary 
 metastases):
-  Interleukin-2
-  IFN-α  
Prior TKI:
- Axitinib
-  Sorafenib
-  Everolimus
Prior cytokines:
- Sorafenib
- Axitinib
- Pazopanib 
Prior TKI:
- Everolimus 
 Poor 
Temsirolimus  
 
Non-clear cell
  
Good, intermediate 
or poor  
Patients should be treated in the framework of clinical tri-
als, however temsirolimus appears to offer a modest clinical 
benefi t in overall survival
Table 3. Current treatment strategy for metastatic RCC patients. Adapted from the EAU guide-
lines on renal cell carcinoma – version March 2013 http://www.uroweb.org/gls/pdf/10_Renal_
Cell_Carcinoma_LRV2.pdf
Poor Temsirolimus
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months) in a phase 3 trial 80. There are several other substances in development such as 
erlotinib, tivozanib, dovitinib, axitinib and everolimus. In table 3 an overview of the 
current treatment strategies in metastatic RCC patients is given. However, the fast pace 
of development of TKI treatment will probably change this treatment paradigm in the 
near future.
TKI and tumor vascularisation
Sorafenib, approved for the second-line treatment of metastatic RCC, inhibits the ty-
rosine kinase activity of the vascular endothelial growth factor receptors (VEGFR) and 
platelet derived growth factor receptors (PDGFR) 81. VEGF plays a pivotal role in tumor 
angiogenesis. In ccRCC, VEGF is overexpressed 82, 83 due to activation of the hypoxia indu-
cible factor pathways 84. Bevacizumab is a monoclonal antibody recognizing VEGF-A, and 
is known to inhibit angiogenesis by preventing VEGF-VEGFR interaction. In colorectal 
cancer patients administration of high-dose bevacizumab may lead to a short normaliza-
tion of the tumor microvasculature along with a reduced interstitial fluid pressure 85. This 
normalization of the tumor vasculature may temporarily improve tumor perfusion 86 and 
enhance the delivery of therapeutic agents, which would explain the synergistic effect 
of chemotherapy when combined with bevacizumab in colorectal cancer patients 87. In 
addition, several studies have shown enhanced mAb accumulation after anti-angiogenic 
treatment in experimental tumor models 88, 89. Therefore, co-administration of RIT during 
angiogenesis treatment in mRCC patients might also work synergistically, due to the 
enhanced uptake of the radiolabeled mAb in the tumor.
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Thesis outline
The aim of this thesis was to investigate new strategies for imaging and treatment of 
ccRCC lesions based on the use of the anti-CAIX monoclonal antibody cG250. Preclinical 
and clinical studies are presented in this thesis. 
In chapter 2, the mechanism of CAIX expression in ccRCC through the mutational loss 
of Von-Hippel Lindau protein is described. We examined the literature on prognostic ac-
curacy of CAIX expression patterns and reviewed the current diagnostic and therapeutic 
applications of CAIX and mAb cG250 in ccRCC. 
In chapter 3, the phase I study to determine the maximum tolerated dose of 177Lu-cG250 
radioimmunotherapy in patients with metastasized RCC is described. The side effects, 
immunological response patterns and the preliminary therapeutic efficacy of escalating 
activity doses of 177Lu-cG250 are described.
Chapter 4 describes the dosimetric analyses of the 111In-cG250 and 177Lu-cG250 scans 
acquired in the phase I radioimmunotherapy study. This analysis provided insight in 
the radiation absorbed doses of normal organs, red bone marrow and metastases during 
radioimmunotherapy with 177Lu-cG250. Simulations of 177Lu-cG250 and 90y-cG250 radioi-
mmunotherapy radiation doses were performed based on the 111In-cG250 data. These 
data were compared to the actual 177Lu-cG250 absorbed doses to validate the dosimetric 
analyses. The correlation between the estimated radiation doses to the red marrow and 
hematological toxicity was determined.
The effects of neo-adjuvant treatment with sorafenib on the uptake of intravenously 
administered 111In-labeled bevacizumab were studied in chapter 5. Changes in tumor 
vascularity, expression patterns of VEGF and subsequent tumor uptake of the radiolabe-
led antibody as seen after tyrosine kinase inhibitor treatment were determined. 
In chapter 6, a study is described examining the tumor targeting characteristics of 124I-
cG250 and 89Zr-cG250 in mice with human RCC xenografts and investigated which PET 
radionuclide was optimal for cG250-based immunoPET imaging of RCC.
A novel diagnostic modality, optical imaging, was used in chapter 7 to detect and de-
pict RCC xenografts in nude mice. Studies were performed to establish antigen-specific 
binding of the cG250-fluorophore conjugate, cG250-IRdye800CW to RCC tumors. We ex-
plored this new technique, which may herald a new diagnostic era in intra-operative 
detection of positive surgical margins and tumor-affected lymph nodes.
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abstract
Context
The clinical management of patients with renal cell carcinoma (RCC) remains difficult and the 
development of new diagnostic, prognostic and therapeutic tools is still required.
 
Objective
To review the current knowledge on the RCC-associated antigen carbonic anhydrase IX 
(CAIX) and provide evidence  how this antigen may aid in the clinical management of RCC.
 
Evidence acquisition
Clinical papers describing diagnostic, prognostic and/or therapeutic applications of CAIX 
in RCC were selected from the Pubmed database. The search was manually augmented by 
reviewing the reference lists of articles.
 
Evidence synthesis
Expression of CAIX is regulated by the Von Hippel Lindau (VHL) protein. Because of the inva-
riable VHL mutational loss in clear cell RCC (ccRCC) patients, CAIX expression is ubiquitous in 
ccRCC. Determination of CAIX expression in nephrectomy specimens of RCC patients improves 
prognostic accuracy; high CAIX expression appears to be correlated with a favorable prognosis 
and a greater likelihood of response to systemic treatment for metastatic disease. Therefore, 
CAIX expression might be used to stratify metastatic ccRCC (mRCC) patients for systemic treat-
ment. When incorporated in the RCC nomogram, CAIX expression seems to improve diagnostic 
accuracy for primary as well as mRCC patients, but further evidence is required. Clinical studies 
with the CAIX-specific monoclonal antibody (mAb) cG250 have provided unequivocal evidence 
that ccRCC lesions can be imaged with radiolabeled cG250. Results are awaited of a large rando-
mized trial which aims to establish the value of cG250-imaging for primary RCC. The outcome of 
another large, placebo-controlled study is awaited to establish the usefulness of CAIX-targeted 
therapy in the adjuvant setting. Therapeutic trials with high-dose radiolabeled cG250 and CAIX-
loaded dendritic cells in mRCC patients are still in phase I or II. 
Conclusion
CAIX improves diagnostic accuracy and is an attractive target for imaging and therapy 
of ccRCC.
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1. INTRODuCTION
RCC represents 3% of all malignancies, with 57,760 new cases in the US alone in 2009 
(1). About one fourth of patients presents with synchronous or metachronous metasta-
ses and will eventually succumb to the disease. When the tumour is confined to the 
kidney, tumor nephrectomy is the indicated, intentionally curative treatment. In the 
case of residual or metastatic disease systemic treatment is warranted. Recently, anti-
angiogenic treatments were introduced for the treatment of metastatic RCC (mRCC) 
which are more effective as compared to the previous immunotherapeutic treatment 
regimes (2;3). Unfortunately, complete responses (CR) to these angiogenesis inhibitors 
are sporadic, whereas treatment with high-dose interleukin-2 (IL-2) and low-dose 
IFN-α2a have demonstrated stable CR rates of around 5% (4) and 1% (5), respectively. 
Furthermore, treatment with angiogenesis inhibitors is continuous and side effects are 
common and often severe in nature (6). Therefore, more effective and less toxic treat-
ments need to be developed to ensure effective anti-RCC treatment while maintaining 
the quality of life of patients.
Treatment with angiogenesis inhibitors appears to be mainly effective in patients 
with ccRCC metastases (7). Therefore, classification of the RCC subtype is crucial to de-
termine which systemic treatment is most suitable. Determination of the histological 
subtype of RCC is based on its morphological and phenotypical characteristics. One 
marker, almost invariably present on ccRCC, the CAIX antigen,  may be useful in the 
diagnostic process and could serve as a prognostic factor in patients with ccRCC. Mo-
reover, therapeutic strategies are being explored using CAIX as a target for treatment 
of RCC. This review will describe the potential use and limitations of the CAIX antigen 
in the prognosis, diagnosis and therapy of ccRCC.
2. EVIDENCE aCquISITION
A literature search was conducted using the Pubmed database. The database was 
searched using the terms: CAIX, G250, prognosis, diagnosis, therapy and/or RCC with 
the limits English, publication date from 1980/01/01, Humans. We augmented this 
literature search by manually reviewing the reference lists of included studies to iden-
tify additional relevant articles. The antigen has been named MN, G250 and CAIX in 
literature. The term CAIX will be used in this review. 
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3. EVIDENCE SyNTHESIS
3.1 CaIX
3.1.1 CAIX function
The distribution of CAIX was first described in 1986 (then named G250-antigen) in an im-
munohistochemical study describing the specificity analysis and tumor specificity of mAb 
G250. Based on this analysis it was suggested that the recognized moiety could potentially 
serve as a target for therapy and/or diagnosis in RCC (8). Subsequent studies demonstrated 
that the antigen recognized, (CAIX), (9) is a cytosolic as well as a transmembraneous glyco-
protein belonging to the carbonic anhydrase group of enzymes which catalyze the reaction 
CO2 + H2O  HCO3- + H+. These enzymes are critical in the regulation of proton flux in cells and 
thus in pH regulation (10). In contrast to most carbonic anhydrases, the catalytic site of CAIX 
is located extracellularly, where it is involved in creating an acidic microenvironment (11).  
3.1.2 CAIX expression in tumors and normal tissue
CAIX antigen expression in the different histological subtypes of RCC has been deter-
mined by RT-PCR and immunohistochemistry. The majority of clear cell tumors (>95%) 
showed high and homogeneous levels of CAIX expression, while expression of CAIX in 
oncocytomas, chromophobe and papillary RCC was considerably lower (12). Furthermore, 
alveolar and/or tubular growth patterns demonstrated high (94-99%) CAIX expression. 
Papillary, solid and cystic growth patterns were characterized by significantly lower 
(14-60%) CAIX expression (12). In various other tumors, immunohistochemical analyses 
revealed high levels of CAIX expression: carcinomas of the uterine cervix, esophagus, 
lung, breast, brain and vulva also express CAIX, albeit all very heterogeneously (13-20). In 
an extensive analysis, CAIX expression in normal tissue was observed on gastric mucosa, 
pancreatobiliary epithelium and small intestine crypt bases, but not on normal kidney. 
CAIX was also detectable in mesothelial cells, ovarian surface epithelium and fetal rete 
testis, albeit at a much lower level (21). 
3.1.3 Regulation of CAIX expression
CAIX expression has shown to be governed by the transcription factor hypoxia inducible 
factor-1α (HIF-1α) (for review see (22)). Under normoxic conditions HIF-1α is hydroxyla-
ted and ultimately degradated through binding to the Von Hippel Lindau protein (pVHL) 
and subsequent ubiquitination, prohibiting formation of the active HIF-1α-HIF-1β di-
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mer. Under hypoxic conditions, binding of pVHL to HIF-1α is inhibited, leading to ac-
cumulation of HIF-1α and subsequent association with HIF-1β. The resulting HIF-1 
causes the downstream transcription of a number of hypoxia-inducible genes, the CAIX 
antigen being one of those (16) (Figure 1). The almost invariable mutational loss of 
pVHL in ccRCC mimics hypoxic conditions and thus explains the ubiquitous expression 
of CAIX antigen (23). CAIX expression in all other tumor types (e.g. cervix, lung) is 
hypoxia-driven (24). Therefore, CAIX is regarded as a potential marker of hypoxia in many 
malignancies other than ccRCC (14). Expression of CAIX in normal tissues is hypothesized 
to be regulated by either tissue acidosis (25) or glucose deprivation (26), but this remains 
to be clarified. In tumors, high CAIX expression and subsequent acidification is thought 
to (i) aid in the adaptation of tumors to hypoxic conditions (ii) hamper the uptake in 
tumor cells of weakly basic chemotherapeutic agents leading to chemoresistance of CAIX 
expressing tumors (27). 
Figure 1. CAIX expression is molecularly linked with pVHL. In normal kidney, HIF-1α is hydroxy-
lated by prolyl hydroxylase domain proteins (PHDs) and bound by pVHL, catalyzing the polyubi-
quitylation of prolyl-hydroxylated HIF-1α for subsequent degradation via the 26S proteasome. 
In ccRCC the binding of HIF-1α by  pVHL does not occur, thereby escaping degradation an d 
mimicking hypoxic conditions. HIF-1α associates with the constitutively stable partner HIF-1β 
to form an active heterodimeric HIF-1 transcription factor, which binds to hypoxia-responsive 
elements located in the promoter/enhancer regions of numerous hypoxia-inducible genes inclu-
ding pro-angiogenic factors (such as VEGF and PDGF) and CAIX, which is ultimately expressed on 
the tumor cell surface.
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3.2 PROGNOSIS
3.2.1 CAIX expression and survival
The prognostic value of CAIX expression in ccRCC has been the subject of several studies. 
Bui et al. reported that low CAIX expression in primary ccRCC was an adverse predictor of 
survival in a large series of 321 ccRCC patients. In the multivariate analysis CAIX expres-
sion remained an independent prognostic parameter (28). These findings were confirmed 
in a series of 183 ccRCC cases, which showed that CAIX expression was an independent 
predictor of survival (29). Patard et al. reported that CAIX was an independent predictor of 
survival in a series of 100 ccRCC cases (30). However, Leibovich et al. could not confirm these 
results in a series of 730 ccRCC patients. Although low CAIX expression was associated with 
death from ccRCC in univariate analysis, this association failed to reach statistical signifi-
cance in the multivariate analysis, when death from ccRCC and low CAIX expression was cor-
rected for nuclear grade, tumor necrosis and sarcomatoid differentiation. (21). The discrepancy 
to the other results may be explained by a difference in patient population (in this study, 
only 11% mRCC patients were included, whereas the other studies included 40-60% mRCC pa-
tients), or the use of tissue microarray analysis instead of immunohistochemistry to quantify 
CAIX expression. Recently, CAIX polymorphisms were analyzed in 54 mRCC tissue samples. 
The single nucleotide polymorphism rs12553173 and CAIX both proved to be independent 
prognostic factors for OS and were associated with a greater likelihood of response to IL-2 
immunotherapy (31). Thus, many studies suggest that CAIX is an independent prognostic mar-
ker in RCC with a correlation between low CAIX expression and death from ccRCC. 
3.2.2 CAIX expression incorporated in RCC nomograms
To predict RCC disease-free survival rates after nephrectomy or predict survival in meta-
static patients various clinical and pathological features are taken into account, such as 
clinical symptoms, age, performance status, TNM stage, nuclear grade and tumor necrosis 
(for review see (32)). In an effort to improve the nomogram for RCC patients, Kim et al. 
studied a number of molecular markers, a.o. vimentin, p53, pTEN and CAIX (33;34). In the 
first nomogram the prognostic accuracy of these biomarkers was examined in 318 pa-
tients with primary RCC, regardless of the presence of synchronous metastases. Inclusion 
of the biomarkers improved the prognostic accuracy as compared to the TNM (C=0.79 
vs. C=0.73; p<0.001) and UCLA integrated staging system (UISS) (C=0.79 vs. C=0.75; 
p=0.038) staging systems alone (34). The second nomogram was designed to predict the 
survival of mRCC patients and incorporated the aforementioned biomarkers, T category 
and ECOG performance status. This nomogram based on the combination of biomarkers 
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and clinical parameters proved to be a more accurate prognostic model for mRCC patients 
as compared to the UISS staging system (C=0.68 vs C=0.62; p=0.0033) (33). Incorporation 
of CAIX expression in nomograms is complicated due to the lack of commercial availa-
bility of the mAb M75, needed for the immunohistochemical detection of CAIX in tissue 
samples. Commercially available mAb NB100-417 is reported to be a CAIX-specific mAb 
with similar staining characteristics as M75, recognizing the membraneous epitope of 
CAIX (35;36), but cross-reactivity at high dilutions with beta-tubulin (36) makes specific 
CAIX detection by mAb NB100-417 impossible. Incorporation of CAIX expression in the 
RCC nomogram improves prognostic accuracy, but since mAb M75 is not commercially 
available, widespread use is not yet possible.
3.2.3 CAIX expression and response to systemic treatment
Since the implementation of angiogenesis inhibitors, treatment strategies of mRCC pa-
tients have changed significantly. However, immunotherapy still plays a role in the 
treatment of mRCC since CRs are rarely seen with the use of angiogenesis inhibitors, 
whereas a significant, though small (5%) percentage of mRCC patients do show CR after 
IL-2 therapy (4). When treatment with IL-2 is applicable, CAIX expression could be used 
to predict the response to treatment. In 2005 Atkins et al. reported that CAIX expression 
could serve as a predictor of response to IL-2 immunotherapy. Of 66 patients who had 
received IL-2 immunotherapy, 21 of 27 (78%) responding patients had high CAIX expres-
sing primary tumors compared with 20 of 39 (51%) non-responding patients (p=0.04). 
Moreover, median survival was prolonged in the high CAIX expression group (p=0.03) 
and survival >5 years was only seen in patients with high CAIX expressing tumors (37). 
A prospective, non-randomized trial (‘SELECT’ trial) is currently investigating in 110 pa-
tients whether CAIX expression is a predictor of response to IL-2 therapy (38). These, and 
other (39) observations might lead to improved response rates in CAIX-stratified patients 
treated with IL-2.
Thus far, patient stratification is based on factors determined in the cytokine era, and 
these may not be entirely applicable to mRCC patients who are receiving targeted the-
rapy. Evidence is mounting that there is a correlation between CAIX expression and res-
ponse to treatment with angiogenesis inhibitors. In 118 patients the prognostic utility 
of RCC subtype and CAIX expression in mRCC patients who received sunitinib or sorafenib 
treatment after nephrectomy was evaluated. A significantly higher treatment response 
rate, more tumor shrinkage and a longer duration of response was independently associ-
ated with ccRCC as compared to other RCC subtypes (p=0.02). CAIX expression was not 
associated with a response to sunitinib treatment, but high CAIX expression could serve 
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as a predictive biomarker for response to sorafenib treatment (40). In a side-study of a 
randomized phase 2 trial where patients received varying doses of temsirolimus (41) no 
correlation between CAIX or HIF-1α expression and response to temsirolimus treatment 
was seen (42). However, this was a highly inhomogeneous patient population, with many 
poor prognosis or non-ccRCC patients. Therefore, more research is warranted to evaluate 
the predictive value of CAIX expression for the response to targeted agents in the mRCC 
patient population.
3.3 DIaGNOSIS
CAIX imaging 
Approximately 50% of all renal lesions are found incidentally due to improved and incre-
ased radiological evaluation. Consequently, new functional and molecular imaging techni-
ques are needed to aid in the differentiation between benign and malignant renal lesions. 
Positron emission tomography (PET) with [18F]FDG is a molecular imaging technique 
widely used in various types of cancer for diagnosis, (re)staging and evaluation of res-
ponse to treatment (43). Trials with relatively small patient cohorts have shown the high 
specificity of [18F]FDG to detect RCC lesions. Sensitivity, however, appears to be relatively 
low and FDG-PET is now considered unsuited for staging of patients with RCC (44;45).
MAb G250 has a high affinity (Ka = 4.109 M-1) for the CAIX antigen. Although G250 
recognizes a different CAIX epitope than mAb M75, no discrepancy between both mAbs 
has been described. Since the discovery of G250 (8), many animal and clinical studies 
have been performed and confirmed the promising characteristics of this mAb for RCC 
targeting (Table 1). Immunohistochemical analyses have indicated that CAIX is ex-
pressed in the vast majority of ccRCC lesions, these studies indicate the possibilities 
Table 1. Clinical diagnostic studies with labeled cG250.
Abbreviations: vs.: versus, M+ RCC: metastatic renal cell carcinoma
Author	   year	   Murine/	  	  
chimeric	  
Imaging	  agent	   #	  patients	   Imaging	  moment	   Diagnostic	  accuracy	   Special	  features	  
Oosterwijk	  et	  al	  
(74)	  
1993	   Murine	   131I-­‐mG250	   15	   Prior	  to	  nephrectomy	   12/12	  primary	  ccRCC	   Protein	  dose	  escalation	  
Steffens	  et	  al	  (47)	   1997	   Chimeric	   131I-­‐cG250	   16	   Prior	  to	  nephrectomy	   13/13	  primary	  ccRCC	   Protein	  dose	  escalation	  
Brouwers	  et	  al	  (48)	   2002	   Chimeric	   131I-­‐cG250	  vs.	  
[18F]-­‐FDG	  
20	   M+RCC	  patients	   131I-­‐cG250:	  30%	  
[18F]-­‐FDG:	  69%	  
Comparative	  intrapatient	  
study	  
Brouwers	  et	  al	  (49)	   2003	   Chimeric	   131I-­‐cG250	  vs.	  
111In-­‐cG250	  
5	   M+RCC	  patients	   131I-­‐cG250:	  30	  lesions	  
111In-­‐cG250:	  47	  lesions	  
Comparative	  intrapatient	  
study	  
Divgi	  et	  al	  (52)	   2007	   Chimeric	   124I-­‐cG250	   26	   Prior	  to	  nephrectomy	   15/16	  primary	  ccRCC	   cG250-­‐immunoPET	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Abbreviations:	  vs.:	  versus,	  M+	  RCC:	  metastatic	  renal	  cell	  carcinoma 
 
 
Author	   year	   Murine/	  
chimeric	  
Therapy	   #	  patients	   CR/PR/SD/PD	   CR/PR/SD	  
duration	  
Special	  features	  
Davis	  et	  al	  (55)	   2007	   Chimeric	   Cold	   13	   1	  CR;	  9	  SD;	  3	  PD	   6-­‐66	  weeks	   Phase	  I	  
Bleumer	  et	  al	  (56)	   2004	   Chimeric	   Cold	   36	   1	  CR;	  1	  PR;	  8	  SD;	  
26	  PD	  
1-­‐20+	  weeks	   Phase	  II	  
Davis	  et	  al	  (75)	   2007	   Chimeric	   Cold	  +	  l.d.	  IL-­‐2	   9	   2	  SD;	  7	  PD	   6	  &	  12	  weeks	   Phase	  I	  
Bleumer	  et	  al	  (59)	   2006	   Chimeric	   Cold	  +	  l.d.	  IL-­‐2	   35	   2	  PR;	  6	  SD;	  27	  
PD	  
24+	  weeks	   Phase	  II	  
Divgi	  et	  al	  (46)	   1998	   Murine	   131I-­‐mG250	   33	   17	  SD;	  16	  PD	   2-­‐3	  months	   Phase	  I/II	  
Steffens	  et	  al	  (60)	   1999	   Chimeric	   131I-­‐cG250	   12	   1	  PR;	  1	  SD;	  10	  
PD	  
3	  &	  9+	  months	   Phase	  I	  
Divgi	  et	  al	  (66)	   2004	   Chimeric	   131I-­‐cG250	   15	   7	  SD;	  8	  PD	   2-­‐11	  months	   Phase	  I	  dose	  fractionation	  
Brouwers	  et	  al	  (50)	   2005	   Chimeric	   131I-­‐cG250	   27	   5	  SD;	  22	  PD	   3-­‐12	  months	   Two	  high-­‐dose	  treatments	  
Bleumer	  et	  al	  (68)	   2007	   n.a.	   Dendritic	  cells	   6	   6	  PD	   n.a.	   CAIX	  peptide	  pulsed	  DC	  
Uemura	  et	  al	  (69)	   2006	   n.a.	   Peptides	   23	   3	  PR;	  6	  SD;	  14	  
PD	  
7-­‐18	  months	   CAIX	  derived	  peptides	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of clinical ccRCC imaging with mAb cG250. Since administration of murine G250 led to 
formation of human anti-mouse antibodies (HAMA) in all patients (n=33) (46), a chimeric 
variant of G250 (cG250) was constructed, allowing multiple administrations of the mAb 
in the same patient (47). The pharmacokinetics and biodistribution of the chimerized mAb 
was determined in presurgical RCC patients and the optimal protein dose was found to 
be 5-10 mg. Clear visualization of all 13 CAIX-positive tumors as well as metastases was 
noted. Focal uptake of cG250 in primary RCC lesions was very high (up to 0.52 %ID/g) 
(47). To compare 131I-cG250 radioimmunoscintigraphy (RIS) with [18F]FDG-PET, 20 mRCC 
patients were scanned using both techniques. Of the 112 metastases documented, 131I-
cG250 RIS detected 34 (30%) and [18F]FDG-PET 77 (69%) lesions (48). The low percentage 
of RCC metastases detected by cG250-RIS in this study contrasts with results of other 
studies, where excellent visualization of metastases in all sites was noted and often new 
lesions were diagnosed, which were not seen using conventional imaging techniques 
(49-51).
ImmunoPET, i.e. combining the favorable characteristics of PET (higher spatial reso-
lution, 3D imaging and superior quantitative estimations of uptake) with mAb cG250 
seems ideal for imaging (m)RCC lesions. However, the combination of the relatively slow 
pharmacokinetics of iv injected radiolabeled mAb (optimal tumor uptake after several 
days) and the most commonly used positron emitters (11C and 18F) is difficult due to their 
too short half-life (2 min to 1.8 h). The positron emitters 89Zr and 124I (half-lives 78 and 
100 h, respectively) seem better candidates to match these slow kinetics (Figure  2). In 
a prospective study Divgi et. al. studied 25 patients with suspect renal lesions scheduled 
for nephrectomy with 124I-cG250. The authors hypothesized that 124I-cG250 PET imaging 
might allow visualization of ccRCC in patients with suspect renal masses versus non-
ccRCC. Of sixteen patients with histologically confirmed ccRCC after surgery, 15 had a 
positive (tumor-to-normal kidney ratio ≥ 3:1) scan. The failure in one patient was attri-
buted to technical problems with the radiolabeled material. None of the 9 patients with 
non-ccRCC showed any 124I-cG250 uptake. The study showed that immunoPET might be 
helpful in clinical decision making and might aid in the surgical management of small re-
nal masses scheduled for partial nephrectomy (52). Recently, a large multicenter phase III 
registration trial comparing conventional diagnostic CT to 124I-cG250 immunoPET/CT for 
the detection of ccRCC in 226 patients scheduled for nephrectomy has been completed 
(53). This trial will give insight in the sensitivity and specificity of 124I-labeled cG250 for 
PET imaging of ccRCC lesions. If the results confirm the earlier observations, 124I-cG250 
immunoPET/CT might become a useful, noninvasive tool to prevent unnecessary surgery 
in patients with undetermined renal masses. 
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3.4 Therapy
3.4.1 CAIX-directed therapy
Antibodies have the capacity to initiate cell lysis through antibody-depen-
dent cellular cytotoxicity (ADCC) or complement directed lysis. After establi-
shing that cG250 could facilitate ADCC and elicit cell lysis of CAIX-positive cells 
in vitro (54), a phase I study with escalating doses of 5-50 mg/m2 cG250 
was initiated, with weekly infusions for 6 weeks. CG250 treatment up to 
50 mg/m2 was safe and well tolerated. Of the 11 mRCC patients treated, one showed a 
CR and nine patients had stable disease after one treatment cycle (55). In the subsequent 
phase II study 36 mRCC patients were included, all receiving 50 mg cG250 weekly for 12 
weeks. No drug-related grade 3-4 toxicity occurred during this trial. Before treatment, 
80% of patients were progressive. After one treatment cycle, 28% of patients had stable 
disease (SD) and during follow-up one complete (CR) and one partial response (PR) were 
noted. The median survival of 15 months suggested that cG250 might be able to modu-
late the natural course of mRCC (56). Based on these results, an adjuvant phase III trial 
is ongoing aiming at reducing the recurrence of disease in nephrectomized RCC patients 
 
 
Figure 2. 3D reconstructed PET-CT image of a mouse with a s.c. CAIX expressing ccRCC 
tumor on the right flank 7 days after injection with 89Zr-cG250. Note the high uptake in the 
tumor (red arrow) and the low aspecific uptake in the liver (blue arrow) and spleen (green 
arrow). 
 
 
Figure 2. 3D reconstructed PET-CT image of a mouse with a s.c. CAIX expressing ccRCC tumor on 
the right fl ank 7 days after injection with 89Zr-cG250. Note the high uptake in the tumor (red 
arrow) and the low aspecifi c uptake in the liver (blue arrow) and spleen (green arrow).
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who have a high risk of relapse (57). 
IL-2 activated effector cells were more effective in eliciting cG250 ADCC (54;58). The ad-
dition of IL-2 to cG250 therapy was studied in a phase II trial, in which 35 patients with 
progressive mRCC received weekly i.v. infusions of 50 mg cG250 and daily s.c. low-dose 
IL-2, for 11 weeks. Treatment was well-tolerated with little toxicity, attributable to IL-2. 
Clinical benefit was noted in 8 of 35 patients, with 2 PR and 6 long-lasting (>24 weeks) 
stabilizations of disease. Mean survival was 24 months in this trial. It was considered 
unlikely that the increased survival was due to the low-dose IL-2, as a 6-fold decrease 
of the normal IL-2 dose was used. It was hypothesized that the result was due to a 
synergistic effect of cG250 and IL-2 (59). Larger, randomized trials are warranted to fully 
determine the effect of the IL-2/cG250 treatment combination on ccRCC.
3.4.2 CAIX radioimmunotherapy
Since accumulation of cG250 in RCC lesions is very high, up to 10 times higher than 
uptake seen with mAbs in other tumors, several strategies to deliver tumor-sterilizing 
radiation doses to tumor cells with cG250 as carrier molecule have been examined 
(Table 2). The maximum tolerated dose (MTD) of 131I-cG250 in progressive mRCC pa-
tients was determined in a radioactivity dose escalation trial. In the initial RIT trials 
hepatic toxicity was observed, most likely due to cG250 accumulation in the liver. In 
subsequent trials patients first received a 131I-cG250 scout dose to prevent administra-
tion of high 131I-cG250 to patients with CAIX-negative tumors. Unexpectedly, through 
the administration of the scout dose liver toxicity was avoided, most likely due to sa-
Table 2. Clinical therapeutic studies with (un)labeled cG250 or G250 peptide fragments.
Abbreviations: cold: unlabeled monoclonal antibody, l.d.: low dose, IL-2: Interleukin-2, n.a.: not 
applicable, CR: complete responses, PR: partial responses, SD: stable disease, PD: progressive 
disease, DC: dendritic cells.
Author	   year	   Murine/	  	  
chimeric	  
Imaging	  agent	   #	  patients	   Imaging	  moment	   Diagnostic	  accuracy	   Special	  features	  
Oosterwijk	  et	  al	  
(74)	  
1993	   Murine	   131I-­‐mG250	   15	   Prior	  to	  nephrectomy	   12/12	  primary	  ccRCC	   Protein	  dose	  escalation	  
Steffens	  et	  al	  (47)	   1997	   Chimeric	   131I-­‐cG250	   16	   Prior	  to	  nephrectomy	   13/13	  primary	  ccRCC	   Protein	  dose	  escalation	  
Brouwers	  e 	  al	  (48)	   2002	   Chimeric	   131I-­‐cG250	  vs.	  
[18F]-­‐FDG	  
20	   M+RCC	  patients	   131I-­‐cG250:	  30%	  
[18F]-­‐FDG:	  69%	  
Comparative	  intrapatient	  
study	  
Brouwers	  et	  al	  (49)	   2003	   Chimeric	   131I-­‐cG250	  vs.	  
111In-­‐cG250	  
5	   M+RCC	  patients	   131I-­‐cG250:	  30	  lesions	  
111In-­‐cG250:	  47	  lesions	  
Comparative	  intrapatient	  
study	  
Divgi	  et	  al	  (52)	   2007	   Chimeric	   124I-­‐cG250	   26	   Prior	  to	  nephrectomy	   15/16	  primary	  ccRCC	   cG250-­‐immunoPET	  
 
Table 1. Clinical diagnostic studies with labeled cG250. 
Abbreviations:	  vs.:	  versus,	  M+	  RCC:	  metastatic	  renal	  cell	  carcinoma 
 
 
Author	   year	   Murine/	  
chimeric	  
Therapy	   #	  patients	   CR/PR/SD/PD	   CR/PR/SD	  
duration	  
Special	  features	  
Davis	  et	  al	  (55)	   2007	   Chimeric	   Cold	   13	   1	  CR;	  9	  SD;	  3	  PD	   6-­‐66	  weeks	   Phase	  I	  
Bleumer	  et	  al	  (56)	   2004	   Chimeric	   Cold	   36	   1	  CR;	  1	  PR;	  8	  SD;	  
26	  PD	  
1-­‐20+	  weeks	   Phase	  II	  
Davis	  et	  al	  (75)	   2007	   Chimeric	   Cold	  +	  l.d.	  IL-­‐2	   9	   2	  SD;	  7	  PD	   6	  &	  12	  weeks	   Phase	  I	  
Bleumer	  et	  al	  (59)	   2006	   Chimeric	   Cold	  +	  l.d.	  IL-­‐2	   35	   2	  PR;	  6	  SD;	  27	  
PD	  
24+	  weeks	   Phase	  II	  
Divgi	  et	  al	  (46)	   1998	   Murine	   131I-­‐mG250	   33	   17	  SD;	  16	  PD	   2-­‐3	  months	   Phase	  I/II	  
Steffens	  et	  al	  (60)	   1999	   Chimeric	   131I-­‐cG250	   12	   1	  PR;	  1	  SD;	  10	  
PD	  
3	  &	  9+	  months	   Phase	  I	  
Divgi	  et	  al	  (66)	   2004	   Chimeric	   131I-­‐cG250	   15	   7	  SD;	  8	  PD	   2-­‐11	  months	   Phase	  I	  dose	  fractionation	  
Brouwers	  et	  al	  (50)	   2005	   Chimeric	   131I-­‐cG250	   27	   5	  SD;	  22	  PD	   3-­‐12	  months	   Two	  high-­‐dose	  treatments	  
Bleumer	  et	  al	  (68)	   2007	   n.a.	   Dendritic	  cells	   6	   6	  PD	   n.a.	   CAIX	  peptide	  pulsed	  DC	  
Uemura	  et	  al	  (69)	   2006	   n.a.	   Peptides	   23	   3	  PR;	  6	  SD;	  14	  
PD	  
7-­‐18	  months	   CAIX	  derived	  peptides	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turation of the liver compartment. Besides mild nausea without vomiting and transient 
fatigue (both grade 1 CTC) no other non-hematological side effects occurred. The MTD 
was 2220 MBq/m2, with hematological toxicity as the dose-limiting factor. Of the 8 
patients receiving treatment, one patient showed stable disease and one patient had a 
PR (60). A study by Brouwers et al. was designed to evaluate the effect of two sequential 
high-dose 131I-cG250 treatments. Similar to the earlier trial, progressive mRCC patients 
received a scout dose of 185 MBq 131I-cG250. When tumor targeting was observed, this 
was followed by 2220 MBq/m2 131I-cG250. After 3 months, if disease progression had 
halted and tumor targeting with another scout dose was established, patients received 
the second high-dose injection 131I-cG250. MTD of the 2nd RIT was set at 1665 MBq/m2 
again due to hematological toxicity. In total, 29 patients entered the study, of which 18 
patients were evaluable for tumor response. No objective responses were seen, but 5 pa-
tients had stabilization of their disease, lasting 3-12 months (50). An inverse correlation 
between the size of metastases and radiation absorbed dose was observed. Therapeutic 
radiation doses (more than 50 Gy) were only guided to the lesions smaller than 5 grams 
(51). It was concluded that RIT in mRCC patients could best be given in the setting of 
small volume disease or as adjuvant therapy.
When the radiolabeled mAb cG250 has bound to the CAIX antigen expressed on ccRCC 
cells, part of the antibody-antigen complex is internalized. Intracellular 131I-cG250 is 
metabolized and tyrosine-131I is rapidly excreted by the tumor cell upon internalization. 
Metallic radionuclides, such as 111In, 90y and 177Lu, are trapped in the lysosomes and resi-
dualize after internalization of the mAb-antigen complex by the target cells (61-63). In an 
intrapatient comparison, 5 mRCC patients were injected with 131I-cG250 and 111In-cG250 
one week apart. 111In-cG250 revealed 47 metastatic lesions where 131I-cG250 detected 
only 30 lesions (49). The therapeutic properties of cG250 labeled with 4 different radionu-
clides at MTD have been tested in nude mice with human RCC xenografts. Tumor growth 
was delayed most effectively by cG250 labeled with 177Lu, followed by 90y, 186Re and 131I 
(delays of 185, 125, 90 and 25 days, respectively). Therefore, 177Lu and 90y were conside-
red better candidates for RIT with cG250 than 131I (64). Based on these data, a phase I/II 
177Lu-cG250 dose escalation RIT study in mRCC patients was designed, which is currently 
ongoing. In this trial in patients with progressive mRCC, adequate targeting of tumors 
is verified with an imaging dose of 111In-cG250. This is followed by up to three cycles of 
high-dose 177Lu-cG250 to determine MTD and assess preliminary therapeutic efficacy (65). 
So far, most patients (70%) had stable disease after one treatment cycle and one PR was 
observed lasting 9 months.
Thiry et al. raised the question whether therapies directed at CAIX might induce ful-
minant toxicities due to the expression of CAIX in normal tissue, predominantly in the 
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epithelial structures (14). Cross-reactivity with non-target tissues is a known feature of 
many mAbs, but this generally does not lead to toxicity. Therapeutic trials with either 
labeled or unlabeled cG250 have thus far shown little toxicity in CAIX expressing normal 
organs (50;55;56;60;66), except for the liver toxicity in the first RIT trial, which was not seen in 
later RIT trials. Whether CAIX-related toxicity will occur when small molecules inhibiting 
CAIX are administered remains to be determined.
3.4.3 Cellular and humoral immunotherapy with CAIX derived peptides
Exploiting the highly immunogenic characteristics of ccRCC, 6 progressive, cytokine-
refractory mRCC patients received vaccinations of mature dendritic cells (DC) loaded 
with CAIX-derived peptides. These peptides define two different epitopes (HLA-A2.01 
and HLA-DR) of the CAIX antigen and are able to induce cytotoxic T-lymphocytes (CTL) 
responses against CAIX expressing cells in vitro (67). Although skin biopsies suggested an 
increased influx of T-helper cells, no evidence was found for induction of CAIX-specific 
immunity. The treatment was not associated with any toxicity, but clinical responses 
were absent (68). In retrospect, the DCs in this trial were probably not adequately ma-
tured. Therefore, a new trial with mature DCs is warranted. Multiple vaccinations with 
three CAIX-derived peptides defining the HLA-A24 epitope resulted in development of 
peptide-specific CTL’s and peptide-reactive serum immunoglobulin G in 23 progressive, 
cytokine-refractory mRCC patients (69). No major adverse events occurred, 3 patients 
had a PR and 6 patients had stable disease for >6 months, with a median survival of 
all patients of 21 months. Because of the higher response rate, the approach of direct 
vaccination with CAIX-derived peptides, without the use of DCs, seems more promising 
as an anti-RCC treatment, but larger, prospective trials are needed to establish it as a 
treatment modality. 
Several investigators have examined the potential of fusing the cG250 mAb with im-
munomodulatory factors, specifically enhancing the immunologic anti-RCC response of 
mRCC patients. Tso et al. fused cG250 with granulocyte/macrophage-colony stimulating 
factor (GM-CSF). This fusion protein (FP) could enhance macrophage and granulocyte 
natural cytotoxicity against CAIX expressing tumor cells in vitro (70). The gene encoding 
for this FP (GM-CAIX gene) was then used to transduce DCs with a recombinant adeno-
virus containing this fusion gene. These DCs were able to induce CAIX-specific cytotoxic 
lymphocytes in vitro and GM-CAIX gene transduced kidney cancer cells were able to in 
vivo produce a GM-CAIX protein that was targeted to the cell membrane (71). Currently, 
a clinical trial in mRCC patients is ongoing in which patient-specific DCs are transduced 
with the adenoviral GM-CAIX construct (72). Bauer et al. constructed a cG250-tumor ne-
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crosis factor (TNF) FP. TNF is a mediator of hemorrhagic tumor necrosis which causes in 
vivo regression of xenografted human tumors. Systemic TNF administration leads to pro-
found toxicity, prohibiting its application as systemic cancer therapy in humans. Specific 
cG250-TNF targeting might alleviate toxicity, while retaining its anti-cancer properties. 
In nude mice bearing CAIX-positive RCC xenografts specific accumulation and retention 
of cG250-TNF was observed, which resulted in growth inhibition and improved survival. 
Co-administration of IFN-γ, known to enhance TNF-mediated RCC rejection, resulted in 
synergistic tumoricidal activity (73).
4. CONCluSIONS
The vast majority of primary and metastatic ccRCC lesions have high and homogeneous 
CAIX expression. CAIX expression on primary ccRCC tumors is a prognostic factor for sur-
vival and is a predictor of response to IL-2 immunotherapy in ccRCC patients. Whether 
high CAIX expression also predicts response to treatment with angiogenesis inhibitors 
needs further investigation. Imaging ccRCC lesions with mAb cG250, targeting CAIX, 
is a promising tool for diagnosing and (re)staging of the disease and results of a large 
prospective trial are upcoming. Given the high expression of CAIX in ccRCC the outcome 
of a large, placebo-controlled study is awaited to establish the usefulness of CAIX-
targeted therapy in the adjuvant setting. Therapeutic trials in mRCC patients are still in 
the phases I and II.
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abSTRaCT
Background
Patients with metastatic clear cell Renal Cell Carcinoma (ccRCC) have a dismal prognosis. There-
fore, new and less toxic treatments are needed.
Objective
Here, we determined the maximum tolerated dose (MTD) and potential therapeutic efficacy 
of multiple infusions of 177Lu-cG250 on various dose levels in a phase I trial in patients with 
progressive metastasized ccRCC.
Design, setting and participants
In this uncontrolled case series in 23 patients with progressive ccRCC metastases cG250 accu-
mulation was verified by diagnostic 111In-cG250 imaging. Patients then received a high-activity 
dose of 177Lu-cG250. 
Interventions
Groups of three patients received 177Lu-cG250, starting at a dose level of 1110 MBq/m2 177Lu-
cG250, with dose increments of 370 MBq/m2 per group. In the absence of persistent toxicity, 
progressive disease and accelerated blood clearance, patients were eligible for re-treatment 
after 3 months with 75% of the previous activity dose. Patients could receive in total 3 treat-
ment cycles.
Outcome measurements 
Determination of the MTD was the primary and therapeutic efficacy the secondary outcome 
measurement of the study.
Results and limitations
The MTD was 2405 MBq/m2, as higher doses resulted in dose-limiting myelotoxicity. Some pa-
tients received 2nd (13/23, 56%) and 3rd (4/23, 17%) treatment cycles. Most patients (17/23, 
74%) demonstrated stable disease 3 months after the first treatment and one patient showed a 
partial response, which lasted for 9 months. Mean growth of target tumor lesions was reduced 
from 40.4% (95%CI ±17.0) during the last 3 months before study entry to 5.5% (95%CI ±5.3, 
p<0.001) at 3 months after the 1st treatment cycle. No major non-hematological side effects 
were observed.
Conclusions
177Lu-cG250 radioimmunotherapy in metastatic ccRCC patients is well-tolerated at an activity 
dose level as high as 2405 MBq/m2 (MTD). Radioimmunotherapy with 177Lu-cG250 may stabilize 
previously progressive metastatic ccRCC.
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INTRODuCTION
Clear cell Renal Cell Carcinoma (ccRCC) is the most common malignancy arising in the kidney.(1) 
Current first-line treatment for metastasized disease is angiogenesis inhibition with a variety of 
drugs.(2) Response rates to treatment with these agents are relatively high, but mainly restricted 
to transient disease stabilizations and partial responses while side-effects are common and 
may be severe in nature.(3;4) Although progress has been made in the management of advanced 
ccRCC, there is a great need for effective and less toxic treatment modalities.
Chimeric monoclonal antibody (mAb) cG250 (Girentuximab) is reactive with CAIX,(5-7) a heat-
sensitive, transmembraneous glycoprotein.(8-10) Previous studies showed an almost ubiquitous 
expression (>90%) of CAIX in ccRCC. Expression in normal tissues has been evaluated extensi-
vely and is restricted to the gastrointestinal mucosa and gastrointestinal related structures with 
much lower expression levels than ccRCC. (11;12) 
Various studies have been performed with radiolabeled mAb cG250 in ccRCC patients.(12;13) In 
an activity dose-escalation study with 131I-cG250 in progressive ccRCC patients a maximum 
tolerated dose (MTD) of 2220 MBq/m2 was established.(6) These findings led to a phase I/II 
study in which metastatic ccRCC (mRCC) patients were treated with 2220 MBq/m2 131I-cG250. 
After three months patients were retreated with 131I-cG250, the MTD of this 2nd injection was 
found to be 75% of the first dose. Stabilization of previously progressive disease was noted in 4 
of 16 (25%) patients treated at the optimal dose level at six months,(14) clearly indicating that 
improvements were necessary.
In radioimmunotherapy experiments in nude mice with human RCC xenografts, tumor growth 
was delayed more effectively with 177Lutetium(177Lu)-cG250 than with 131I-cG250.(15) Moreover, 
an intrapatient comparison revealed higher uptake of cG250 labeled with the residualizing 
radionuclide 111In as compared to 131I-cG250,(13) indicating that higher radiation doses could 
be guided to tumor lesions when cG250 was labeled with a residualizing radionuclide such as 
177Lu. Here, we report the results of a phase 1 study of radioimmunotherapy with 177Lu-labeled 
cG250 in mRCC patients. 
The primary aim of the study was to determine the MTD and toxicity of 177Lu-cG250. The secon-
dary aim was to determine the preliminary therapeutic efficacy of a maximum of three doses 
of 177Lu-cG250.
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PaTIENTS aND METHODS
Patient Characteristics
25 progressive mRCC patients were included (21 males and 4 females, mean age 57 years, range 
29-74 years) from 2005 until 2010. The inclusion and exclusion criteria are given in Table 1. 
The study (ClinicalTrials NCT00142415) was approved by the regional Medical Ethical Review 
Committee of the Radboud University Medical Centre and the institutional review board of the 
Ludwig Institute for Cancer Research. Written informed consent was obtained from all patients.
Study Design
The primary endpoint was to determine the MTD and to evaluate toxicity of increasing activity 
doses of 177Lu-cG250 in progressive mRCC patients. The secondary endpoint was to evaluate the 
preliminary therapeutic efficacy of the treatment on the metastases as reflected by tumor res-
ponse on contrast enhanced CT scans of the chest and abdomen using RECIST v1.0, progression 
free survival (PFS) and overall survival (OS).
Monoclonal Antibody cG250 and Radiolabeling
Chimeric mAb G250 (Girentuximab) is a high affinity (Ka = 4 x 109 M-1) IgG1 mAb, reactive with 
CAIX. Clinical grade cG250 conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraace-
tic acid (DOTA; Macrocyclics, Dallas, Texas, USA) was obtained from the Ludwig Institute for 
Cancer Research, New york. The conjugation with DOTA was performed as described earlier.(16) 
Proven advanced and progressive clear cell renal 
cell carcinoma. 
Previous tumour nephrectomy. 
At least one measurable metastasis less than  
5 cm diameter.
Performance status: Karnofsky score ≥ 70%.
Table 1. In- and Exclusion criteria
Known brain metastases.
Untreated hypercalcemia.
Metastatic disease limited to the bone.
Pre-exposure to murine/chimeric antibody therapy
Baseline CT scan of chest and abdomen within  
4 weeks before study entry
Laboratory values obtained less than 14 days 
prior to registration:
•	 White	blood	cells	(WBC)	>	3.5	x	109/l
•	 Thrombocyte	count	>	100	x	109/l
•	 Hemoglobin	>	6	mmol/l	
•	 Total	bilirubin	<	2	x	upper	limit	of	normal	(ULN)	
•	 ASAT,	ALAT	<	3	x	ULN	(<	5	x	ULN	if	liver	meta-
stases present)
•	Serum	creatinine	<	2	x	ULN
Age over 18 years.
Ability to given written informed consent.
Chemotherapy, external beam radiation or im-
munotherapy within 4 weeks prior to study. Limi-
ted field external beam radiotherapy to prevent 
pathological fractures was allowed.
Cardiac disease with New york Heart Association 
classification of III or IV.
Patients who are pregnant or nursing. 
Life expectancy shorter than 6 months.
Inclusion Criteria Exclusion Criteria
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Diagnostic injections consisted of 185 MBq 111In-cG250 (protein dose 10 mg). The administered 
177Lu activity dose was adjusted on the activity-dose level, the body surface area, calculated 
with the formula from Mosteller,(17) and treatment cycle, but the cG250 protein dose was 10 mg/
injection in all patients.
Study Procedures
Patients received a diagnostic i.v. infusion of 185 MBq /10 mg 111Indium(111In)-cG250 (total 
volume 10 ml) followed by acquisition of three whole-body scintigraphic images; directly, 2-4 
days and 5-7 days after injection. If targeting of 111In-cG250 to metastatic lesions was observed 
in the scintigraphic images, patients were eligible for treatment with 177Lu-cG250 a week after 
the diagnostic infusion. Patients were followed-up weekly and blood laboratory parameters 
were analyzed. Toxicities were scored according to the U.S. National Cancer Institute Common 
Toxicity Criteria (CTC version 3.0). Dose-limiting toxicity (DLT) was defined as ≥ grade 3 non-
hematological toxicity or ≥ grade 4 hematological toxicity which lasted for more than 4 weeks 
or the occurrence of hemoglobin < 4.9 mmol/l or thrombocytes < 10 x 109/l. Three patients 
were entered at each dose level, starting at 1110 MBq/m2, with dose increments of 370 MBq/m2 
if all three patients did not show a DLT. If one out of three patients had a DLT, another three pa-
tients were entered at the same dose level. The MTD was defined as the dose level at which no 
more than one out of six patients showed a DLT. When MTD was reached, the dose was reduced 
with 185 MBq/m2 to evaluate an intermediate dose level. A CT scan was performed 3 months 
after the 177Lu-cG250 radioimmunotherapy infusion to evaluate therapeutic efficacy. If this scan 
showed no progression of disease, the patient was eligible to receive a second radioimmuno-
therapy infusion, provided that thrombocyte and leucocyte levels had fully recovered. One week 
before the second treatment a second diagnostic infusion (185 MBq/10 mg 111In-cG250) was 
administered mainly to rule out the presence of Human Anti Chimeric Antibodies (HACA) that 
would lead to rapid clearance of the radiolabeled antibody from the blood and enhanced uptake 
in liver, spleen and bone marrow. In the absence of rapid clearance the patient was retreated at 
75% of the 177Lu-cG250 activity dose administered in the first radioimmunotherapy infusion.(14) 
If the CT scan made 3 months after the second radioimmunotherapy infusion showed no sign of 
disease progression, a third diagnostic infusion of 111In-cG250 was administered. Again, if there 
were no signs of rapid clearance of the radiolabeled mAb and myelotoxicity was absent, a third 
radioimmunotherapy infusion was administered at an activity dose level of 75% of the second 
infusion. The last CT-scan was made 3 months after the third radioimmunotherapy infusion.
Tumor Responses
Tumor responses were evaluated according to the RECIST criteria. Measurements were performed 
3 months prior to baseline, at baseline and 3 months after each radioimmunotherapy infusion. 
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HACA analysis
Serum samples were analyzed for the presence of human anti-chimeric antibodies (HACA) as 
described previously.(5,6) 
Statistical Analysis
Statistical analysis of the tumor response was analyzed using a paired t-test. The difference was 
considered statistically significant when p ≤ 0.05.
RESulTS
Radioimmunoscintigraphy
Of the 25 patients who received a first scout injection of 111In-cG250, 23 showed visible target-
ing in at least one of the known metastatic lesions at 5-7 days after injection. Two patients 
did not show targeting of 111In-cG250 to the tumor lesions, but fast clearance and high liver 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anterior Anterior 
a. Day 7 post-injection 185 MBq/10 mg 111In-cG250  b. Day 6 post-injection 1887 MBq/10 mg 177Lu-cG250  
Figure 1. Clear visualization of ccRCC metastases in lung, abdomen and pelvis on 
immunoscintigraphy a. 111In-cG250 immunoscintigram of a patient with metastatic 
ccRCC, acquired 7 days after injection of 185 MBq 111In-cG250 b. 177Lu-cG250 
immunoscintigram of the same patient, acquired 6 days after injection of 1887 MBq 
177Lu-cG250. 
Posterior Posterior 
Figure 1a. and 1b. Clear visualization of ccRCC metastases in lung, abdomen and pelvis on im-
munoscintigraphy a. 111In-cG250 immunoscintigram of a patient with metastatic ccRCC, acquired 
7 days after injection of 185 MBq 111In-cG250 b. 177Lu-cG250 immunoscintigram of the same 
patient, acquired 6 d ys after injection of 1887 MBq 177Lu-cG250.
1a. Anterior 1a. Posterior 1b. Anterior 1b. Posterior
13054 Alexander proefschrift_01.indd   59 09-01-14   20:33
RADIOIMMUNODIAGNOSIS AND -THERAPy OF RENAL CELL CARCINOMA60
and spleen uptake of the 111In-cG250. Fast protein liquid chromatography analysis of these 
two cG250 preparations showed signs of aggregation of the radiolabeled mAb. As a result, 23 
patients received the first high-dose 177Lu-cG250 injection. Metastases were visualized highly 
similar at all sites (lymph node regions, bone, abdominal organs, lung) with the scout dose 
111In-cG250 and the high dose 177Lu-cG250 (Figure 1).
Patient Characteristics, Toxicity and Clinical Observations
Most patients (15/23) had received prior IFN-α immunotherapy, with or without Interleukin-2 
and 5-Fluorouracil (Table 2). When this study started, angiogenesis inhibitors were not yet 
standard for the treatment of mRCC. Therefore, 21 of 23 patients had not been treated with 
these agents before study entry. Radiolabeled antibody injections were well tolerated and no 
infusion-related or acute allergic reactions were noted after injection of 111In-cG250 or 177Lu-
cG250. 
Hematological toxicity was the most prominent toxicity and was dose-limiting. At the first 
two dose levels (1110 and 1480 MBq/m2) no DLT was noted. In these patients the nadir in the 
thrombocyte counts was observed 4-6 weeks and the nadir in the leucocyte counts 5-7 weeks af-
ter injection of 177Lu-cG250 (Fig. 2). Patient #8, treated at the next dose level (1850 MBq/m2), 
experienced a grade 4 thrombocyte and leucocyte toxicity after the first injection of 177Lu-
cG250. Due to this DLT, three additional patients were entered at this dose level, and because 
no DLT was noted in these patients dose escalation was continued. No DLT was observed at 
the 2220 MBq/m2 dose level. At the 2590 MBq/m2 dose level, two patients experienced long-
lasting grade 4 toxicity of both thrombocytes and leucocytes, requiring hospital admission and 
multiple thrombocyte infusions. Since both patients experienced a DLT, the dose was reduced to 
2405 MBq/m2. At this dose level, one of the three patients developed a DLT existing of grade 4 
toxicity, and three additional patients were entered who experienced no DLT. Thus, the MTD of 
177Lu-cG250 radioimmunotherapy in this study was 2405 MBq/m2. Second radioimmunotherapy 
injections with 75% of the previously administered dose caused higher myelotoxicity than after 
the first administration in 2 out of 13 patients, which was not clinically significant (≤ grade 2) 
in both cases. One out of the four patients receiving a 3rd radioimmunotherapy injection experi-
enced higher myelotoxicity as compared to the toxicity after the 2nd radioimmunotherapy dose 
(grade 2 instead of grade 1 thrombocyte toxicity) (Table 2). 
Patient #11 died while on study due to the sequelae of an ischemic cerebrovascular accident 
8 weeks after the second radioimmunotherapy administration, judged unrelated to the study 
drug. Most patients (14/23, 61%) complained of mild fatigue or nausea (CTC grade 1 at most) 
in the first 2-3 weeks after radioimmunotherapy injection, but these symptoms recovered com-
pletely.
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Figure 2. Mean leucocyte and thrombocyte counts ± SD of all patients after the first 
radioimmunotherapy 177Lu-cG250 dose 
 
 
 
Leucocyte counts after RIT 1
Trombocyte counts after RIT 1
Figure 2. Mean leucocyte and thrombocyte counts ± SD of all patients after the first radioimmu-
notherapy 177Lu-cG250 dose.
Tumor Response
In total, 23 patients were evaluable after the first RIT cycle with 177Lu-cG250. Patient #8 sho-
wed a partial response after two RIT treatments which lasted 9 months. Seventeen patients 
(74%) had stable disease during the three months after the first RIT dose. Of these, 12 patients 
were eligible for a second cycle: two patients were suspected for HACA and three patients ex-
perienced grade 4 myelotoxicity after the first radioimmunotherapy. 
Seven patients had stable disease after the second radioimmunotherapy, of which four patients 
went on to receive a third treatment cycle. Two patients were excluded from further treatment 
because of rapid progression of non-target lesions (#12) or prolonged myelotoxicity (#15). 
Patient #23 did not receive the 3rd administration for logistical reasons. 
Of the four patients receiving three radioimmunotherapy cycles, two patients experienced long-
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lasting stabilizations of disease for two years (#7) and almost six years (#3), respectively. Mean 
growth of the longest diameter of all target lesions in all 23 study patients was reduced from 
40.4% (95%CI ±17.0) during the 3 months before treatment to 5.5% (95%CI ±5.3) after the 
1st treatment cycle (p<0.001) (Fig. 3). Mean PFS of all patients, treated at various dose levels, 
was 11.1 months (95%CI ±6.3). At disease progression most patients received angiogenesis 
inhibitors. Mean OS was 25.3 months (95%CI ±7.1).
HACA response
Four patients developed elevated HACA levels during treatment (#3, #5, #8 and #9). HACA 
levels in patients #5 and #9 procluded administration of a subsequent treatment cycle.
 
 
Figure 3. Tumor growth of all target lesions at each dose level. Mean growth of all tumor 
lesions in 23 study patients is reduced from 40.4% (95%CI ±17.0) during the 3 months before 
treatment to 5.5% (95%CI ±5.3) during the 3 months of the first treatment (p<0.001). 
 
 
177Lu-cG250 radioimmunotherapy stabilizes ccRCC growth
Figure 3. Tumor growth of all target lesions at each dose level. Mean growth of all tumor lesions 
in 23 study patients is reduced from 40.4% (95%CI ±17.0) during the 3 months before treatment 
to 5.5% (95%CI ±5.3) during the 3 months of the fi rst treatment (p<0.001).
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DISCuSSION
The primary aim of the present study was to determine the MTD of radioimmunotherapy with 
177Lu-cG250. Besides the hematological toxicity, antibody administrations were well tolerated 
and besides some mild fatigue and mild nausea no other toxicities were observed. The MTD 
of radioimmunotherapy with 177Lu-cG250 in mRCC patients was 2405 MBq/m2. This is similar 
to the observations of Vallabhajosula et al.(18), who treated 35 patients with prostate cancer 
with high activity doses 177Lu-labeled humanized J591 (huJ591), an anti-PSMA mAb with a 
MTD of 2590 MBq/m2 177Lu-huJ591. Successive injections with 75% of the previous dose were 
administered 3 months apart and no clinically significant higher toxicity levels were noted in 
patients after the second and/or third radioimmunotherapy injections. Total activity doses of 
up to 11,285 MBq 177Lu-cG250 have been given to individual patients without dose-limiting 
toxicity. However, two patients (#8 and #15) experienced prolonged myelotoxicity after the 
2nd radioimmunotherapy injection. The 3rd radioimmunotherapy injection was therefore not 
administered to avoid bone marrow aplasia. These data indicate that, in some patients, 75% 
of the previous activity dose may still be too high when given 3 months apart. Blumenthal 
et al.(19-21) postulated that normal thrombocyte or leucocyte counts after a myelosuppressive 
therapy do not accurately reflect the status of the bone marrow. Peripheral blood cell counts 
may have normalized, while there still is an incomplete myelorecovery reflected by a reduced 
number of pluripotent stem cells and/or enhanced proliferation of stem cells in the bone mar-
row. When a second myelosuppressive therapy is given while stem cells are still recovering and 
actively proliferating, this may enhance toxicity. There is a great need for an improved method 
to predict myelotoxicity during radioimmunotherapy, since it would allow for optimal dosing 
in each patient.
High and specific uptake of the radiolabeled anti-CAIX antibody was seen in tumor lesions 
in almost all patients. Also lung lesions, that were notoriously difficult to visualize with 131I-
cG250(13,14,22), showed high and preferential uptake on the 111In-cG250 and 177Lu-cG250 scinti-
grams. The full dosimetric analysis of this study has been published elsewhere.(23) The use of 
124I-labeled cG250 has been evaluated in positron emission tomography (PET) for pre-operative 
assessment of patients with suspected renal masses.(24) In 15 of 16 patients with ccRCC 124I-
cG250 visualized the tumors, whereas scans in patients with non-clear cell renal masses (n=9) 
were negative. The advantages of PET over conventional scintigraphy are the higher spatial 
resolution and the ability to accurately determine antibody uptake in tissues quantitatively(25). 
This allows for imaging of smaller lesions and may allow for dose optimization in patients 
eligible for radioimmunotherapy; PET could therefore be more suitable than conventional scin-
tigraphy. 
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Our secondary endpoint was to evaluate the therapeutic efficacy of a maximum of three con-
secutive treatments with 177Lu-cG250. One patient had an objective response which lasted 9 
months after receiving two radioimmunotherapy administrations of 3996 MBq and 3034 MBq 
177Lu-cG250, respectively. This patient had small volume disease, with only one small (2.4 cm 
in diameter) lymph node metastasis. This observation is in line with previous studies, where 
it was noted that radioimmunotherapy in solid malignancies could be best applied in patients 
with small volume disease, since higher doses would be guided to these lesions.(26, 27) In this 
study, at various 177Lu-cG250 dose levels, disease had stabilized or responded in 8/12 (67%) 
patients evaluable after six months. This is superior over two consecutive 131I-cG250 treatments 
at MTD, which showed no objective responses and only four of 16 patients (25%) had stable 
disease after six months.(14) Evaluation of all target tumor lesions prior to and after the first 
radioimmunotherapy showed that mean growth was significantly reduced suggesting that 177Lu-
cG250 had therapeutic efficacy in patients with metastatic RCC. Four patients completed all 
three radioimmunotherapy administrations, of which two had stabilization of disease lasting 
for almost two and six years. The results of our present study are encouraging and indicate an 
overall improvement of therapeutic efficacy of radiolabeled cG250 RIT when using 177Lu as a 
radionuclide, as compared to 131I.
In conclusion, in this phase I dose escalation study in which patients were treated with a 
maximum of three consecutive radioimmunotherapy doses, 177Lu-cG250 radioimmunotherapy 
was well tolerated and safe. MTD was determined at 2405 MBq/m2. The clinical observations in 
this study in patients with progressive metastasized RCC suggest that 177Lu-cG250 RIT may pre-
vent disease progression, albeit the patient population was heterogeneous and not all patients 
received the same number of treatment cycles. The phase II study has recently been initiated 
to evaluate the therapeutic efficacy of multiple doses 177Lu-cG250 at MTD.
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abSTRaCT
Background
This study aimed to estimate the radiation absorbed doses to normal tissues and tumor les-
ions during radioimmunotherapy with 177Lu-cG250. Serial planar scintigrams after injection of 
111In/177Lu-cG250 in patients with metastasized renal cell carcinoma (mRCC) were analyzed 
quantitatively. The estimated radiation doses were correlated with observed hematological 
toxicity. In addition the accuracy of the predicted therapeutic absorbed doses, based on diag-
nostic 111In-cG250 data, were determined.
Methods
Twenty patients received a diagnostic tracer activity of 111In-cG250 (185 MBq) followed by 
radioimmunotherapy with 177Lu-cG250. The administered activity of 177Lu-cG250 was escalated 
by entering three patients at each activity level starting at 1110 MBq/m2 with increments of 
370 MBq/m2. After each diagnostic and therapeutic administration whole body scintigraphic 
images and pharmacokinetic data were acquired. Hematologic toxicity was graded based on the 
Common Toxicity Criteria version 3.0. Diagnostic 111In-cG250 data were used to simulate 177Lu- 
and 90y-data by correcting for the difference in physical decay. Absorbed doses were calculated 
for the whole body, red marrow, organs and tumor metastases for the therapeutic 177Lu-cG250, 
simulated 177Lu-cG250 and simulated 90y-cG250 data.
Results
Observed hematological toxicity, especially platelet toxicity, correlated significantly with the 
administered activity (r = 0.85), whole body absorbed dose (r = 0.65) and red marrow dose 
(r = 0.62 and 0.75). An inverse relationship between the mass and absorbed dose of the 
tumor lesions was observed. Calculated mean absorbed doses were similar for the simulated 
and measured 177Lu-cG250 data. Absorbed doses (whole body, red marrow) based on the simu-
lated 177Lu-cG250 data correlated with the observed platelet toxicity (r = 0.65 and 0.82). The 
tumor-to-red marrow dose ratio was higher for radioimmunotherapy with 177Lu-cG250 than for 
radioimmunotherapy with 90y-cG250, indicating that 177Lu has a wider therapeutic window for 
radioimmunotherapy with cG250 as compared to 90y.
Conclusion
In patients with mRCC, hematological toxicity after treatment with 177Lu-cG250 can be predic-
ted on the basis of administered activity, whole body and red marrow absorbed dose. Diag-
nostic 111In-cG250 data can be used to accurately predict absorbed doses and myelotoxicity of 
radioimmunotherapy with 177Lu-cG250. These estimations indicate that in these patients higher 
radiation doses can be guided to the tumors with 177Lu-cG250 than with 90y-cG250.
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INTRODuCTION
Renal cell carcinoma (RCC) is a disease with ~ 58,000 new patients each year in the USA 
and accounts for 3% of all malignancies.1 The only curative option to date for RCC is 
(partial) nephrectomy. Prognosis of untreated mRCC is poor with a median survival of 12 
months. With the advent of targeted agents, this prognosis has increased dramatically, 
more than doubling overall survival.2 However, side effects of these compounds are com-
mon and often severe.3 Therefore we aim to develop an effective radioimmunotherapeu-
tic approach for the treatment of RCC using the radiolabeled anti-CAIX antibody, cG250. 
The main goal in radioimmunotherapy is to maximize the absorbed dose to the tumor, 
while maintaining the dose to healthy tissues at acceptable levels. The dose-limiting 
normal tissue in radioimmunotherapy is the red marrow. Thrombocytopenia and leuc-
openia are generally the initial and most severe manifestations of myelotoxicity after 
radioimmunotherapy.4 
In several studies, methods are defined to estimate the red marrow dose based on blood 
activity data or planar scintigrams.5-8 Previous studies on the relationship between ra-
diation dose estimates and myelotoxicity were variable.7, 9-15 Results might have been 
influenced by the used method to calculate the red marrow dose, the radionuclide used 
or patient specific factors. Recently, Baechler et al. showed for example that the elapsed 
time since the last chemotherapy is an important parameter in the prediction of toxi-
city.16 
The ability to predict the therapeutic dose to tumor lesions and healthy organs could 
provide tools for treatment planning. For individual dosing each radioimmunotherapy 
treatment can be preceded by a diagnostic infusion of the same monoclonal antibody 
(mAb) labeled with a γ-emitter.11 The analysis of the images of an antibody labeled with 
111In could potentially be used to predict the targeting of the same antibody labeled 
with the β-emitting radionuclide 90y or 177Lu. In a study of DeNardo et al. mAb Lym-1 
labeled with 111In was used to calculate the absorbed doses for 90y-Lym-1 in patients 
with non-Hodgkin’s lymphoma.17 Vallabhajosula et al. used 111In-J591 as a surrogate for 
90y-J591.10 However, because 90y is not suitable for imaging since it is a pure β-emitting 
radionuclide, the accuracy of these dosimetric predictions could not be proven. 
During a phase I study at our institution, patients with progressive clear cell RCC could 
receive multiple therapeutic doses of 177Lu-cG250. Before each therapeutic administra-
tion patients received a diagnostic infusion with 111In-cG250.  We used the pharmacoki-
netic and scintigraphic data to estimate radiation doses of the therapeutic injections 
to normal tissues and metastases and investigated whether these doses correlated with 
the observed hematological toxicity. We investigated whether the dosimetric analysis of 
the diagnostic injections could be used to predict the radiation doses of the therapeutic 
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injections after the first treatment cycle. Furthermore absorbed dose predictions were 
made for radioimmunotherapy with 90y-cG250 to determine the most suitable β-emitter for 
radioimmunotherapy with the radiolabeled anti-CAIX antibody in these patients. 
MaTERIalS aND METHODS
Patients
Twenty patients with progressive mRCC (16 males, 4 females) who had all undergone a nephrec-
tomy of the tumorous kidney were included. The mean age of the patients was 58 years (range 
29 - 74 yrs). The study (ClinicalTrials NCT00142415) was approved by the regional Medical 
Ethical Review Committee of the Radboud University Nijmegen Medical Centre and the Institu-
tional Review Board of the Ludwig Institute for Cancer Research. The study was monitored by 
the Omnicare corporation, commissioned by the Ludwig Institute for Cancer Research. Written 
informed consent was obtained from all patients before study entry.
MAb cG250 and radiolabeling 
cG250 is a high-affinity (Ka = 4 x 10
9 M-1) chimeric, IgG1 mAb, reactive with the CAIX antigen, 
a transmembrane glycoprotein overexpressed on the cell surface of the majority (> 95%) of 
clear cell RCCs.18 Vials (10 mg/mL) clinical grade cG250 were obtained from The Ludwig Insti-
tute for Cancer Research (New york, Ny). Conjugation of cG250 with 1,4,7,10-tetraazacyclodo-
decane-1,4,7,10-tetraacetic acid (DOTA) (Macrocyclics, Dallas, TX) was performed as described 
previously 19 at Memorial-Sloan Kettering Cancer Centre (New york, Ny). The cG250-DOTA con-
jugate was radiolabeled with 111In (Covidien, Petten, The Netherlands) for tracer injections in a 
0.25 M ammonium acetate buffer, pH 5.4 for 30 min at 45 ˚ C. Labeling of cG250-DOTA with 177Lu 
(IDB Holland, Tilburg, The Netherlands) for therapeutic injections was performed in 0.25 M am-
moniumacetate buffer, pH 5.4 for 60 min at 45 ˚C. All labeling procedures using 111In or 177Lu 
were performed under strict metal-free conditions. All radiolabeled cG250 preparations were 
purified by gel filtration on a PD-10 column (GE Healthcare, Woerden, The Netherlands) eluted 
with phosphate-buffered saline (PBS) supplemented with 5 mM DTPA and 10 mM ascorbic acid. 
For all preparations, the amount of non-mAb-associated radiolabel was determined by instant 
thin-layer chromatography (ITLC) with ITLC silica gel strips (Pall Corporation Life Sciences, New 
york, Ny, USA), using 0.1 M citrate buffer, pH 6.0 as the mobile phase (Rf = 0 for radiolabeled 
antibody, and Rf = 0.8–1 for free and chelated radionuclides).18 The radiochemical purity was 
>99% for 111In-DOTA-cG250 and 99.3 ± 0.9% for 177Lu-DOTA-cG250. The immunoreactive fraction 
determined as described previously was 90.1 ± 5.3% and 89.8 ± 6.8% for the 111In-cG250 and 
177Lu-cG250 preparations, respectively.
13054 Alexander proefschrift_01.indd   73 09-01-14   20:33
RADIOIMMUNODIAGNOSIS AND -THERAPy OF RENAL CELL CARCINOMA74
Study design 
In this phase I study the maximum tolerated dose (MTD) of 177Lu-cG250 radioimmu-
notherapy was determined by entering three patients at each activity level, starting 
at 1110 MBq /m2 with dose increments of 370 MBq/m2. The MTD was defined as the 
administered activity at which no more than 1 out of 6 patients showed dose limiting 
toxicity (DLT). DLT was defined as ≥ grade 3 non-hematological toxicity or ≥ grade 4 
hematological toxicity (platelets < 25 x 109/l or leucocytes < 1.0 x 109/l) which lasted 
for more than 4 weeks or the occurrence of hemoglobin < 4.9 mmol/l or thrombocytes 
< 10 x 109/l at any time point. The administered 177Lu dose was adjusted on the activity 
level, the body surface area, calculated with the formula from Mosteller.20
Toxicity was monitored weekly, by determining the hematological and blood chemistry 
laboratory parameters, and was scored according to the U.S. National Cancer Institute 
Common Toxicity Criteria (CTC version 3.0). Response to treatment was determined by 
comparing the baseline computed tomography (CT) scan to CT-scans acquired 3 months 
after each radioimmunotherapy administration. 
All radioimmunotherapy administrations were preceded by a diagnostic tracer of 111In-
cG250 (185 MBq, 10 mg cG250, total volume 5 ml) to visually assess preferential uptake 
of the radiolabeled antibody in the tumor lesions and to exclude the presence of human 
anti-chimeric antibodies (HACA), that would cause accelerated clearance of the radiola-
beled antibody from the blood and enhanced uptake in liver, spleen and bone marrow. 
Imaging and pharmacokinetics 
Following each 111In-cG250 administration three whole-body scintigrams were acquired 
(directly, 2-4 days and 5-7 days post injection (p.i.)). The images were recorded in 
conjugate view using a double-headed gamma camera (ECAM, Siemens Inc., Hoffman 
Estates, IL, USA), equipped with parallel-hole medium-energy collimators. Symmetric 
energy windows were set at 15% of the 111In photopeaks at 172 and 247 keV. Images 
consisted of summed counts collected in both windows. The scan speed was 8 cm/min, 6 
cm/min and 4 cm/min at day 0, 2-4, and 5-7 p.i., respectively. The matrix size was 256 
x 1024, with a pixel size of 2.4 x 2.4 mm2. Images obtained after infusion of 177Lu-cG250 
were recorded using a symmetric 15% energy window of 208 keV at the same time points 
and with the same scan speeds as after the 111In-cG250 infusion. 
Blood samples were drawn directly, 30, 60, 120 minutes, 2-4 days and 5-7 days after 
the 111In-cG250 and 177Lu-cG250 infusions. The activity concentration in the serum from 
these samples was counted in a shielded 3-inch well-type gamma counter (Wizard, LKB/
Wallac, Perkin-Elmer, Boston, MA). To correct for radioactive decay, reference samples 
containing a known fraction of the administered activity were measured simultaneously. 
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The activity concentrations in the serum samples were corrected for the hematocrit con-
tent in the patient’s blood to obtain blood activity concentrations. 
Dosimetry 
The radiation absorbed dose to the whole body, liver, red marrow, lungs, heart, testes, 
normal kidney and metastases delivered by therapeutic 177Lu-cG250 injections were cal-
culated  according to the Medical Internal Radiation Dose (MIRD) scheme.21
Metastatic lesions measurable on CT and visualized in at least one of the scintigraphic 
images were analyzed. The volume   and background correction factor of the metastatic 
lesions were derived from CT imaging. Tumor volumes were converted to mass assuming 
that the tumor density equals 1 g/cm3. 
The residence times of the source organs and metastases were calculated using SPRIND, 
a software package for integrated data processing for internal dose assessment.6 Regions 
of interest (ROI) for source organs and tumors were drawn on both anterior and poste-
rior scintigraphic images. The counts within the ROI were corrected for attenuation and 
background contribution as described by Visser et al.6 The geometric mean was calcula-
ted and the data were integrated over time using the trapezoid method. After the last 
scan, SPRIND assumes only physical decay of the radionuclide in the source organs. To 
calculate the absorbed doses, residence times were imported into the software package 
OLINDA/EXM.22 Radiation absorbed doses to the whole body and organs of interest were 
calculated using the adult male and the adult female phantom. The spheres model was 
used to determine the radiation absorbed doses of the metastases.22
The red marrow absorbed dose was calculated using two methods. First, the absorbed 
dose to the red marrow was calculated using the scintigraphic images. In SPRIND, ROIs 
were drawn over the left and right part of the cranium. The residence times of the left 
and right cranium were summed and divided by the fraction of the red marrow mass in 
the cranium to the total red marrow mass in the body, for which the default value of 
0.119 was taken from ICRP23’s Reference Man.23 The second method was the blood-based 
method as described by Shen et al.5 This method was also implemented in SPRIND, for 
more information we refer to Visser et al.6
In the blood-based method the dose to the red marrow is composed of the dose from the red 
marrow to the red marrow (rm ← rm) and the dose from the whole body to the red marrow 
(rm ← wb). The electron contribution (rm ← rm) of the red marrow absorbed dose 
can be calculated in the absence of whole body planar scintigrams with the following 
equation.5
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Drm = red marrow absorbed dose due to electron-radiation [Gy]
Aadm = administered activity [Bq]
Δel  = mean electron energy emitted per nuclear transition [J]
Φel (rm ← rm) = absorbed fraction of electron radiation from red marrow to red marrow [-]
Rrm,bl  = red marrow to blood concentration ratio [-]
τbl  = residence time of the blood [s]
mbl  = total blood mass [kg] 
The fraction of the red marrow dose due to electron contribution was calculated for each 
patient to determine if an estimation of the red marrow dose can be made in the absence 
of scintigraphic images. An estimation of the red marrow dose, based on blood samples 
alone will have the advantage that whole body scintigrams can be cancelled. 
Predictive dosimetry 
Data obtained after the diagnostic 111In-cG250 infusion were used to estimate therapeu-
tic doses from 177Lu-cG250, assuming identical biodistribution and biological clearance 
of 111In-cG250 and 177Lu-cG250. Simulated 177Lu scans were generated by correcting the 
111In whole body scintigrams for the difference in physical decay of 111In and 177Lu. 
Each 111In-cG250 scintigram (anterior and posterior images) was pixel-wise multiplied 
by (t = time p.i.) to obtain simulated whole body scintigrams for 177Lu . 
The resulting simulated 177Lu scintigrams were used to calculate residence times with 
SPRIND and the simulated absorbed doses with OLINDA for the organs of interest and 
metastases.
The blood-based red marrow absorbed dose for 177Lu was also simulated. To simulate the 
blood residence time of 177Lu, 111In-cG250 blood data and reference samples were used 
to determine the biological clearance of activity from the blood, physical clearance was 
incorporated by multiplication with . 
To provide insight in the absorbed doses for radioimmunotherapy with 90y-cG250, the 
same methods were used to simulate 90y data.
Statistical analysis 
The Pearson correlation coeffi cient was determined to evaluate the relationship between 
(i) the image and blood-based method to calculate the red marrow dose (ii) the tumor 
mass and tumor absorbed dose and (iii) the calculated absorbed doses for 177Lu-cG250 
and the simulated data. Hematological toxicity was correlated with administered acti-
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vity, whole body dose, red marrow dose and the electron contribution of the red marrow 
dose. In addition the relationship between hematological toxicity and the simulated 
whole body and red marrow dose was determined. Because the red marrow is the dose li-
miting organ, tumor-to-red marrow dose ratios were determined to compare (simulated) 
177Lu-cG250 data with simulated 90y-cG250 data. 
RESulTS
Patients
All 20 patients completed at least one cycle of 111In/177Lu-cG250 radioimmunotherapy. In 
each patient only data from  the first treatment cycle were used for dosimetric analysis. 
DLT was noted in one patient at the 1850 MBq/m2 activity level. The other five patients 
that received this activity showed no DLT, so the administered activity was further in-
cremented. On the 2590 MBq/m2 activity level, DLT was seen in all 3 patients, therefore 
the administered activity was reduced to 2405 MBq/m2. This activity level proved to be 
safe in 6 patients (only 1 out of 6 patients had DLT) and by definition the latter dose 
was designated as the MTD.
Data 
The first treatment cycle was used to determine the absorbed dose in the organs of in-
terest and metastases after administration with 177Lu-cG250. The diagnostic 111In-cG250 
data of the first cycle were also used to evaluate the predictive value of the simulated 
177Lu-cG250 data and to calculate absorbed doses for radioimmunotherapy with 90y-
cG250. 
The 177Lu-cG250 data of two patients had to be excluded from the analysis due to in-
complete or inconsistent scintigraphic data. Another patient (patient 17) showed an 
unexpected high uptake in the liver and red marrow after injection of 177Lu-cG250 due 
to the presence of HACA or due to the presence of aggregates in the radiolabeled an-
tibody preparation. The dosimetric results of this patient were therefore excluded from 
the analysis. 
For the 177Lu-cG250 and 111In-cG250 data a total of respectively 40 and 48 metastases 
were used for tumor absorbed dose calculations. The weight of these tumors, determined 
on the CT images, ranged from 0.6 to 319 gram. 
A complete set of blood activity data was acquired from 15 (177Lu-cG250) and 16 (111In-
cG250) patients. These pharmacokinetic data were used to calculate the blood-based red 
marrow absorbed dose in these patients.
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TABLE 1 
Radiation absorbed dose in whole body, organs and metastases for 177Lu-cG250, simulated 177Lu-cG250 and 
simulated 90Y-cG250 (mGy/MBq) 
 
 177Lu-cG250   radioimmunotherapy 
simulated 177Lu-cG250 
radioimmunotherapy 
simulated 90Y-cG250 
radioimmunotherapy 
Organs Mean +/- SD Min Max Mean +/- SD Min Max Mean +/- SD Min Max 
Whole body 0.24  ± 0.04 0.19 0.36 0.25 ± 0.03 0.21 0.33 0.64 ± 0.08 0.57 0.82 
Liver 1.26 ± 0.25 0.93 1.75 1.22 ± 0.23 0.93 1.75 3.03 ± 0.63 2.27 4.49 
Heart wall 0.76 ± 0.16 0.47 1.12 0.68 ± 0.13 0.47 0.93 2.05 ± 0.38 1.41 2.69 
Red marrow          
Image-based 0.44 ± 0.07 0.32 0.62 0.41 ± 0.06 0.35 0.57 0.90 ± 0.11 0.78 1.11 
Blood-based 0.35 ± 0.07 0.24 0.46 0.31 ± 0.07 0.21 0.46 0.81 ± 0.21 0.47 1.23 
Kidney 1.30 ± 0.35 0.78 1.92 1.43 ± 0.49 0.76 2.57 3.77 ± 1.26 2.00 6.24 
Lungs 0.49 ± 0.13 0.34 0.74 0.48 ± 0.10 0.37 0.65 1.45 ± 0.35 1.06 2.08 
Testes 1.90 ± 0.45 1.20 2.70 1.64 ± 0.36 1.11 2.36 4.32 ± 0.99 2.84 6.26 
Metastases 5.72 ± 4.52 0.47 17.29 4.86 ± 4.69 0.52 19.92 9.76 ± 8.88 1.31 37.52 
 435 
 
 
 
TABLE 2 
Pearson correlation coefficients (and its two-tailed significance) between the toxicity grade and administered 440 
activity or absorbed dose calculations for 177Lu-cG250 and simulated 177Lu-cG250 (mGy). (RM = Red marrow, * 
correlation is significant at the 0.01 level, † correlation is significant at the 0.05 level). 
  177Lu-cG250  
  
Administered 
Activity [MBq] 
Total whole body 
dose 
Total RM dose 
(image-based) 
Total RM dose 
(blood-based) 
Electron 
contribution      
RM dose 
 
Pearson Correlation 0.85* 0.65* 0.62* 0.75* 0.76*  
Sig. (2-tailed) <0.001 0.005 0.007 0.001 0.001  
Thrombocyte 
toxicity  
N 20 17 17 15 15  
Pearson Correlation 0.66* 0.32 0.27 0.53† 0.56†  
Sig. (2-tailed) 0.001 0.214 0.287 0.043 0.029  
Leukocyte 
toxicity  
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177Lu-cG250 radiation doses
The estimated mean radiation absorbed doses after 177Lu-cG250 radioimmunotherapy 
were 0.24 ± 0.04 mGy/MBq for the whole body, 0.49 to 1.90 mGy/MBq for the healthy 
organs, 0.44 ± 0.07 mGy/MBq (image-based) and 0.35 ± 0.07 mGy/MBq (blood-based) 
for the red marrow (Table 1).
The results of the image- and blood-based method to calculate the red marrow absorbed 
dose, correlated significantly (r = 0.68, P = 0.005, Fig.1). Observed thrombocyte toxicity 
correlated significantly with the administered activity (r = 0.85), whole body dose (r = 
0.65) and image-and blood-derived red marrow dose (r = 0.62 and 0.75, respectively, 
Fig. 2). Leukocyte toxicity correlated significantly with the administered activity (r = 
0.66) and the blood-based red marrow dose (r = 0.53). However, there was no significant 
relationship between the leukocyte toxicity and the whole body dose or the image-based 
red marrow dose. The electron contribution was 61.6 – 77.3% (N = 15,   = 71.3%) of 
the blood-based red marrow dose. This part of the red marrow absorbed dose correlated 
significantly with the thrombocyte (r = 0.76) and leukocyte toxicity (r = 0.56). The cor-
relations are summarized in Table 2.
Absorbed doses to the tumor lesions varied widely from 0.47 to 17.29 mGy/MBq. The 
mean tumor-to-red marrow dose ratio for 177Lu-cG250 was 13.0 and 16.3 for respectively 
the image- and blood-based method. The total tumor dose during the first treatment 
cycle varied from 1.9 to 92.0 Gy. The radiation dose to the tumor lesions correlated in-
versely with the mass of the tumor lesions (r = -0.44, P < 0.005, Fig. 3). 
Figure 2. Platelet toxicity (grade according to CTC version 3.0) plotted against the red 
marrow dose based on the image-based method (r = 0.62, p = 0.07) and the blood-based 
method (r = 0.75, p = 0.01).
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117Lu-cG250
Table2. Pearson correlation coefficients (and its two-tailed significance) between the toxicity 
grade and administered activity or absorbed dose calculations for 177Lu-cG250 and simulated 
177Lu-cG250 (mGy). (RM = Red marrow, * correlation is significant at the 0.01 level, † correlation 
is significant at the 0.05 level).
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TABLE 1 
Radiation absorbed dose in whole body, organs and metastases for 177Lu-cG250, simulated 177Lu-cG250 and 
simulated 90Y-cG250 (mGy/MBq) 
 
 177Lu-cG250   radioimmunotherapy 
simulated 177Lu-cG250 
radioimmunotherapy 
simulated 90Y-cG250 
radioimmunotherapy 
Organs Mean +/- SD Min Max Mean +/- SD Min Max Mean +/- SD Min Max 
Whole body 0.24  ± 0.04 0.19 0.36 0.25 ± 0.03 0.21 0.33 0.64 ± 0.08 0.57 0.82 
Liver 1.26 ± 0.25 0.93 1.75 1.22 ± 0.23 0.93 1.75 3.03 ± 0.63 2.27 4.49 
Heart wall 0.76 ± 0.16 0.47 1.12 0.68 ± 0.13 0.47 0.93 2.05 ± 0.38 1.41 2.69 
Red marrow          
Image-based 0.44 ± 0.07 0.32 0.62 0.41 ± 0.06 0.35 0.57 0.90 ± 0.11 0.78 1.11 
Blood-based 0.35 ± 0.07 0.24 0.46 0.31 ± 0.07 0.21 0.46 0.81 ± 0.21 0.47 1.23 
Kidney 1.30 ± 0.35 0.78 1.92 1.43 ± 0.49 0.76 2.57 3.77 ± 1.26 2.00 6.24 
Lungs 0.49 ± 0.13 0.34 0.74 0.48 ± 0.10 0.37 0.65 1.45 ± 0.35 1.06 2.08 
Testes 1.90 ± 0.45 1.20 2.70 1.64 ± 0.36 1.11 2.36 4.32 ± 0.99 2.84 6.26 
Metastases 5.72 ± 4.52 0.47 17.29 4.86 ± 4.69 0.52 19.92 9.76 ± 8.88 1.31 37.52 
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FIGURE 3 Absorbed dose in the metastases for 177Lu-cG250 radioimmunotherapy plotted against the weight of 455 
metastatic lesions on logarithmic scales (r = -0.44, P < 0.005). The striped-line is the 95% confidence interval. 
 
 
FIGURE 4 Mean absorbed dose (± 1 SD) in the organs of interest, whole body and metastases for the 177Lu-
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Figure 3. Absorbed dose in the metastases for 177Lu-cG250 radi immunotherapy plotted against 
the weight of metastatic lesions on logarithmic scales (r = -0.44, P < 0.005). The striped-line is 
the 95% confidence interval.
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Simulated 177Lu-cG250 radiation doses 
The simulated 177Lu-cG250 absorbed doses for the whole body, organs and metastases, 
based on the diagnostic 111In-cG250 data are presented in Table 1. The calculated doses 
were similar to the doses as derived from the 177Lu-cG250 images (Figure 4). However, 
for the individual patient slight differences were found. For example, the largest diffe-
rences in calculated red marrow dose were -20.0% and 14.9% for the image-based me-
thod and -25.5% and 7.7% for the blood-based method. There is a significant correlation 
between the 177Lu-cG250 and simulated absorbed dose calculations for the whole body, 
liver, heart wall, red marrow, lungs, testes and metastases (r = 0.82-0.98, P < 0.001). In 
contrast, the calculated kidney absorbed dose of the simulated data in comparison to 
the 177Lu-cG250 data did not show any correlation (r = -0.28). 
Thrombocyte and leukocyte toxicity correlated significantly with the simulated whole 
body and red marrow (image-based) dose (r = 0.55-0.82, P < 0.05). In addition, throm-
bocyte toxicity correlated significantly with the blood-based red marrow dose (r = 0.65, 
P < 0.01). These correlations are summarized in Table 2. For the simulated 177Lu-cG250 
data the tumor-to-red marrow dose ratio was 11.9 (image-based) and 15.7 (blood-based).
Simulated 90y-cG250 radiation doses 
Simulated mean radiation absorbed doses for radioimmunotherapy with 90y-cG250 
were 0.64 mGy/MBq for the whole body, 1.45 to 4.32 mGy/MBq for the normal organs, 
0.90 mGy/MBq (image-based) and 0.81 mGy/MBq (blood-based) for the red marrow 
(Table 1). Radioimmunotherapy with 90y-cG250 resulted in a theoretical mean absorbed 
dose of 9.76 mGy/MBq to the metastases. The tumor-to-red marrow dose ratio for this 
simulated 90y-cG250 data was 10.8 and 12.0 for the image and blood-based method res-
pectively. Mean absorbed doses to the bone marrow (mGy/MBq) were approximately 2-3 
times as high as compared to the (simulated) 177Lu-cG250 data (Figure 4).  
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DISCuSSION
This study was designed to estimate the radiation absorbed doses to normal tissues 
and tumor lesions during radioimmunotherapy with 177Lu-cG250 in patients with ccRCC. 
Radiation-induced myelotoxicity was dose limiting in these patients. An accurate es-
timation of the red marrow dose is essential for reliable predictions of the maximum 
activity that can be administered safely. The radiation dose to the red marrow dose can 
be estimated based on the activity levels in the blood 5 as long as the radiolabeled an-
tibody does not bind specifically to the cells in the bone marrow. However, various other 
imaging methods to estimate the red marrow dose have been described.6-8 DeNardo et 
al. showed for example that an image-based method, unlike the blood-based method, 
was able to predict thrombocytopenia and leucopenia.7 In the present study both the 
blood-based method and an image-based method were used to estimate the red marrow 
dose. The calculated mean absorbed doses for both methods were in the same range, 
0.35 versus 0.44 mGy/MBq. In addition, there was a significant correlation between the 
red marrow dose calculated with both methods (r = 0.68, P = 0.005). The blood-based 
red marrow absorbed dose was 0.35 ± 0.07 mGy/MBq for 177Lu-cG250, which is somewhat 
higher than reported by Vallabhajosula et al. 10 for radioimmunotherapy with 177Lu-J591 
(0.32 ± 0.10 mGy/MBq). This slight difference in red marrow dose is in agreement with 
the difference in MTD: 2405 MBq/m2 for 177Lu-cG250 and 2590 MBq/m2 for 177Lu-J591.10
In this patient population the observed hematological toxicity ranged from grade 0 to 4. 
The relationship between hematological toxicity, the administered activity and the ab-
sorbed dose calculations (whole body, red marrow) were analyzed. Myelotoxicity, especi-
ally thrombocyte toxicity, correlated significantly with the administered activity, whole 
body dose and red marrow dose. The correlation between myelotoxicity and the blood-
based red marrow dose was higher in comparison to the image-based method. Therefore, 
in these patients, the blood-based method was a better predictor of myelotoxicity. 
In a series of previous radioimmunotherapy studies no correlations were found between 
radiation absorbed doses and myelotoxicity.7, 9, 12, 13 On the other hand, Divgi et al.14, 
showed a significant correlation between the whole-body absorbed dose and the hema-
tological toxicity after radioimmunotherapy with 131I-cG250. Juweid et al.15 described a 
significant correlation between the calculated red marrow dose and hematologic toxicity 
for radioimmunotherapy with a 131I-labeled anti-CEA antibody. Furthermore, Vallabha-
josula et al.10 showed that myelotoxicity correlated with the administered activity and 
red marrow absorbed dose for radioimmunotherapy with 177Lu-J591. Moreover, Vallabha-
josula et al.10 showed that the blood-based red marrow dose correlated best with the 
fractional decrease of thrombocytes. Similarly, in our study the blood-based red marrow 
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dose correlated best with the thrombocyte toxicity grade (r = 0.75). 
The red marrow absorbed dose during radioimmunotherapy consists of a dose due to 
emitted electrons and a dose due to emitted photons. For 177Lu-labeled cG250 the elec-
tron contribution accounted for approximately 71% of the red marrow dose. An esti-
mation of the red marrow dose can be made by calculating the electron contribution 
based on the blood data and subsequently add 29% for the photon contribution. In 
addition there was a significant correlation between the red marrow absorbed dose due 
to electron radiation and thrombocyte (r = 0.76) and leukocyte toxicity (r = 0.56). This 
indicates that in the absence of scintigraphic data, blood samples alone can be used to 
estimate the red marrow dose and predict myelotoxicity.
Normal organs receiving the highest absorbed doses were the liver, kidney and testes, 
with a mean dose of respectively 1.26, 1.30 and 1.90 mGy/MBq. This was 5.8 Gy, 6.0 Gy 
and 8.8 Gy at MTD, for a mean body surface area of 1.79 m2 24. The liver and kidney doses 
were well below the threshold for deterministic effects, which are respectively 30 Gy and 
23 Gy.25, 26 Based on experiments using external beam radiation therapy it was suggested 
that a fractionated dose ≥2 Gy to the testes could cause permanent infertility.27 This 
dose was exceeded for radioimmunotherapy with 177Lu-cG250, but fertility status of men 
in this study was not investigated.
To accurately estimate the tumor absorbed dose, the tumor specific volume and back-
ground correction factor were determined by CT. The total tumor dose varied widely 
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Figure 4. Mean absorbed dose (± 1 SD) in the organs of interest, whole body and metastases for 
the 177Lu-cG250,  simulated 177Lu- and 90y-cG250 data (RM = red marrow).
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from 0.47 to 17.3 mGy/MBq, mainly due to differences in uptake of the radiolabeled 
antibody in the lesions. In 17 of the 40 tumors 177Lu-cG250 activity was highest at the 
last scintigraphic acquisition, which means that there is a slow accumulation of radio-
labeled cG250 during 5-7 days. Because there were no scintigraphic data available after 
5-7 days p.i., the tumor absorbed dose might be slightly underestimated if only physical 
decay is taken into account. Conversely, an overestimation of the tumor dose could have 
occurred due to biological clearance of the radiolabel after the last imaging time point. 
As described in several other studies9, 11, 28, an inverse relationship between tumor dose 
and tumor mass was observed in this study. Tumor doses exceeding 50 Gy are considered 
to be required to achieve a therapeutic response in these patients.29 In this study only 
2 out of 40 tumor lesions received a tumor dose of > 50 Gy during the first treatment 
cycle. Twelve out of 40 tumors received a tumor dose > 25 Gy during the first cycle, sug-
gesting that for these tumors a tumor sterilizing dose can be reached during subsequent 
treatment cycles. 
Diagnostic 111In-cG250 data were used to predict therapeutic absorbed doses by cor-
recting scintigrams and blood activity data for the physical decay difference between 
the radionuclides. The simulated absorbed doses were compared with the standard ac-
quired absorbed doses for 177Lu-cG250. There was no significant difference between the 
mean absorbed doses for the simulated and measured 177Lu-cG250 data. In addition, the 
simulated absorbed dose correlated significantly with the absorbed dose after radioim-
munotherapy for the whole body, liver, heart wall, red marrow, lungs, testes and tumor 
lesions (r = 0.818-0.982, P < 0.001). Unfortunately, the calculated kidney absorbed dose 
for 177Lu-cG250 in comparison to the simulated data based on the 111In-cG250 data did 
not correlate. For an accurate simulation, the biodistribution of 111In-cG250 should be 
identical to the biodistribution of 177Lu-cG250 at all time points. Activity in the colon, 
overlapping the kidney region, limits the accuracy of the kidney absorbed dose measu-
rements. The distribution of activity in the colon is time dependent. However, not all 
scans were acquired at exactly the same time points, which resulted in a variation in 
calculated kidney doses for simulated and 177Lu-cG250 scintigrams. In this study it was 
shown that simulations, based on diagnostic data, can be used to predict the absorbed 
doses, but also to predict myelotoxicity, since the simulated whole body and red marrow 
absorbed dose correlated significantly with thrombocyte and leukocyte toxicity. These 
results provide tools for treatment planning, because a toxicity risk assessment can be 
made prior to radioimmunotherapy.
Another suitable radionuclide for radioimmunotherapy with cG250 is 90y.30 An advantage 
of 90y is the long range of the β-emissions which could overcome the intratumoral hete-
rogeneity of the antibody uptake. A disadvantage is the inability to reliably image the 
13054 Alexander proefschrift_01.indd   84 09-01-14   20:33
CHAPTER 4 85
90y activity distribution, due to the absence of γ-emissions. We showed that the 111In-
cG250 scintigrams and pharmacokinetic data could be used to accurately estimate the 
radiation doses after radioimmunotherapy with 177Lu-cG250. Therefore, it was assumed 
that 90y-cG250 absorbed doses can also be predicted based on the 111In-cG250 data. 
The calculated absorbed doses (mGy/MBq) for 90y-cG250 were approximately 2-3 times 
higher than for 177Lu-cG250. This is in the same range as described by Vallabhajosula 
et al.10 who reported a 3 times higher bone marrow dose for radioimmunotherapy with 
90y-J591 compared to 177Lu-J591. Considering the ratio of blood-based red marrow dose 
between 177Lu and simulated 90y found in the present study and assuming this is the 
main determinant of MTD, the anticipated MTD of 90y-cG250 radioimmunotherapy would 
be around 25-28 MBq/kg, which is substantially lower than that of 177Lu-cG50. A more 
relevant parameter to compare tumor doses of 90y and 177Lu-cG250 is the ratio between 
the tumor and red marrow dose, rather than the absolute doses to the tumor and the red 
marrow. The tumor-to-red marrow dose ratio was higher for (simulated) 177Lu-cG250 in 
comparison to 90y-cG250. The tumor absorbed dose depends on the accumulation of ra-
dioactive cG250. Due to the slow accumulation of cG250 in the metastases and a longer 
half-life of 177Lu, as compared to that of 90y, the radiation dose that can be guided to 
the tumor lesions is anticipated to be higher for radioimmunotherapy with 177Lu-cG250. 
CONCluSION
In patients with RCC, hematological toxicity, especially thrombocyte toxicity, after ra-
dioimmunotherapy with 177Lu-cG250 can be predicted on the basis of administered acti-
vity, whole body and red marrow dose. In the absence of whole body scintigrams, blood 
activity data alone can be used to estimate the red marrow dose and predict hemato-
logical toxicity. Diagnostic 111In-cG250 data can be used to predict absorbed doses for 
radioimmunotherapy with 177Lu-cG250 and 90y-cG250. In these patients treatment with 
177Lu-cG250 provides a higher tumor-to-red marrow dose ratio in comparison to treat-
ment with 90y-cG250. 
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abSTRaCT
Background
Clear cell renal cell cancer (ccRCC) prominently expresses vascular endothelial growth factor-A 
(VEGF-A), and new treatment strategies for RCC aim at inhibition of VEGF-VEGFR signaling. 
This study explores the ability of 111In-bevacizumab scintigraphy to depict RCC and to evaluate 
treatment response of neoadjuvant treatment with sorafenib, a VEGFR inhibitor. 
Methods
The ability to depict RCC with 111In-bevacizumab scintigraphy was tested in fourteen patients 
scheduled to undergo a tumor nephrectomy, of these nine RCC patients were treated in a neoad-
juvant setting with sorafenib 400 mg bid orally. In the latter group baseline and post treatment 
111In-bevacizumab scans were compared. The intratumoral distribution of 111In-bevacizumab 
was determined scintigraphically ex vivo in a 1-cm lamella of the resected tumorous kidney. 
Expression of  VEGF-A, GLUT-1, CAIX, alpha smooth muscle actin and Ki67 was determined by 
immunohistochemistry and compared to the local concentration of 111In-bevacizumab. Additio-
nally, the VEGF-A content in tumor samples was determined quantitatively by ELISA. 
Results
In all five non-neoadjuvant treated patients, preferential accumulation of 111In-bevacizumab 
was observed in the tumors. All ccRCC with enhanced 111In-bevacizumab targeting expressed 
high levels of VEGF-A. Treatment with sorafenib resulted in a significant decrease of 111In-
bevacizumab uptake in the tumor in the  patients with ccRCC (mean change -60.5%, range 
+1.5 to -90.1%). The decrease in uptake was due to destruction of the tumor neovasculature, 
whereas the VEGF-A expression remained intact. In the patient with papillary RCC limited up-
take without change after sorafenib was observed.
Conclusions
RCC lesions were clearly delineated with 111In-bevacizumab scintigraphy. Neoadjuvant treat-
ment with sorafenib resulted in a significant decrease of 111In-bevacizumab uptake in RCC. 
111In-bevacizumab scintigraphy can be an attractive biomarker for response and needs further 
study.
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INTRODuCTION 
Treatment options for patients with metastatic renal cell cancer (mRCC) have improved 
substantially in the past 5 years. Long mired in therapeutic nihilism because of chemo-
therapy resistance and modest effects of immunotherapy, recently multiple active agents 
with marked clinical effects have become available for mRCC. Knowledge of underlying 
molecular characteristics identified the vascular endothelial growth factor-A (VEGF-A) 
and the mammalian target of rapamycin (mTOR) pathways as fundamental to the biology 
of RCC. This biological insight provided a rationale for targeting these growth factor 
signaling pathways in RCC. Small molecules inhibiting the tyrosine kinase portion of the 
intracellular receptor for VEGF (VEGFR) have undergone extensive clinical testing. Two 
of these drugs, sunitinib and sorafenib, are now widely used in clinical practice. These 
agents inhibit not only VEGFR but also a broad spectrum of related receptor tyrosine 
kinases.
As the development of angiogenesis inhibitors was not paralleled by appropriate eva-
luation methods for this kind of drugs, new predictive biomarkers are urgently needed. 
Currently, CT-scans are mostly used to diagnose RCC and to evaluate treatment effects 
of TKIs. CT scans are volumetric assessments of tumors, and do not provide functional 
information. The Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, used 
to evaluate treatment response, are based on the sum of one-dimensional measurements 
of the greatest diameter of the tumor and/or metastases.(1), (2) However, treatment with 
TKIs can result in necrosis and cavitation without a change in size, leading to an unde-
restimation of  therapeutic efficacy.(3) Molecular imaging may be an alternative method 
to evaluate the efficacy of these new drugs. In clear cell RCC a loss of function of the 
Von Hippel-Lindau (VHL) gene product leads to accumulation of the hypoxia inducible 
factor 1α  (HIF-1α), with subsequent upregulation of HIF target genes, including vas-
cular endothelial growth factor (VEGF-A). (4), (5), (6) This is independent from hypoxia and 
results in highly vascularized tumors.  Therefore, molecular imaging of VEGF-A in ccRCC 
might be achieved and might provide functional information about the effects of TKI 
treatment.(4), (5), (6)
Bevacizumab-based scintigraphy may be an interesting approach to image VEGF-produ-
cing tumors.  Bevacizumab is a humanized monoclonal antibody (mAb) directed against 
all VEGF-A isoforms which inhibits angiogenesis by preventing VEGF-A from binding to 
and activating its receptors. VEGF-A is the best characterized member of the VEGF family 
and is considered the predominant and most critical regulator of neovascularization in 
various tumor types.(7) Alternative splicing results in at least six isoforms of VEGF-A: 
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VEGF121, VEGF145, VEGF165, VEGF183, VEGF189 and VEGF206. In tumors, VEGF121 and 
VEGF165, and to a lesser extent VEGF189, are predominant.(8), (9) VEGF165 and VEGF189 
are cell- or matrix-associated isoforms and are angiogenic, whereas VEGF121 is freely 
diffusible and mainly induces vasodilatation and vascular permeability.(10), (11), (8) Accumu-
lation of antibodies like bevacizumab in tumors is the result of multiple factors, such as 
antigen density, circulating antigen concentration, and tumor physiological parameters 
such as microvessel density, vessel permeability, blood flow and interstitial fluid pressu-
re. In two animal studies and in one clinical study tumor-specific accumulation of radio-
labeled bevacizumab has been described.(12), (13), (14) Remarkably, no correlation between 
VEGF-A levels in plasma or tumor tissue extracts and bevacizumab uptake was observed 
in a study in patients with metastatic colorectal cancer.(14) In this study, plasma VEGF-A 
was determined in a sample obtained just prior to labeled bevacizumab administration. 
The scintigraphy was performed one week after tracer administration. Tumor VEGF-A was 
determined directly after surgery, 10 days after tracer injection.
In the present study the potential of 111In-bevacizumab to image VEGF-A expressing 
ccRCC tumors was studied in 14 patients with primary RCC scheduled to undergo tu-
mornephrectomy. Nine of these patients were treated with sorafenib for 4 weeks in a 
neoadjuvant setting. The effect of sorafenib on 111In-bevacizumab uptake in RCC was 
explored in these patients.
 
METHODS aND MaTERIalS
Study design
Nine patients suspected of primary RCC and with baseline enhanced 111In-bevacizumab 
uptake in the renal tumors were treated with sorafenib for four weeks after which 111In-
bevacizumab scintigraphy was repeated to observe the effect of sorafenib on 111In-be-
vacizumab uptake. As a control, in five patients suspected of primary RCC and scheduled 
to undergo tumornephrectomy a 111In-bevacizumab scintigraphy was performed prior to 
surgery. 
Exclusion criteria for all patients were prior use of bevacizumab or drugs targeting VEGF 
or VEGFR, prior anticancer therapy, uncontrolled comorbidity, pregnancy and lactation. 
For the sorafenib treated group, adequate bone marrow (white blood cells (WBC) ≥  3.5 
x 109/L, platelets ≥ 100 x 109/L, Hemoglobin ≥ 6 mmol/L) renal (serum creatinine ≤ 2 x 
upper limit of normal (ULN) and hepatic function (total bilirubin ≤ 1.5 ULN, AST and ALT 
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≤2.5 x ULN (≤5 x in case of liver metastases) were required. The study was approved by the 
regional internal review board. Written informed consent was obtained from all patients. 
Study drug
Sorafenib (Nexavar®, Bayer, München, Germany) was administered 400 mg bid orally 
during four weeks prior to nephrectomy. Dose interruptions and dose reductions were 
allowed in case of Common Toxicity Criteria (CTC) ≥ grade 3 adverse events.
For scintigraphic imaging, bevacizumab (Avastin®, Roche, Basel, Switzerland) was 
conjugated with isothiocyanatobenzyldiethylenetriaminepentaacetic acid (DTPA) as 
described previously. (15) Kits containing 1 mg of bevacizumab-DTPA conjugate in 1.0 
ml of 0.15 M citrate buffer, pH 5.5, ready for radiolabeling were stored at -20 °C 
until use. The dose of 1 mg was selected for imaging because optimal accumulation 
in VEGF-A expressing tumors are obtained at relatively low antibody protein doses. 
(13) Upon referral of a patient, a kit was labeled with 100 MBq 111In (Covidien, Petten, 
The Netherlands). Radiochemical purity of all preparations used in this study exceeded 
95%, as determined by instant thin layer chromatography (ITLC). The immunoreactivity 
was assessed in an ELISA as described previously.(16)
Imaging
In the control group, ten days prior to nephrectomy, patients were intravenously 
injected with 1 mg  DTPA-conjugated bevacizumab labeled with 100 MBq 111In within 
one hour after preparation. A whole-body scan was acquired directly and 7 days after 
injection, using a double-headed gamma camera (E-Cam, Siemens Inc., Hoffman Es-
tates, IL, USA), equipped with parallel-hole medium-energy collimators (symmetric 
15% window over 172 and 247 keV), scan speed 8 cm/min (day 0) and 4 cm/min 
(day 7). This seven day interval was based on our previous work in which we ob-
served best tumor-to-background ratios in the scans that were acquired 7 days post 
injection.(17), (18) To allow quantification of antibody targeting to the tumor, a known 
aliquot of the injected dose in an Adams’ phantom was scanned simultaneously. 
Targeting of the radiolabeled mAb in tumor tissue was determined by comparing 
the accumulation of the radiolabeled antibody in the renal cell tumors to that in 
the contralateral kidney. In addition, the targeting of 111In-bevacizumab was sco-
red semi-quantitatively as described previously.(19) In brief, regions of interest were 
drawn around tumors and the normal kidney on the planar images. 111In-bevacizumab 
targeting was expressed as the percentage injected dose/tissue weight (as measured 
on baseline CT), assuming a tissue density of 1.0 g/ml.
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Patients underwent nephrectomy 10 days after 111In-bevacizumab administration. 
After tumornephrectomy, a 1-cm thick slice containing both normal kidney tissue 
and tumor tissue was obtained from the surgical specimen and distribution of the 
radiolabeled antibody in the slice was imaged for 45 minutes on the gamma camera 
after which the slice was cut into 1 cm3 cubicles. The radioactivity in each of the 
samples was quantified in a well-type gamma counter and thereafter tissue blocks 
were processed for immunohistochemical analysis.
In the sorafenib treated group, the same imaging procedures were used. Seven 
days prior to start of sorafenib treatment and after 21 days  of treatment 111In-
bevacizumab was administered, each time followed by a scintigraphy after 7 days. 
The sorafenib treatment was discontinued at the day of the last scan. The tumor 
nephrectomy was performed three days after stop of sorafenib treatment and the 
tissue was processed as mentioned above for the control patients (Figure 1.). 
After evaluation of the control group, the 111In-bevacizumab scintigraphy directly 
after administration of the labeled bevacizumab was no longer performed in the 
sorafenib treated group, because only the blood biodistribution was visualized at 
these early scans, providing no additional information but did, however, increase 
the burden to the patients.
Immunohistochemical analysis
Vessel density and VEGF-A expression was determined immunohistochemically in 4-µm 
formalin fixed and paraffin-embedded sections by staining with anti-CD31 (monoclonal 
antibody Jc70A, Dako, Glostrup, Denmark) and anti-VEGF monoclonal antibody G153-
694 (Pharmingen, San Diego, USA), respectively. An antibody against α-smooth muscle 
actin (α-SMA, Sigma, Zwijndrecht, The Netherlands) was used for the detection of pe-
ricytes as a measure of vessel maturation. To detect CAIX expression, the samples were 
stained with the anti-CAIX antibody G250 (Wilex AG, München, Germany). As a marker 
of proliferation Ki67 was stained (clone SP6, Lab Vision Corporation, Fremont, CA, USA). 
Expression of VEGF-A, CAIX and CD31 were scored semi-quantitatively on a scale ranging 
from undetectable (-), low (±), moderate (+), high (++) to very high (+++).
VEGF-A levels in tumor extracts
In the control group, 10 µm cryosections of each sample of the kidney slice were pooled 
in RIPA buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1% NP-40, 0.5% 
sodiumdeoxycholate) containing a protease inhibitors cocktail (Roche, Basel, Switzer-
land) and heparin (5 U/ml) to release matrix-bound isoforms of VEGF-A. Sections were 
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homogenized, incubated on ice for 20 minutes and centrifuged (800 g, 20 min, 4 °C) to 
prepare a clear lysate. The Bradford method (Biorad, Hercules, CA) was used to determine 
protein concentration. To measure VEGF-A, a four-antibody sandwich ELISA was used 
which detects all VEGF-A isoforms. (20) Data were expressed as ng VEGF/mg protein for 
each sample, therefore providing information about the VEGF-A levels in normal kidney 
tissue as well as in tumor samples. 
VEGF-A levels in plasma
In all patients blood samples were collected to determine circulating VEGF-A concen-
trations prior to injection of 111In-bevacizumab. In the sorafenib treated group, a blood 
sample was also taken after 21 days of treatment with sorafenib, prior to injection of 
the labeled bevacizumab. Plasma samples were stored at -80 °C within one hour after 
venipuncture. Plasma concentrations were measured with the four-antibody sandwich 
ELISA.(20) This ELISA measures the unbound VEGF in plasma, which is relevant for the 
formation of immune complexes with radiolabeled bevacizumab.
Statistics
In the control group, based on the Kolmogorov-Smirnov test and Shapiro-Wilk test, we 
used the non-parametric 2-tailed Spearman’s rho test to analyze the correlation between 
VEGF-A values and 111In-bevacizumab uptake per sample and in each tumor. In the so-
rafenib treated group, a non-parametric Wilcoxon signed-ranked test was performed to 
assess the change in 111In-bevacizumab uptake in the tumor before and after sorafenib 
treatment. A 2-tailed paired t-test on log transformed values was used to determine the 
change in VEGF plasma levels. A p-value < 0.05 was considered significant.
 
RESulTS
Patients
In the control group, pathological examination of the surgical specimens of all five 
patients (mean age 61 years; 3 male and 2 female) revealed ccRCC; in one speci-
men a sarcomatoid component was observed (patient 4). This patient also had pul-
monary metastases at presentation. One patient had a synchronous renal oncocytoma 
(patient 5). (Table 1) 
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Ten patients were included, one of whom was unevaluable as the tumor proved to be 
not an ccRCC but an oncocytoma. Nine ccRCC patients were treated with sorafenib (2 
females, 7 males, median age 61, range 45-78, all ECOG 0-1) after showing enhanced 
111In-Bevacizumab accumulation. Pathological examination identified 8 ccRCC and 1 pa-
pillary RCC (Table 1). Metastases, as assessed on a preoperative CT scan, were found in 
6 patients. Neoadjuvant treatment with sorafenib was safe and well tolerated, although 
3 patients needed a dose interruption and subsequent dose reduction (200 mg bid), be-
cause of grade 3 skin toxicity according to the common toxicity criteria adverse events 
(CTCAE) 3.0. No additional toxicities were noted after nephrectomy. 
Scintigraphic Imaging of RCC with 111In-bevacizumab 
Immediately after intravenous injection 111In-bevacizumab distributed in the vascular 
system and in well perfused organs such as the liver and spleen as judged by 111In-
bevacizumab images. The tumors were not visualized on these early images of any of 
the 14 patients. In all 14 patients, preferential accumulation of 111In-bevacizumab was 
observed in the tumors 7 days after the injection. 
The mean 111In-bevacizumab uptake in ccRCC calculated from the images was 0.015 % in-
jected dose per gram (%ID/g) tumor as quantified at the images (median 0.006 %ID/g, 
range 0.002-0.028 %ID/g). In patient 4 enhanced accumulation was also observed in 
the pulmonary metastases (Table 1). The scintigraphic images of this patient are shown 
in Fig. 2a. Patient 5, who had a synchronous ccRCC and renal oncocytoma showed only 
enhanced targeting of the ccRCC. The baseline uptake of 111In-bevacizumab in the papil-
lary RCC was relatively low as compared to the mean baseline uptake in the ccRCC tumors 
(0.003 vs. 0.019 %ID/g).
In all five control patients, preferential accumulation of 111In-bevacizumab in the tu-
morous regions was observed, as established by ex vivo scintigraphy of the 1-cm slice 
taken from the tumorous kidneys. Further quantification of 111In-bevacizumab uptake 
revealed that the antibody accumulated in areas of viable tumor tissue, while necrotic 
Figure 1. Treatment schedule sorafenib treated group.
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Figure 3. Anterior and posterior 111In-bevacizumab scintigraphy at baseline [A] and after four 
weeks of treatment with sorafenib [B]. Decrease of 111In-bevacizumab uptake, more enhanced in 
the central parts of the tumor.
Figure 2a. Anterior and posterior whole body images of patient 4: targeting ccRCC of the right 
kidney (large arrow) and pulmonary metastases (small arrows); B. Macroscopic picture of the 
slice of patient 4.
Figure 2b. Image of resection specimen showing enhanced VEGF-A targeting of 111In-bevaci-
zumab in the in the ccRCC part of the renal tumor (solid arrows), and decreased uptake in the 
sarcomatoid part, (dashed arrow) corresponding with the immunohistochemistry results which 
showed low vessel density in the sarcomatoid part which hampers 111In-bevacizumab delivery.
Imaging VEGF-A expression in clear cell renal cell carcinoma (ccRCC) 
with 111In-bevacizumab
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Figure 5. Immunohistochemical analyses. Neoadjuvant treatment with sorafenib results in 
enhanced necrosis (HE), decreased vessel density (CD31) with excessive loss of young immature 
vasculature (alpha-SMA). No changes in VEGF-A expression were observed.
HE; Haematoxylin and Eosin, alpha-SMA: α-smooth muscle actin, VEGF-A;
vascular endothelial growth factor A.
Figure 4. Image of the surgical specimen of patient 7, showing extensive necrosis in almost the 
whole tumor, except for the more vital borders in which VEGF-A targeting of 111In-bevacizumab is 
preserved.
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parts showed lower concentrations of the antibody.(Fig. 2b) The quantitative values 
and the measurements of the percentage of the injected dose per gram tumor tissue are 
summarized in Table 1. 
After treatment with sorafenib a significant reduction in 111In-bevacizumab accumulati-
on in the tumors was observed in seven patients with histologically proven ccRCC (mean 
0.019 %ID/g vs. 0.007 %ID/g, Table 1, Fig. 3). In one patient only the pretreatment 
scan was available due to technical problems at the time of the second scan. 111In-
bevacizumab targeting did not change in the patient with papillary RCC. In the ccRCC 
patients, a mean decrease of 111In-bevacizumab uptake of 60.5% was observed (median 
-46.2%, range +1.5% to -90.1%, p=0.011). The pattern of uptake of the 111In-labeled 
antibody in the tumor slices corresponded well with macroscopic discernable vital and 
necrotic areas in the tumor, with relatively high uptake in the vital areas and low uptake 
in the necrotic areas (Fig. 4). The overall tumor uptake as derived from the quantitative 
analysis of the images are shown in Table 1. Tumors resected from sorafenib treated 
patients contained much larger necrotic areas than tumors of similar size from untreated 
patients. Only one out of six sorafenib treated patients with metastases had pulmonary 
metastases larger than 1 cm and was therefore candidate for 111In-bevacizumab uptake 
evaluation in the metastasis. In this patient the uptake in the metastasis decreased from 
0.034 to 0.002 %ID/g tumor (reduction of >95%). 
Immunohistochemical analysis 
The results of the immunohistochemical analyses of the viable parts of the tumors are 
presented in Table 1 and Figure 5.
Control group: All ccRCC with enhanced 111In-bevacizumab accumulation stained positive 
for VEGF-A. The oncocytoma of patient 5, in which no accumulation of 111In-bevacizumab 
was found, contained minimal amounts of VEGF-A. High expression of VEGF-A was found 
in viable parts of the tumors, while more necrotic parts and normal kidney tissue only 
showed limited VEGF-A expression. CAIX expression was high in all viable ccRCC areas. 
The RCC tumors of patients 2-5 highly expressed CD31 on their vasculature, although not 
in the sarcomatoid dedifferentiated part of the tumor of patient 4.  Low CD31 expres-
sion, indicating low vessel density, was observed in the tumor of patient 1.
Sorafenib treated group: All treated tumors expressed VEGF-A. Notably, VEGF-A was also 
found in necrotic tumor parts. In general, the vessel density was low, as evidenced by 
low CD31 staining (Fig. 5) with a relatively large fraction of the remaining vessels lined 
with α-SMA positive cells (=mature vessels). The majority of these vessels showed an 
abnormal aspect with apoptotic cells. All ccRCC were CAIX positive, the papillary RCC was 
CAIX-negative. Cell proliferation, as judged by Ki67 staining, was low. (Table 1)
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VEGF analysis
Besides the VEGF staining, we also measured the concentration of VEGF-A in samples of the 
kidney slices from non-treated patients. The concentration of VEGF-A in these specimens 
ranged from 0.08-21.10 ng/mg protein (mean 3.67 ng/mg protein). In extracts containing at 
least 50% vital RCC as estimated on the H&E stained sections of each tumor sample, the mean 
VEGF-A concentration was 3.24 ng/mg protein (n=40, range 0.12-13.24 ng/mg protein) and in 
those extracts containing at least 75% vital tumor, the mean VEGF-A concentration was 3.12 
ng/mg protein (n=20, range 0.24-7.27 ng/mg protein). Interestingly, in extracts containing a 
maximum of 20% vital tumor, and thus with a high fraction of necrotic material (>80%), the 
mean VEGF-A concentration was higher: 5.11 ng/mg protein (n=47, range 0.12-21.10 ng/mg 
protein). Surprisingly, a negative correlation between the VEGF-A concentration in the tissue 
extract and the 111In-bevacizumab uptake in the tissue cubicles was found (n=89, Spearman ρ 
r -0.274, p=0.010). This negative correlation was even more significant in a subgroup-analysis 
when only extracts containing at least 75% viable tumor were analyzed (n=20, r=-0.565, 
p=0.009). In the samples containing a maximum of 20% viable tumor no correlation between 
VEGF concentration and 111In-bevacizumab uptake was found (n=47, r=-0.231, p=0.119). Ac-
cumulation of 111In-bevacizumab in within tumors was very heterogeneous and did not corre-
late with VEGF-A concentration of the same samples (r=0.185, p=0.095). In patients 1 and 4, 
a negative correlation was found, while patient 2 and 5 showed a positive correlation between 
VEGF-A concentration and 111In-bevacizumab concentration/accumulation. 
The mean VEGF plasma level in the control patients was 1.49 ng/ml (range 0.78-2.71 ng/ml). 
A significant increase in VEGF plasma levels was found after four weeks of treatment with so-
rafenib (mean 1.55 ng/ml vs. 2.02 ng/ml, p=0.026). There was no correlation between tumor 
and plasma VEGF-A levels.
DISCuSSION
In the present study, we show that 111In-bevacizumab preferentially accumulated in primary 
RCC and its metastases and that treatment with sorafenib resulted in a dramatic decrease in 
111In-bevacizumab accumulation, suggesting that sorafenib-induced (vascular) changes are 
reflected in the reduced accumulation of the radiolabeled antibody.
The reduced uptake of 111In-bevacizumab was not the consequence of reduced VEGF-A expres-
sion since VEGF-A expression in the RCC lesions was comparable (irrespective of treatment) 
as evidenced by the immunohistochemical analyses. It is likely that the destruction of the 
tumor vasculature resulted in decreased 111In-bevacizumab delivery and consequently decre-
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ased accumulation. We observed extensive necrosis in the tumors after treatment with sora-
fenib, which was more extensive than observed in untreated RCC tumors of similar size. The 
macroscopic pattern of viable and necrotic tissue regions corresponded with the intratumoral 
distribution of 111In-bevacizumab. Immunohistochemical analysis corroborated that the 
tumor vasculature was greatly altered after sorafenib treatment: a minimal presence of 
immature vessels was observed, as judged by CD31/α-SMA staining, and the remaining 
mature vessels were lined with apoptotic cells. In most tumors, the necrosis was located 
in the central part of the tumors, while the more vital tumor areas were in located at the 
tumor periphery. The uptake of 111In-bevacizumab in these vital parts of the tumor was not 
enhanced. There was a three day interval between the ending of sorafenib and the tumor 
nephrectomy. Therefore, the observed immunohistochemical changes might be not a true 
reflection of the treatment induced features during sorafenib. However, this interval is short 
and major changes within this interval are unlikely.
It is important to realize that vascular changes due to treatment with sorafenib are most li-
kely quite dynamic. A time dependent change in tumor vascularization during treatment with 
anti-angiogenic drugs, starting with normalization of the vasculature and ending with loss of 
vasculature and necrosis, has been described.(21) Tumor perfusion would increase temporarily 
with concomitant enhancement of 111In-bevacizumab uptake. However, at later stages, when 
necrosis prevails, perfusion is decreased and 111In-bevacizumab uptake will be reduced. Our 
results strongly suggest that after 4 weeks sorafenib treatment the latter scenario prevails, 
which was also the case with 125I-cG250 accumulation in a RCC mice model treated with 
several TKIs, including sorafenib.(22) Multityrosine kinase inhibitors can be given in two ap-
proaches: 1) as an anti-angiogenic drug and 2) as a signal transducer inhibitor, focused on 
optimization of the tumor microenvironment with sustained tumor vasculature normalization 
and reduced hypoxia in order to enhance combination therapy with for example chemothe-
rapy or radiotherapy.(23) The present study indicates that further investigations focusing on 
dosing and timing of (combined) treatment and imaging are warranted. 
It is interesting to speculate on the observed vascular changes resulting from sorafenib tre-
atment. Sorafenib treatment caused less effects on the more mature and larger tumor vessels. 
One could hypothesize that these remnant vessels play an important role in acquiring resis-
tance against sorafenib and other angiogenesis inhibitors. Furthermore, this might support 
sorafenib treatment at an earlier stage of disease, when more immature vessels are present. 
This  is currently under investigation in large adjuvant trials such as the SORCE trial.(24)
We found a negative correlation between VEGF-A expression and the 111In-bevacizumab con-
centration in tissue. For 111In-bevacizumab VEGF-A expression, circulating VEGF-A levels, 
bevacizumab concentrations and tumor delivery of bevacizumab are important parameters 
that also affect will determine the extent of tumor accumulation. The relatively low VEGF-A 
13054 Alexander proefschrift_01.indd   103 09-01-14   20:33
RADIOIMMUNODIAGNOSIS AND -THERAPy OF RENAL CELL CARCINOMA104
concentrations in samples with at least 75% vital tumor, combined with the high 111In-beva-
cizumab uptake in these samples, suggest that antigen expression is not the major parameter 
determining bevacizumab accumulation. Other factors, such as tumor vessel characteristics 
appear to be more important. In earlier studies we have shown that high antigen expression 
is a prerequisite for high antibody uptake, but that fulfillment of other conditions is equally 
pivotal to establish high antibody uptake.(25) The intratumoral heterogeneity, intrapatient 
differences and the lack of bevacizumab uptake in a benign VEGF-expressing oncocytoma 
support this notion. Vessel characteristics can influence 111In-bevacizumab uptake in two 
ways: nonspecific accumulation of antibodies due to enhanced vascular permeability, or 
insufficient delivery of antibodies due to poor vascularization. Studies in nude mice with 
human tumors did not demonstrate any accumulation  when an antigen blocking dose of 
antibody was co-administered, suggesting that accumulation of bevacizumab in the tumor 
was antigen-specific.(13), (12) Obviously, it is difficult to extrapolate results obtained in xeno-
grafted mice to patients with RCC. 
Two other explanations for the negative correlation between VEGF-A levels and uptake of 
111In-bevacizumab can be considered. First, one could hypothesize that the relatively low 
bevacizumab dose used in this study (1 mg) could be saturated by circulating VEGF-A (1.49 
ng/ml). However, this low antibody protein dose is still more than a 100-fold molar excess 
as compared to the VEGF concentration in plasma. This molar excess remains after sorafenib 
induced increases of plasma VEGF-A  (mean baseline 1.55 ng/ml vs. mean after sorafenib 
2.02 ng/ml). Only 1% of the administered bevacizumab activity could be complexed with 
plasma VEGF-A. We therefore did not examine immune complex formation.  Second, RCC is 
known to preferentially express VEGF189, VEGF165 and VEGF121.(26), (27) Bevacizumab binds 
all VEGF isoforms, but tumor accumulation of 111In-bevacizumab is mediated by the cell and 
matrix-bound VEGF-A isoforms; such as VEGF165 and VEGF189.(10), (11) In contrast, the ELISA 
used to determine VEGF content in the tumor tissue detects all isoforms of VEGF-A, since no 
isoform specific ELISA was available. Therefore, the freely diffusible VEGF121 can be a dis-
turbing factor. If vital RCC produce relatively high levels of VEGF121 while the VEGF165 and 
VEGF189 amounts are similar, then this would explain the negative correlation since wash 
out of immune complexes of bevacizumab and VEGF121 will occur. In the same way, when 
tumors have lower amounts of VEGF but with relatively high levels of VEGF165 and VEGF189, 
111In-bevacizumab uptake can be enhanced. The expression patterns of VEGF isoforms within 
RCC do differ and a relation with tumor histology, tumor growth or stage has been suggested.
(26), (27), (28), (29) 
The implementation of therapeutics targeting the VEGF pathway with their effects on tumor 
physiology, and the need for patient stratification, warrants imaging techniques that are 
able to determine VEGF expression in vivo and that provide functional information. 111In-be-
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vacizumab scintigraphy could provide functional information about the effect of neoadjuvant 
treatment with sorafenib in RCC. The next step will be the comparison of 111In-bevacizumab 
scintigraphy not only to conventional CT scans defining response with the RECIST criteria, 
but also to new approaches, for example incorporation of (modified) Choi criteria in RCC 
evaluations (30) or dynamic contrast enhanced MRI (DCE-MRI).(31) 
CONCluSION
In conclusion, 111In-bevacizumab scintigraphy is able to depict RCC lesions. Furthermore, 
neoadjuvant treatment with sorafenib significantly reduces accumulation of 111In-beva-
cizumab in RCC lesions. 111In-bevacizumab is an attractive biomarker for clinical response 
and needs further study. 
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abSTRaCT
Introduction
Monoclonal antibody (mAb) cG250 recognizes carbonic anhydrase IX (CAIX), overex-
pressed on clear cell renal cell carcinoma (ccRCC). 124I-cG250 is currently under clinical 
investigation for the detection of ccRCC. However, the 124I label is rapidly excreted 
from the tumour cells after internalization of the radiolabeled mAb. We hypothesized 
that labeling cG250 with the residualizing positron emitter 89Zr would lead to higher 
tumour uptake and more sensitive detection of ccRCC lesions.
Materials and methods
Nude mice with CAIX-expressing ccRCC xenografts (SK-RC-52 or NU-12) were i.v. 
injected with 89Zr-cG250 or 124I-cG250. To determine specificity of 89Zr-cG250 uptake 
in ccRCC, one control group was i.v. injected with 89Zr-MOPC21 (irrelevant mAb). PET 
images were acquired using a small animal PET camera and the biodistribution of the 
radiolabeled mAb was determined.
Results
The ccRCC xenografts were clearly visualized after injection of 89Zr-cG250 and 124I-
cG250. Tumour uptake of 89Zr-cG250 was significantly higher than that of 124I-cG250 
in the NU-12 tumour model (114.7 ± 25.2 % injected dose per gram (%ID/g) vs. 38.2 
± 18.3 %ID/g, p=0.029), but in the SK-RC-52 the difference in tumor uptake was not 
significant (48.7 ± 15.2 %ID/g vs. 32.0 ± 22.9 %ID/g, p=0.26). SK-RC-52 tumours 
were not visualized with 89Zr-MOPC21 (tumour uptake 3.0 %ID/g). Intraperitoneal  
SK-RC-52 lesions as small as 7 mm3 were visualized with 89Zr-cG250 PET.
Conclusion
ImmunoPET imaging with cG250 visualized s.c. and i.p. ccRCC lesions in murine mo-
dels. This confirms the potential of cG250 immunoPET in the diagnosis and (re)staging 
of ccRCC. PET imaging of ccRCC tumours with 89Zr-cG250 could be more sensitive than 
124I-cG250-PET.
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INTRODuCTION
Renal cell carcinoma (RCC) accounts for 2% of all malignancies and the current treatment 
for localized disease is tumour nephrectomy. When metastasized, prognosis is bleak with 
a median survival of 12 months (1). With the advent of targeted agents (e.g. sunitinib, 
sorafenib and temsirolimus), it is crucial to adequately diagnose and (re)stage RCC. 
Considering that a number of patients have long-lasting stable disease without treat-
ment, adequate timing of when to start these treatments is crucial, because considera-
ble toxicities are associated with the use of these targeted agents (2). The preoperative 
characterization of renal lesions suspect for RCC is difficult with the current radiological 
techniques. Moreover, since conventional radiological follow-up may not be adequate 
for response assessment of targeted agents (3), new techniques are warranted to assess 
biological tumour changes and hence predict the response to treatment.
The diagnosis and (re)staging of RCC is currently performed with conventional radio-
logical techniques, such as computed tomography (CT) or ultrasound. The diagnosis of 
primary RCC by FDG PET is hampered by the low FDG-avidity of RCC and the physiologic 
uptake in the normal kidneys due to the renal clearance of the tracer (4). FDG PET has 
been studied in a small number of patients for the detection and follow-up of RCC meta-
stases. Although a high specificity was reported, sensitivity was relatively low and FDG 
PET is now considered unsuited for staging of patients with RCC (4). 
Monoclonal antibody (mAb) cG250 has a high affinity for carbonic anhydrase IX (CAIX), 
a tumour-associated antigen ubiquitously expressed on clear cell RCC (ccRCC) (5). The use 
of cG250 in radioimmunoscintigraphy (RIS) and radioimmunotherapy (RIT) to detect or 
treat ccRCC has been investigated extensively (6-10). A few investigations have studied 
the capabilities of cG250-based immunoPET, i.e. combining the favorable characteristics 
of PET (high spatial resolution, three-dimensional (3D) imaging and accurate quantifica-
tion of tumour uptake) with the high and specific targeting of cG250 to CAIX-expressing 
cells (11-13). The relatively slow pharmacokinetics of i.v. injected radiolabeled mAbs (op-
timal tumour uptake after several days) prevents the use of the most commonly used 
positron emitters (11C and 18F) because their half-lives (20 and 110 min, respectively) 
are too short to be used in immunoPET. The half-lives of the positron emitters 89Zr (T½ 
= 78 h, mean β+ 397 keV (23% yield), γ 909 keV),  and 124I (T½ = 100 h, mean β+ 
824 keV (23% yield), γ 603 (63% yield) and 722/1691 keV (10% yield) do match the 
relatively slow kinetics of antibodies. In a prospective study by Divgi et al. 25 patients 
with suspect renal lesions scheduled for nephrectomy were studied with 124I-cG250. Of 
sixteen patients with pathologically confirmed ccRCC after surgery, 15 had a positive 
scan (tumour-to-normal kidney ratio ≥ 3:1). The failure in one patient was attributed 
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to technical problems with the labeled material. The study showed that 124I-cG250 could 
aid in the preoperative characterization of suspect renal masses and might guide crucial 
aspects of surgical RCC management (11). A large multicenter trial comparing conventio-
nal diagnostic CT to 124I-cG250 immunoPET/CT for the detection of ccRCC in 226 patients 
scheduled for nephrectomy showed a significantly higher rate of ccRCC detection with 
124I-cG250 immunoPET/CT over conventional CT (p=0.016) (14). 
We hypothesized that, due to its residualizing characteristics and favourable lower beta+ 
emission, labeling cG250 with 89Zr instead of 124I will lead to higher tumour uptake, 
higher tumour-to-background (T/B) ratios and higher PET resolution and hence more 
accurate detection of ccRCC lesions. 
Here, we studied the biodistribution of 89Zr-Df-cG250 and 124I-cG250 in nude mice with 
subcutaneous (s.c.) ccRCC xenografts. FDG PET was used as a reference in this study. The 
specific targeting of cG250 to ccRCC was assessed by comparing tumour uptake of 89Zr-
Df-cG250 and an irrelevant control mAb. The feasibility of 89Zr-immuno-PET with 89Zr-Df-
cG250 was studied in mice with intraperitoneally growing ccRCC tumours.
Materials and methods
Chimeric monoclonal antibody G250. The isolation and immunohistochemical reactivity 
of mAb G250 have been described elsewhere (15). To reduce the immunogenicity of the 
murine form of G250, a chimeric version (cG250) has been developed (10). MAb cG250 
IgG1 is reactive with the transmembrane glycoprotein carbonic anhydrase isoenzyme IX 
(Ka = 4 x 109 M-1). Expression on the cell surface of ccRCC cells is ubiquitous (>95%), 
whereas expression on normal tissues is restricted to the epithelial structures of the up-
per gastrointestinal tract and larger bile ducts (16).
Murine monoclonal antibody MOPC21. MOPC21 is a myeloma-produced murine IgG1 mAb 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) which is not directed against any known 
antigen and was used as an isotype control mAb to investigate the specificity of uptake 
of mAb cG250 in CAIX-positive ccRCC xenografts. 
Conjugation, radiolabeling and quality control. For 89Zr labeling, cG250 and MOPC21 were 
conjugated with desferal (Df) essentially as described previously (17). Briefly, desferal 
(Novartis Pharma AG, Bern, Switzerland) was succinylated, temporarily filled with Fe3+ 
and coupled to the mAb via the tetrafluorophenolester of Df. After the conjugation of Df 
to the mAb and removal of the Fe3+, the Df-conjugated mAb was labeled with 89Zr (IBA 
Pharma, Leuven, Belgium) during 30 minutes in 0.25 M HEPES buffer, at pH 7.3 at 37 ˚C. 
The 89Zr-Df-cG250 and 89Zr-Df-MOPC21 were purified on a PD10 column (Amersham Phar-
macia Biotech, Uppsala, Sweden), that was eluted with 0.9% NaCl, 5 mg/mL gentisic 
acid, pH 5.0. The specific activity of 89Zr-Df-cG250 was  0.41 MBq/µg or 0.54 MBq/µg. 
13054 Alexander proefschrift_01.indd   113 09-01-14   20:33
RADIOIMMUNODIAGNOSIS AND -THERAPy OF RENAL CELL CARCINOMA114
Radioiodination of cG250 with 124I (IBA Pharma, Leuven, Belgium) was performed accor-
ding to the Iodogen method (10). The 124I-cG250 was purified on a PD-10 column that was 
eluted with 0.5 M PBS. Specific activity of 124I-cG250 was 0.24 MBq/µg or 1.7 MBq/µg.
Labeling efficiency was between 55 and 70% (89Zr-Df-cG250/MOPC21) and between 73 
and 82% (124I-cG250). After purification, at the time of i.v. injection, instant thin layer 
chromatography showed a radiochemical purity of > 95% of all preparations used in 
the studies. The immunoreactive fraction at infinite antigen excess of all radiolabeled 
cG250 preparations was determined on freshly trypsinized SK-RC-52 RCC cells essentially 
as described by Lindmo et al. (18). The immunoreactive fraction of 89Zr-Df-cG250 was 
between 75% and 89% and the immunoreactive fractions of all 124I-cG250 preparations 
exceeded 83%.
RCC tumours in nude mice. The ccRCC cell lines SK-RC-52 (CAIX-positive) and SK-RC-59 
(CAIX-negative) were derived from metastases of primary ccRCC patients as described 
by Ebert et al (19). To induce s.c. tumours, 2-3.106 cells were injected subcutaneously in 
the flank of 6-8 weeks old male BALB/c nu/nu mice and tumours were established after 
2-3 weeks. To obtain intraperitoneally growing SK-RC-52 lesions, 2-3.106 SK-RC-52 cells 
were injected intraperitoneally and after 3 weeks multiple tumour nodules were found 
in the abdominal cavity. The ccRCC cell line NU-12 (CAIX-positive) was derived from a 
primary ccRCC (20) and tumours were noted 6-8 weeks after serial s.c. transplantation. 
Animals were housed and fed according to the Dutch animal welfare regulations. Ex-
periments were approved by the Institutional Animal Care and Use Committee of the 
Radboud University Nijmegen Medical Center, and were performed in accordance with 
their guidelines.
MicroPET imaging. Mice with s.c. SK-RC-52 tumours were i.v. injected with 12.3 MBq 
89Zr-Df-cG250/MOPC21 (30 µg) or 7.2 MBq 124I-cG250 (30 µg) (21). Mice with s.c. NU-12 
tumours were i.v. injected with 1.5 MBq 89Zr-Df-cG250 (3 µg) or 5.1 MBq 124I-cG250 (3 
µg) (21). Mice injected with FDG (IBA, Amsterdam, The Netherlands) received 10 MBq. PET 
images were acquired with a dedicated animal PET/CT scanner (Inveon, Siemens Precli-
nical Solutions, Knoxville, TN) with an intrinsic spatial resolution of 1.5 mm. Mice were 
placed in a prone (experiments 1 and 2) or supine (experiment 3) position in the scanner 
and body temperature was maintained at 37 °C using a warmed mattress (M2M imaging 
Inc, Cleveland, OH). Scans were reconstructed using Inveon Acquisition Workplace soft-
ware version 1.2 (Siemens Preclinical Solutions, Knoxville, TN). PET reconstruction was 
performed using an ordered subset expectation maximization-3D/maximum a posteriori 
(OSEM3D/MAP) algorithm (22). All animals were gas-anesthetized with a mixture of ni-
trous oxide/oxygen/isoflurane. Before intravenous injection of FDG, mice were fasted 6 
hours. Emission images after injection of FDG were acquired 1 h p.i. CT images were ac-
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quired with the same Inveon animal PET/CT scanner (80 kV, 500 µA, exposure time 300 
msec, 360° rotation in 180 steps, 0.5 mm aluminum filter). Scans were reconstructed 
using COBRA software version 6 (Exxim Computing Corporation, Pleasanton, USA). CT 
acquisition was performed 7 days after injection of 89Zr-Df-cG250, 89Zr-Df-MOPC21 and 
124I-cG250, or 1 h after injection of [18F]FDG. 
At the end of the experiments (1 h p.i. of FDG or 7 days p.i. of 89Zr-Df-cG250, 89Zr-Df-
MOPC21 and 124I-cG250) mice were euthanized and the biodistribution of the radiolabel 
was determined. Tumour and samples of normal tissues (blood, muscle, lung, spleen, 
kidney, liver, small intestine, stomach and thyroid) were dissected, weighed and coun-
ted in a γ-counter (1480 Wizard 3’’, LKB/Wallace, Perkin-Elmer, Boston, MA). Injection 
standards were counted simultaneously to correct for radioactive decay.
Biodistribution studies. Biodistribution of 89Zr-Df-cG250 and 124I-cG250 was studied in 
mice with either a s.c. SK-RC-52 or NU-12 tumour using FDG as reference. Six groups of 
mice were studied, with 3 groups bearing a s.c. SK-RC-52 tumour and 3 groups bearing 
a s.c. NU-12 tumour. Groups consisted of 6 mice and were injected with 89Zr-Df-cG250, 
124I-cG250 or FDG (1.5 – 12.3 MBq/mouse). 
The specificity of cG250-targeting to CAIX-expressing ccRCC tumours was evaluated in 
two groups of mice with a s.c. SK-RC-52 tumour (CAIX-positive) in the left flank and a 
s.c. SK-RC-59 tumour (CAIX-negative) in the  right flank. One group of mice received 89Zr-
Df-cG250 (12.3 MBq/mouse), the other group received 89Zr-Df-MOPC21 (12.3 MBq/mouse).
To determine immunoPET imaging of intraperitoneally growing ccRCC lesions 6 mice with 
i.p. SK-RC-52 tumours were injected with 89Zr-Df-cG250 (16.2 MBq/mouse).
Statistical analysis. Statistical analysis was performed using the non-parametric repeated 
measures one-way analysis of variance (ANOVA). Differences were considered significant 
when p < 0.05, two-sided. All values are expressed as mean ± standard deviation (s.d.).
 
Results
The biodistribution of 89Zr-Df-cG250 and 124I-cG250 7 days after injection in mice with 
CAIX-expressing ccRCC tumours is summarized in Figure  1. In the NU-12 tumour model 
tumour uptake of 89Zr-Df-cG250 was significantly higher than that of 124I-cG250 (114.7 
± 25.2 %ID/g vs. 38.2 ± 18.3 %ID/g, respectively, p=0.029) (Figure 1a), whereas in the 
SK-RC-52 tumour model uptake of 89Zr-Df-cG250 and 124I-cG250 was similar (48.7 ± 15.2 
%ID/g vs. 32.0 ± 22.9 %ID/g, respectively, p=0.257) (Figure 1b). When comparing the 
biodistribution of 89Zr-Df-cG250 with that of 124I-cG250, uptake of 89Zr-Df-cG250 was hi-
gher in liver (p<0.001) and spleen (p<0.001) and uptake of 124I was higher in the thyroid 
(p<0.001) in both models. Uptake of the two cG250 preparations in other organs did 
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not differ significantly. PET images of mice injected with 89Zr-Df-cG250 and 124I-cG250 is 
shown in Figure  2. Tumours were visualized from day 1 onwards with both radiolabe-
led antibody preparations and optimal image contrast was seen day 7 p.i. The physical 
characteristics of 124I caused more noisy and lower contrast images. Uptake of FDG in the 
NU-12 and SK-RC-52 tumours was relatively low (2.7 ± 0.5 %ID/g vs. 5.7 ± 3.9 %ID/g) 
and both tumours were not visualized on PET images since uptake in the tumor was similar to 
that in surrounding tissues (results not shown).
A
B 
Figure 1. 
Fig 1a.
Fig 1b.
Figure 1. Biodistribution of 89Zr-Df-cG250 and 124I-cG250 in mice with a s.c. NU-12 tumour 
(Figure 1a.) or a s.c. SK-RC-52 tumour (Figure 1b.), 7 days p.i. Values are expressed as mean 
± s.d. Antibody dosing was 3µg cG250/mouse in NU-12  and 30µg cG250/mouse in SK-RC-52 
tumours. Significant differences (p<0.05) in uptake between 89Zr-Df-cG250 and 124I-cG250 are 
marked with an asterisk*.
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The biodistribution of 89Zr-Df-cG250 and 89Zr-Df-MOPC21 7 days p.i. were compared to deter-
mine the specificity of cG250 localization in CAIX-positive tumours (Figure  3a). Uptake of 
89Zr-Df-cG250 in the CAIX-positive SK-RC-52 tumour was high (36.5 ± 6.2 %ID/g), whereas 
the uptake was significantly lower in the CAIX-negative SK-RC-59 tumour (6.7 ± 1.4 %ID/g, 
p=0.029). Uptake of 89Zr-Df-cG250 and 89Zr-Df-MOPC21 differed significantly in the CAIX-po-
sitive SK-RC-52 tumour (36.5 ± 6.2 %ID/g vs. 6.8 ± 2.3 %ID/g, p=0.010), indicating that 
the uptake of 89Zr-Df-cG250 in the CAIX-positive tumour was due to the affinity of the cG250 
      A	  
 
 
      B 
 
Figure 2. 
Fig 2a.
Fig 2b.
Figure 2. 3D reconstructed PET images of representative mice with a s.c. NU-12 tumour on the 
right flank 0, 1 and 4 days after injection and fused PET/CT images after 7 days of 89Zr-Df-cG250 
(Figure 2a.) or 124I-cG250 (Figure 2b.). Antibody dosing was 3µg cG250/mouse. Note the 
clear visualization of the s.c. tumour (green arrows) from day 1 p.i. onwards with both radio-
labeled mAbs.
Day 0 Day 1 Day 4 Day 7
Day 0 Day 1 Day 4 Day 7
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Figure 5.  
Fig 3a. 
Biodistribution 89Zr-cG250/MOPC21 in SK-RC-59 tumor
Fig 3b.
Figure 3. Biodist ibution 7 days after injection of 89Zr-Df-cG250 or 89Zr-Df-MOPC21 in mice with 
a s.c. SK-RC-52 tumour and a s.c. SK-RC-59 tumour (Figure 3a.). Values are expressed as mean ± 
s.d. Antibody dosing was 30µg cG250/mouse
3D reconstructed PET/CT images 7 days p.i. 89Zr-Df-cG250 (Figure 3b.) or 89Zr-Df-MOPC21 
(Figure 5c.) in representative mice with a s.c. SK-RC-52 tumour on the left flank and a s.c. SK-
RC-59 tumour on the right flank. Note the high uptake of 89Zr-Df-cG250 in the SK-RC-52 tumour 
(green arrow), which is not seen in the SK-RC-59 tumour (red arrow). No specific uptake in both 
tumours is noted after injection with 89Zr-Df-MOPC21.
Fig 3c.
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antibody for CAIX. PET images of mice with s.c. SK-RC-52 and SK-RC-59 tumours injected with 
89Zr-Df-MOPC21 or 89Zr-Df-cG250 are shown in Figure  3b. The CAIX-positive SK-RC-52 tumour 
was clearly visualized with 89Zr-Df-cG250 on day 7 p.i. The CAIX-negative SK-RC-59 tumour was 
not visualized with 89Zr-Df-cG250. None of the s.c. tumours was visualized with the irrelevant 
mAb 89Zr-Df-MOPC21. These results demonstrate the specifi c localization of 89Zr-Df-cG250 in 
CAIX-positive tumours.
Intraperitoneally growing SK-RC-52 tumours were clearly visualized 7 days after injection of 
89Zr-Df-cG250 as shown in Figure  4. Tumour lesions as small as 7 mg in the vicinity of the 
liver and spleen were clearly visualized and uptake in individual lesions was as high as up to 
95.9 %ID/g. All tumour lesions that were identifi ed with PET were identifi ed during dissection.
 
  
 
Figure 6.  
 
95.9	  %ID/g,	  16	  mg	  
59.4	  %ID/g,	  7	  mg	  
Figure 4. Upper panels: coronal and sagital sections of a 3D reconstructed PET/CT image 7 days 
after injection of 89Zr-Df-cG250 (left) and anatomical localization of an SK-RC-52 lesion (green 
circles) upon dissection with an uptake of 95.9 %ID/g, weight 16 mg (right). Lower image: 
localization of another SK-RC-52 lesion (yellow circles) with 59.4 %ID/g uptake, weight 7 mg. 
Antibody dosing was 30µg cG250/mouse.
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DISCuSSION
The biodistribution profiles of 89Zr-Df-cG250 and 124I-cG250 in nude mice with s.c. ccRCC xe-
nografts were compared to determine the optimal radionuclide for immunoPET with cG250. In 
both CAIX-positive ccRCC xenografts uptake of 89Zr-Df-cG250 was higher than uptake of 124I-
cG250 7 days after injection of the radiolabeled mAbs, albeit this difference was only statisti-
cally significant in the NU-12 tumour model. In this study, mice were not stratified to groups 
according to size of the tumour xenograft. The group bearing a SK-RC-52 xenograft injected 
with 124I-cG250 consisted of mice with large differences in tumour size (results not shown), evi-
denced by the large standard deviation in tumour uptake of this group. This could explain why 
uptake of 89Zr-Df-cG250 was not significantly higher than 124I-cG250 in the SK-RC-52 tumour 
model. PET images acquired with a dedicated small animal PET camera showed preferential tu-
mour uptake of both radiolabeled mAbs from day 1 p.i. onwards and image contrast improved 
with time. The images obtained with 89Zr-Df-cG250 had less noise and higher contrast, allowing 
for more specific detection of ccRCC lesions with 89Zr-Df-cG250 as compared to 124I-cG250. The 
brightness and contrast settings of the 89Zr-Df-cG250-images in Figure 2 have been chosen 
specifically to show the uptake in the liver for anatomical reference. Moreover, since uptake of 
89Zr-Df-cG250 in ccRCC lesions was higher than that of 124I-cG250, immunoPET imaging of ccRCC 
with 89Zr-Df-cG250 in these models was superior to immunoPET with 124I-cG250. 
The enhanced uptake of 89Zr-Df-cG250 as compared to 124I-cG250 in the NU-12 ccRCC tumour 
model is most likely due to the residualizing properties of the 89Zr radiolabel. Internalized 
radiolabeled antibody is metabolized in the tumor cell lysosomes and the 124I-labeled meta-
bolite (124I-tyrosine) is rapidly excreted from the tumor cell, whereas the metabolite labeled 
with metallic radionuclides, such as 111In, 89Zr and 177Lu, is trapped in the lysosomes (23-25). This 
phenomenon has also been described in a clinical intrapatient comparison study examining 
the differences between 131I-cG250 and 111In-cG250. Five mRCC patients were injected with 
131I-cG250 and 111In-cG250 one week apart. Uptake of 111In-cG250 in ccRCC tumour lesions was 
higher than that of 131I-cG250, which was attributed to the intracellular entrapment of interna-
lized 111In-cG250 metabolites (7). This could also explain the higher liver and spleen uptake of 
89Zr-Df-cG250 as compared to that of 124I-cG250 (26;27). 
FDG PET has a poor sensitivity for detecting RCC lesions mainly due to the fact that many RCC 
lesions are not FDG-avid (4). This was also observed in the present study: none of the CAIX-
positive ccRCC xenografts were visualized by FDG PET, since uptake of FDG was similar to that 
in surrounding tissues. In an earlier study, FDG failed to visualize ccRCC xenografts in nude rats 
(12). ImmunoPET with cG250 could therefore be of value as a functional imaging technique to 
detect ccRCC lesions.
The high tumour uptake of 89Zr-Df-cG250 and 124I-cG250 was the result of specific uptake of 
13054 Alexander proefschrift_01.indd   120 09-01-14   20:33
CHAPTER 6 121
cG250 in the CAIX-positive tumours. The irrelevant mAb 89Zr-Df-MOPC21 did not accumulate 
in the CAIX-positive tumour SK-RC-52, demonstrating that accretion was not the consequence 
of aberrant tumour perfusion, but antigen-driven. 89Zr-Df-cG250 accumulated in the CAIX-po-
sitive tumour, but not in the CAIX-negative tumour, further demonstrating that accretion was 
antigen-driven.
ImmunoPET with cG250 is well suited for imaging ccRCC in patients since PET has the advan-
tage of producing 3D images with a much higher resolution than planar scintigraphy or single 
photon emission computed tomography (SPECT). This is illustrated by the very sensitive de-
tection of ccRCC lesions with a dedicated small animal PET camera. Intraperitoneal lesions as 
small as 7 mm3 were visualized with 89Zr-Df-cG250 and could easily be discriminated from the 
liver and spleen. Preoperative characterization of renal masses with cG250 immuno-PET might 
be useful in the clinical management of RCC patients (11). The results from this study suggest 
that immunoPET in RCC patients may be improved by using 89Zr-Df-cG250 instead of 124I-cG250.
CONCluSIONS
Our results indicate that uptake of 89Zr-Df-cG250 in ccRCC xenografts was higher than uptake 
of 124I-cG250. The higher specific uptake of 89Zr-Df-cG250 produced higher PET image contrast, 
despite higher uptake in various normal tissues, such as the liver and spleen. PET imaging of 
ccRCC tumours with 89Zr-cG250 could be more sensitive than 124I-cG250-PET. Small intraperi-
toneal ccRCC lesions could be visualized and easily discriminated from the liver and the spleen 
with cG250-based immunoPET.
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abSTRaCT
Background
Near-infrared dye tagged antibodies can be used for sensitive detection of tumor tissue in 
vivo. Surgery for clear cell renal cell carcinoma (ccRCC) could potentially benefit from optical 
imaging by facilitating intra-operative detection of Carbonic Anhydrase IX (CAIX) expressing 
tumor lesions with chimeric monoclonal antibody (mAb) girentuximab that has shown excel-
lent imaging capabilities for ccRCC. Here we studied the potential to detect ccRCC tumors with 
fluorescence imaging in nude mice with RCC xenografts using mAb girentuximab conjugated 
with IRDye800CW, using SPECT imaging as a reference.
Methods
Groups of athymic BALB/c mice with s.c. CAIX-positive SK-RC-52 RCC tumors were i.v. injec-
ted with 125I-labeled girentuximab-IRDye800CW or 125I-labeled girentuximab. To determine the 
specificity of the accumulation of the anti-CAIX antibody conjugate in ccRCC, a separate group 
of mice bearing a CAIX-positive SK-RC-52 and CAIX-negative tumor (SK-RC-59) received 125I-
girentuximab-IRDye800CW or 125I-labeled MOPC21-IRDye800CW (control mAb). 
Optical images and microSPECT images were acquired until 3 days p.i. Mice were euthanized 
after the last imaging session and the biodistribution of the radiolabeled antibodies prepara-
tions was determined.
Results
Optical and SPECT imaging one day after injection of 125I-girentuximab-IRDye800CW showed 
clear delineation of the CAIX-expressing ccRCC xenografts and image contrast improved with 
time. Fluorescence imaging and biodistribution studies showed high and specific uptake of 
125I-girentuximab-IRDye800CW in CAIX-positive ccRCC xenografts (SK-RC-52: 31.5 ± 9.6 %ID/g 
at 72 hours p.i.). Tumor uptake was specific, since very low uptake of 125I-girentuximab-IR-
Dye800CW was noted in the CAIX-negative SK-RC-59 tumor (4.1 ± 1.5 %ID/g) and no uptake 
of the control mAb 125I-MOPC21-IRDye800CW was noted in the CAIX-positive SK-RC-52 tumor 
(1.2 ± 0.1 %ID/g).
Conclusion
Subcutaneous CAIX-expressing ccRCC xenografts can be visualized with optical imaging using 
125I-girentuximab-IRDye800CW. Optical images showed good concordance with the microSPECT 
images. The accumulation of 125I-girentuximab-IRDye800CW in ccRCC tumors was high and spe-
cific. Potentially, girentuximab-IRDye800CW could be used for intraoperative detection CAIX-
expressing tumors, assessment of residual tumor in the resection margins and/or metastatic 
lymph nodes in ccRCC patients. 
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INTRODuCTION
Renal cell carcinoma (RCC) accounts for approximately 2% of all malignancies 1. Surgi-
cal resection is usually the first choice for localized disease, but when metastasized, 
prognosis is bleak. Due to the increased use of conventional radiological modalities like 
computed tomography (CT) and ultrasound (US), RCCs are found more frequently and at 
earlier stages of the disease 2. The recommended treatment for localized RCC depends 
on tumor size. Nephron-sparing surgery is performed in case of smaller RCCs (especially 
≤ 4 cm diameter) 3, as overall survival data of T1-T3 tumors are comparable for partial 
and radical nephrectomy 4. Negative surgical resection margins are crucial for the clinical 
outcome, preventing additional surgical interventions 5. Adequate characterization and 
resection of the renal tumor and metastatic lymph nodes is therefore of utmost impor-
tance.
The use of near-infrared (NIR) imaging probes for improved tumor characterization and 
delineation during surgery is increasing, although clinical application has been limited 
so far. Potentially, the sensitivity of NIR imaging is extremely high, and because of the 
low tissue autofluorescence in this part of the light spectrum, the use of NIR imaging 
probes could yield optimal visualization of tissues of interest. Unfortunately, the pe-
netration depth of the emitted light of these agents is limited, hampering whole body 
applications 6. 
Fluorescent agent IRDye800CW is a typical example of a NIR dye and emits near infrared 
789 nm photons when excitated at 774 nm. IRDye800CW can be coupled to targeting 
molecules, such as peptides or monoclonal antibodies (mAbs) and can be detected with 
a NIR imaging camera. 
For clear cell renal cell carcinoma (ccRCC), the most common subtype of RCC which is 
present in approximately 85 percent of the patients presenting with a malignant renal 
tumor, chimeric mAb girentuximab (also known as cG250) could serve as a such a tar-
geting molecule. Girentuximab specifically recognizes carbonic anhydrase IX (CAIX), a 
tumor-associated antigen ubiquitously expressed in ccRCC. The use of girentuximab in 
radioimmunoscintigraphy (RIS) and radioimmunotherapy (RIT) to detect or treat ccRCC 
has been investigated extensively (for review see 7, 8). Because of the high and specific 
targeting and accumulation of girentuximab in ccRCC tumors, we hypothesized that this 
antibody could also act as a carrier for the delivery of IRDye800CW in these tumors. 
When girentuximab-IRDye800CW is administered intravenously before (partial) nephrec-
tomy, sensitive, in vivo, intra-operative detection of positive resection margins, meta-
static lymph nodes or distant ccRCC metastases might be feasible.
Here, we characterized girentuximab-IRDye800CW in a subcutaneous (s.c.) mouse model. 
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The antibody-IRDye800CW conjugate was radiolabeled to quantitatively determine the bio-
distribution. Studies were conducted to demonstrate tumor-specific and antigen-mediated 
uptake of the girentuximab-IRDye800CW conjugate. In addition, tumor targeting and biodis-
tribution of the conjugate was compared with that of unconjugated radiolabeled girentuxi-
mab. This NIR-imaging system could potentially be used intraoperatively to enhance tumor 
visualization and resection in the near future.
MaTERIalS aND METHODS
RCC tumors in nude mice 
Cell lines
The ccRCC cell lines SK-RC-52 (CAIX-positive) and SK-RC-59 (CAIX-negative) were derived 
from metastases of primary ccRCC patients as described by Ebert et al 9. Cells were cultured 
and washed as described previously 10. 
Animal model
The animal experiments were approved by the internal review board of the Radboud Uni-
versity Nijmegen Medical Center, and were performed in accordance with their guidelines. 
Animals were housed and fed according to the Dutch animal welfare regulations. To obtain 
s.c. tumors, 2-3x106 cells were injected s.c. into the flank of 6-8 weeks old male BALB/c nu/
nu mice (Janvier, Cedex, FR) and tumors grew to a size of 50-200 mm3 within 2-3 weeks. 
Imaging agents and labeling
Monoclonal antibody girentuximab
The isolation and immunohistochemical reactivity of mAb G250 have been described else-
where 11. To reduce the immunogenicity of murine G250 in humans, a chimeric version (giren-
tuximab) has been developed 12. mAb girentuximab is reactive with the transmembraneous 
glycoprotein CAIX (Ka = 4 x 109 M-1). Expression of CAIX on the cell surface of ccRCC cells 
is ubiquitous (>95%), whereas expression on normal tissues is restricted to the epithelial 
structures of the upper gastrointestinal tract and larger bile ducts 13, 14. 
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Monoclonal antibody MOPC21
MOPC21 is a murine IgG1 mAb (Sigma-Aldrich, Zwijndrecht, The Netherlands) which is 
not directed against any known antigen and was used as a nonspecific control mAb in 
these studies. 
Conjugation, radiolabeling and quality control 
Conjugation of mAb girentuximab and MOPC21 with IRDye800CW-NHS (LICOR bioscien-
ces, Lincoln, NE) was performed according to the supplier’s protocol. One mg mAb was 
incubated with 0.03 mg IRDye800CW for 2 h at room temperature in 1 ml 10 mM phosp-
hate buffer at pH 8.5. The reaction mixture was transferred into a Slide-A-Lyzer cassette 
(molecular weight cut-off: 10,000 Da,  Pierce, Rockford, IL) and extensively dialysed 
against PBS for three days to remove the unconjugated IRDye800CW.  On average 1.6 
IRDye800CW molecules were conjugated per mAb molecule as determined spectropho-
tometrically. The concentration of the conjugate was adjusted to 1 mg/ml and aliquots 
were stored in the dark at -20 ˚C until use. Girentuximab and girentuximab-IRDye800CW 
were radioiodinated with 125I (Perkin Elmer, Groningen, The Netherlands) according to 
the Iodogen method 12. The 125I-girentuximab was purified by gel filtration on a PD10 
column eluted with PBS containing 0.5% BSA. Specific activity of  125I-girentuximab and 
125I-girentuximab-IRDye800CW was 4.0 and 7.8 MBq/µg, respectively.
The radiochemical purity of the radiolabeled mAb preparations was determined by in-
stant thin layer chromatography (ITLC), using ITLC silica gel strips (Biodex Medical Sys-
tems, Shirley, Ny), and 0.1 M of citrate buffer pH 5.0 as the mobile phase. Labeling effi-
ciency exceeded 90% for all antibody preparations. After purification by gel filtration on 
a PD10 column, the radiochemical purity of all preparations used in the studies exceeded 
95%. The immunoreactive fraction of all radiolabeled girentuximab preparations, as de-
termined on freshly trypsinized SK-RC-52 ccRCC cells essentially as described by Lindmo 
et al. 15, was ≥ 79% for 125I-girentuximab and ≥ 67% for 125I-girentuximab-IRDye800CW .
Optical imaging and microSPECT imaging
Images were recorded at 1 h, 1 day, and 3 days after i.v. mAb injection. Optical images 
were acquired with the IVIS Lumina imaging system (recording time 1-3 min; binning 
factor 4; emission filter ICG; FOV 12.5; excitation filter 745 nm) (Caliper life sciences, 
Hopkinton, MA). Mice were placed in a prone position in the scanner and body tem-
perature was maintained at 37 °C with a heated imaging stage. All animals were gas-
anesthetized with a mixture of oxygen, N2O, and isoflurane. MicroSPECT images were 
acquired with a U-SPECT II (MILabs, Utrecht, The Netherlands) microSPECT scanner using 
the GP-RM 1.0 mm diameter pinhole collimator tube. SPECT images were reconstructed 
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with OSEM (6 iterations, 16 subsets, voxel size 0.1875 mm) using the U-SPECT-Rec soft-
ware (MILabs, Utrecht, The Netherlands). 
Study design
To study changes in girentuximab biodistribution as a result of the conjugation of the 
mAb to IRDye800CW was assessed in two groups of five mice. Mice with a s.c. SK-RC-52 
tumor were injected with either 125I labeled girentuximab-IRDye800CW or unconjugated 
125I-girentuximab. Both groups were studied with microSPECT imaging, and the 125I-
girentuximab-IRDye800CW group was also studied with optical imaging. Biodistribution 
studies were performed in both groups.
To determine if tumor targeting of the girentuximab constructs was CAIX-antigen medi-
ated, two groups of six mice with a s.c. CAIX-positive tumor (SK-RC-52) in the left flank 
and a s.c. CAIX-negative tumor (SK-RC-59) in the right flank were used. One group of 
mice received 125I-girentuximab-IRDye800CW and the other group received the nonspe-
cific 125I-MOPC21-IRDye800CW. Both groups were studied with optical imaging as well as 
microSPECT imaging and biodistribution studies were performed.
To evaluate the specificity of girentuximab targeting to CAIX-expressing ccRCC tumors 
was studied in an additional group of five SK-RC-52 bearing mice. These mice were 
co-injected with 125I-girentuximab-IRDye800CW and an excess (500 µg) of unlabeled 
girentuximab. Again, optical imaging as well as microSPECT imaging and biodistribution 
studies were performed.
Biodistribution studies
After the last images were acquired (three days p.i.), mice were euthanized, and the 
biodistribution of the radiolabel was determined. Tumors and samples of normal tissues 
(blood, muscle, lung, spleen, kidney, liver, small intestine, and stomach) were dissec-
ted, weighed and counted in a γ-counter (1480 Wizard 3’’, LKB/Wallace, Perkin-Elmer, 
Boston, MA). Results of the biodistribution are given as percentage of the injected dose 
per gram tissue (%ID/g). The thyroid was also dissected and counted, and results of 
this organ were expressed as percentage of the injected dose (%ID). Injection standards 
were counted simultaneously to correct for radioactive decay. 
Statistical analysis
Statistical analysis was performed using t-tests. Differences were considered significant 
at p<0.05, two-sided. All values are expressed as mean ± standard deviation (SD).
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FIGURE 1 
A: MicroSPECT images of a mouse bearing a SK-RC-52 tumor on the right flank (indicated 
by the arrow) injected with 125I-girentuximab-IRDye800CW, 1 day and 3 days p.i. In addition 
to tumor uptake, minimal uptake in the heart and thyroid can also be observed. 
B: Optical images of the same mouse 1 day and 3 days p.i. (same image settings used for day 
1 and 3). Some reflectance-induced image artifacts on the back of the mice can also be 
observed. 
C: MicroSPECT images of a mouse bearing a SK-RC-52 tumor on the right flank (indicated 
by the arrow) injected with 125I-girentuximab, 1 day and 3 days p.i. 
D: Biodistribution of 125I-girentuximab-IRDye800CW and 125I-girentuximab in mice with a 
s.c. SK-RC-52 tumor, 3 days p.i. Values are expressed as mean + SD. T/B ratio: tumor-to-
blood ratio. 
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Figure 1a. MicroSPECT images of a mouse be ring a SK-RC-52 tumor on th  right fl ank (indicated 
by the arrow) injected with 125I-girentuximab-IRDye800CW, 1 day and 3 days p.i. In addition to 
tumor uptake, minimal uptake in the heart and thyroid can also be observed.
Figure 1b. Optical images of the same mouse 1 day and 3 days p.i. (same image settings used for day 
1 and 3). Some refl ectance-induced image artifacts on the back of the mice can also be observed.
Figure 1c. MicroSPECT images of a mouse bearing a SK-RC-52 tumor on the right fl ank (indicated 
by the arrow) injected with 125I-girentuximab, 1 day and 3 days p.i.
Figure 1d. Biodistribution of 125I-girentuximab-IRDye800  and 125I-girentuximab in mice with a s.c. 
K-RC-52 tumor, 3 days p.i. Values are expressed as mean + SD. T/B ratio: tumor-to-blood ratio.
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A: MicroSPECT images of a mouse bearing a SK-RC-52 tumor on the r ght flank (indicated 
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B: Optical images of the same mouse 1 day and 3 days p.i. (same image settings used for day 
1 and 3). Some reflectance-induced image artifacts on the back of the mice can also be 
observed. 
C: MicroSPECT images of a mouse bearing a SK-RC-52 tumor on the right flank (indicated 
by the arrow) injected with 125I-girentuximab, 1 day and 3 days p.i. 
D: Biodistribution of 125I-girentuximab-IRDye800CW and 125I-girentuximab in mice with a 
s.c. SK-RC-52 tumor, 3 days p.i. Values are expressed as mean + SD. T/B ratio: tumor-to-
blood ratio. 
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Results
The optical images of mice bearing a s.c. CAIX-positive SK-RC-52 tumor injected with 
125I-girentuximab-IRDye800CW showed targeting of the tumor by the IRDye800CW-
conjugated antibody preparation at 1 day and at 3 days p.i. (Figure 1a). No tumor 
uptake was detected at 1 h p.i. (data not shown). MicroSPECT images of the same ani-
mals confirmed accumulation of 125I-girentuximab-IRDye800CW in the CAIX-expressing 
tumors (Figure 1b.). The biodistribution of the radiolabel in these mice is summarized 
in Figure  1d. These data (SK-RC-52 uptake 6.9 ± 1.1 %ID/g) confirm the preferential 
uptake of 125I-girentuximab-IRDye800CW in the tumors as visualized in the optical 
images and the SPECT images. MicroSPECT images of SK-RC-52 tumor bearing mice 
injected with 125I-girentuximab show tumor uptake at 1 day and at 3 days p.i. (Figure 
1c.). No tumor uptake was detected at 1 h p.i. (data not shown). The biodistribution 
data of 125I-girentuximab confirm the preferential tumor accumulation observed in the 
microSPECT images (14.8 ± 3.3 %ID/g, Figure  1d). Three days p.i., the blood levels of 
125I-girentuximab-IRDye800CW were significantly lower than those of 125I-girentuximab 
(2.7 ± 0.35 vs. 7.1 ± 1.3 %ID/g respectively, p=0.001), suggesting faster clearance 
of the IRdye800CW-conjugated antibody preparation from the blood. However, tumor-
to-blood ratios did not differ significantly between the IRDye800CW-conjugated an-
tibody and the unconjugated antibody (2.6 ± 0.34 vs. 2.1 ± 0.34 %ID/g respectively, 
p=0.053).
In the second experiment we investigated the specificity of the CAIX-mediated target-
ing of girentuximab by administrating 125I-girentuximab-IRDye800CW or 125I-MOPC21-
IRDye800CW to mice with both a CAIX-positive tumor and a CAIX-negative tumor. 
Optical images and biodistribution data are shown in Figure 2. Three days p.i. the 
uptake of 125I-girentuximab-IRDye800CW was high in the CAIX-positive tumors (31.5 ± 
9.6 %ID/g, tumor-to-blood ratio 3.2 ± 2.0), whereas low uptake was observed in the 
CAIX-negative tumors (4.1 ± 1.5 %ID/g, tumor-to-blood ratio 0.4 ± 0.2). Both tumor 
uptake and tumor-to-blood ratios were significantly different between these tumors 
(p=0.003 and p=0.018, respectively). No tumor uptake was detected at 1 h p.i. (data 
not shown). Mice injected with the nonspecific control 125I-MOPC21-IRDye800CW con-
jugate demonstrated significantly lower tumor uptake (CAIX-positive SK-RC-52: 1.2 ± 
0.1 %ID/g, tumor-to-blood ratio 0.4 ± 0.1; CAIX-negative SK-RC-59: 2.0 ± 0.5 %ID/g, 
tumor-to-blood ratio 0.5 ± 0.4) compared to mice that received 125I-girentuximab-
IRDye800CW (p=0.002 and p=0.027 respectively). 
In the third experiment the nonspecific uptake of girentuximab-IRDye800CW in the 
tumors was assessed, by injecting a group of three mice bearing SK-RC-52 tumors 
with 125I-girentuximab-IRDye800CW and an excess unlabeled girentuximab. MicroSPECT 
images acquired 1 h, 1 day, and 3 days p.i. did not show any uptake of the radiola-
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FIGURE 2  
A: Optical images of a mouse bearing a CAIX-positive SK-RC-52 tumor on the left flank and 
a CAIX-negative SK-RC-59 tumor on the right flank (indicated by the arrows), injected with 
125I-girentuximab-IRDye800CW 1 day and 3 days p.i. (same image settings used for day 1 
and 3). Some reflectance-induced image artifacts on the back of the mice can also be 
observed. 
B: Biodistribution 3 days after injection of 125I-girentuximab-IRDye800CW or 125I-MOPC21-
IRDye800CW in mice with a s.c. SK-RC-52 tumor and a s.c. SK-RC-59 tumor. Values are 
expressed as mean ± SD. 
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Figure 2a. Optical images of a mouse bearing a CAIX-positive SK-RC-52 tumor on the left fl ank 
and a CAIX-negative SK-RC-59 tumor on the right fl ank (indicated by the arrows), injected with
125I-girentuximab-IRDye800CW 1 day and 3 days p.i. (same image settings used for day 1 and 3). 
Some refl ectance-induced image artifacts on the back of the mice can also be observed.
Figure 2b. Biodistribution 3 days after injection of 125I-girentuximab-IRDye800CW or 125I-
MOPC21-IRDye800CW in mice with a s.c. SK-RC-52 tumor and a s.c. SK-RC-59 tumor. Values are
expressed as mean ± SD.
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beled mAb in the CAIX-expressing tumors (data not shown). Biodistribution studies 
confi rmed that the nonspecifi c uptake of the IRDye800CW-conjugated antibody in these 
tumors was very low (0.91 ± 0.25 %ID/g, tumor-to-blood ratio 0.31 ± 0.06). Taken toge-
ther, these results show that 125I-girentuximab-IRDye800CW can target CAIX-expressing 
tumors with high specifi city and can be assessed by microSPECT and NIR fl uorescence 
imaging.
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DISCuSSION
Both imaging and ex vivo biodistribution studies demonstrated high and specific tar-
geting and high tumor-to-blood ratios of girentuximab-IRDye800CW in a s.c. xenograft 
model of CAIX-expressing ccRCC tumors. The preferential accumulation of the dual-la-
beled girentuximab in CAIX-expressing tumors was confirmed with both optical and 
microSPECT imaging. In both imaging modalities, the radiolabeled girentuximab-IR-
Dye800CW conjugate accumulated specifically in the CAIX-positive tumors, whereas the 
non-specific mAb MOPC21-IRDye800CW did not. Moreover, girentuximab-IRDye800CW 
accumulated in CAIX-positive tumors, but not in CAIX-negative tumors. These results 
clearly demonstrate that the accumulation of the girentuximab-IRdye800CW conjugate 
is antigen-mediated. The feasibility of optical imaging of CAIX-expressing tumors using 
girentuximab-IRDye800CW suggests a potential role for this tracer in intraoperative de-
tection of positive surgical margins and/or tumor-infiltrated lymph nodes. 
The results of our study are in line with other preclinical and clinical studies on dual-
label imaging. Terwisscha van Scheltinga et al. reported specific and sensitive detection 
of tumor lesions in vivo using fluorescence–labeled antibodies targeting VEGF or HER2 
in a breast cancer xenograft mouse model 16. The animals in this study received a se-
cond injection with the same antibodies labeled with a positron-emitting radionuclide, 
89Zirconium, to enable a comparison between fluorescence and with PET imaging. The 
addition of a radioactive tracer seems to be indispensible for intraoperative tumor de-
tection because of the limited penetration depth of the optical signal. However, it is yet 
to be determined whether co-injection of both an optical and radiotracer will give the 
same results as administration of a dual-label tracer. With co-injection, the biodistribu-
tion of the optical tracer could differ from that of the radiolabeled tracer, in contrast 
to a dual-label tracer, where both signals originate from the same molecule. Clinically, 
non-targeted dual-label tracers have been applied for sentinel lymph node biopsy and 
resection after intratumoral injection of nanocolloid 17. Results clearly demonstrate im-
proved lymph node detection, especially when positive nodes are located in lymph node 
rich regions, for example in the case of prostate cancer or head and neck cancer 18, 19. 
Another study in ovarian cancer patients already showed the feasibility and potential of 
this approach for intraoperative fluorescence imaging in a clinical setting 20. Currently, 
another clinical trial is underway using fluorescently labeled bevacizumab to enable 
image-guided surgery in breast cancer patients (NCT01508572). These preclinical and 
clinical studies demonstrate the feasibility of dual-modality imaging for image-guided 
surgery.
Although the present study demonstrates optical imaging of CAIX-expressing tumors is 
feasible, there are some limitations for direct clinical translation of targeted fluores-
cence imaging in ccRCC patients. In this study, we used 125I for  small animal imaging 
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and ex vivo biodistribution studies. Because of its long half life (59.4 days) and less 
favorable gamma characteristics (Eγ = 35 keV), 125I is not  suitable for SPECT imaging in 
the clinical setting. Labeling girentuximab-IRDye800CW with 124I or with the residuali-
zing radiometal 111Indium using the chelator DTPA, could enable preoperative molecular 
imaging in ccRCC patients, and thus enabling both pre- and peroperative imaging in 
ccRCC 21-24.  Recently, Divgi et al. assessed the accuracy of 124I-girentuximab PET/CT in a 
large cohort of patients with a primary renal mass scheduled for surgery 23. The authors 
found a high sensitivity and specificity of 124I-girentuximab PET/CT  for detecting ccRCC 
lesions (86.2 and 85.9 percent, respectively), which is in concordance with prior expe-
rience with this tracer and indicative that this imaging modality can improve patient 
care in the pre-operative setting 21. Our results also endorse the tumor specific targeting 
of girentuximab and indicate that a whole new application for girentuximab-based ima-
ging, namely the intraoperative detection of ccRCC tumors with optical imaging, might 
be feasible. 
CONCluSIONS
Girentuximab-based fluorescence imaging may support accurate intraoperative tumor 
detection. Clinical studies are warranted to assess safety, feasibility, and validity of this 
fluorescent imaging approach in ccRCC patients.
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SuMMaRy
The aim of the studies described in this thesis was to investigate the potential of diagnostic 
and therapeutic applications of radiolabeled anti-CAIX monoclonal antibody (mAb) cG250 in 
clear cell Renal Cell Carcinoma (ccRCC). 
In Chapter 1 a review of the literature on the use of mAbs in solid malignancies is presen-
ted, with particular attention to the use of the anti-CAIX mAb cG250 in ccRCC. MAb cG250 is 
directed against the carbonic anhydrase isoform IX (CAIX) antigen, an epitope ubiquitously 
expressed on ccRCC cells. Although progress has been made, radioimmunotherapy in solid ma-
lignancies is not as successful as in hematological malignancies. There are several factors that 
limit the accumulation of mAbs in solid malignancies: slow extravasation of antibodies, poor 
tumor perfusion, heterogeneity in target antigen expression and the high interstitial fluid pres-
sure. These factors hamper the adequate delivery of mAbs to the tumor cells. 
The mechanism of CAIX expression and the use of CAIX and antibodies against CAIX in the 
prognosis, diagnosis and therapy of RCC were reviewed in Chapter 2. CAIX expression is mainly 
regulated by the Von-Hippel Lindau (VHL) protein. Through mutational loss of VHL in ccRCC, 
expression of the hypoxia inducible factor (HIF) 1α is upregulated and as a result CAIX is ubi-
quitously expressed in ccRCC. High CAIX expression is correlated with an increased mortality, 
and thus CAIX is an independent prognostic marker in ccRCC patients. Incorporation of CAIX 
expression improves the prognostic accuracy of RCC nomograms. Targeting CAIX with radiola-
beled cG250 in ccRCC patients showed excellent visualization of CAIX-expressing ccRCC primary 
tumors and metastases with single photon emission tomography (SPECT) and positron emis-
sion tomography (PET). Imaging CAIX with cG250 could therefore be an attractive diagnostic 
modality for (re)staging and might prevent unnecessary surgery in patients with renal masses 
of unknown etiology. Radioimmunotherapy with cG250 labeled with high activity doses of 131I 
was investigated in multiple treatment regimens (single high-dose, multiple high-dose and 
fractionated), but results were discouraging with limited therapeutic efficacy.
Brouwers et. al. observed that radioimmunoscintigraphy in patients using cG250 in ccRCC tu-
mors with the residualizing radionuclide 111In gave higher uptake of the radiolabel in the tumor 
as compared to the non-residualizing 131I. Moreover, cG250 radioimmunotherapy in mice with 
human RCC xenografts using cG250 labeled with the residualizing radionuclide 177Lu markedly 
better prolonged survival than when labeled with 131I. These findings led to a phase I study 
in which progressive metastatic ccRCC patients were treated with escalating activity doses of 
177Lu-cG250. The goals of this study were to determine the maximum tolerated dose (MTD) and 
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assess preliminary therapeutic efficacy of maximally three doses of 177Lu-cG250 radioimmuno-
therapy. The results of this trial are described in Chapter 3. The MTD of 177Lu-cG250 radioim-
munotherapy was determined to be 2405 MBq/m2, with hematological toxicity being the dose 
limiting factor. Of the 23 patients treated, 17 had stabilization of their previously progressive 
disease after the first cycle (74%) and one patient had a partial remission. Four patients com-
pleted all three radioimmunotherapy administrations, of which two had stabilisation of disease 
lasting for almost two and six years. Growth of the longest diameter of all target lesions of 
all patients was reduced from 40.4% before treatment to 5.5% after the first treatment cycle 
(p<0.001), which indicates that 177Lu-cG250 radioimmunotherapy could stabilize previously 
progressive metastatic ccRCC. Administrations of 111In-cG250 and 177Lu-cG250 were safe and 
well tolerated. The results of this trial have led to the initiation of a phase II trial, in which 
progressive metastatic ccRCC patients are treated with 177Lu-cG250 radioimmunotherapy at the 
MTD of 2405 MBq/m2, with a maximum of three treatment cycles.
In Chapter 4, the 111In-cG250 and 177Lu-cG250 scans from the study described in chapter 3 
were analyzed dosimetrically to estimate the radiation absorbed doses after 177Lu-cG250 ra-
dioimmunotherapy. Diagnostic 111In-cG250 imaging data were used to estimate the residence 
times of 177Lu-cG250 and 90y-cG250 in the relevant tissues. Radiation absorbed doses were 
calculated for the whole body, red marrow, normal tissues and tumor metastases for the thera-
peutic 177Lu-cG250, simulated 177Lu-cG250 and simulated 90y-cG250 data. The red marrow dose 
was calculated using two methods: a blood-based method using radioactivity measurements of 
blood samples drawn at various time points after administration of the radiolabeled antibody 
and an image-based method by using the uptake in the cranium region on the scintigraphic 
images as a surrogate for the uptake in the red marrow. A strong correlation was found between 
thrombocyte and leukocyte toxicity and the red marrow dose based on the activity measure-
ments in the blood samples. A correlation was also found between thrombocyte toxicity and 
the image-based red marrow dose, but not between leukocyte toxicity and image-based red 
marrow dose. Thus, the 111In-cG250 uptake data could be used to predict the myelotoxicity as 
caused by treatment with 177Lu-cG250. This might lead to patient specific dosing based on a 
toxicity risk assessment based on 111In-cG250 pharmacokinetics or scintigraphy prior to radioi-
mmunotherapy. An inverse relationship was found between tumor size and radiation absorbed 
dose. Tumor-sterilizing doses (> 50 Gy) were found in 2 of the 40 tumors, but 12 of 40 tumors 
reached dose levels of > 25Gy in the first treatment cycle, indicating that with subsequent tre-
atments tumor-sterilizing doses might be achieved. A comparison between the 177Lu-cG250 and 
90y-cG250 dosimetry showed a higher tumor-to-red-marrow ratio for 177Lu-cG250 as compared 
to 90y-cG250 (15.7 vs. 12.0) when the blood-based method was used for red marrow dose cal-
culations. The longer half-life of 177Lu as compared to 90y (6.7 vs. 2.7 days) is more compatible 
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with the slow pharmacokinetics of cG250 accretion in ccRCC, favoring 177Lu as the more suitable 
radionuclide for radioimmunotherapy in ccRCC patients.
Delivery of mAbs to solid tumors is, among other factors, hampered by an aberrant intratumoral 
vasculature. The vascular endothelial growth factor (VEGF) is highly expressed in ccRCC, also 
due to the aforementioned upregulation of HIF-1α. Bevacizumab is a mAb directed against 
VEGF-A. In previous studies 111In-labeled bevacizumab has shown to depict VEGF-A expres-
sion in colorectal carcinoma. Neo-angiogenesis inhibitors such as sorafenib or sunitinib are 
registered for treatment of metastatic ccRCC. However, traditional measurements of response 
to treatment (conventional CT imaging) might not be adequate for neo-angiogenesis treat-
ment, since responses are usually not tumor shrinkage, but central tumor necrosis. This study 
investigated the potential of 111In-bevacizumab imaging of ccRCC and the effect of sorafenib 
treatment on imaging of ccRCC lesions with 111In-bevacizumab. In Chapter 5, 9 RCC patients 
scheduled for tumor nephrectomy were analyzed. Patients were imaged after administration of 
111In-bevacizumab and subsequently treated with sorafenib 2dd400mg for four weeks. In the 
last week of treatment, again 111In-bevacizumab was administered and images were acquired. 
In the control group of 5 patients only 111In-bevacizumab imaging was performed a week before 
tumor nephrectomy. Patients underwent tumor nephrectomy and the change in 111In-bevacizu-
mab uptake in the tumor before and after sorafenib treatment was correlated with immunohis-
tochemical analyses of expression of VEGF-A and vascular markers of the surgical specimen. The 
111In-labeled bevacizumab clearly depicted ccRCC primary tumors and metastases. Neo-adjuvant 
treatment with sorafenib resulted in a significant decrease of 111In-bevacizumab uptake in the 
tumor (mean decrease 60,5%, p=0.011). Immunohistochemistry revealed an unchanged VEGF-
A expression after sorafenib treatment and a destruction of tumour vasculature. These results 
could indicate that the effect of sorafenib on the tumor vasculature caused the reduced uptake 
of the radiolabeled antibody in the tumor. 
In Chapter 6, the most suitable radionuclide for immuno-PET imaging of ccRCC was determined 
in a mouse model. Immuno-PET imaging in patients pre-operatively with 124I-cG250 is well 
characterized. Since 124I is a non-residualizing radionuclide while the positron emitter 89Zr is 
residualizing, the hypothesis of this study was that 89Zr-cG250 would be more suitable than 
124I-cG250 for immuno-PET of ccRCC. Mice with CAIX-positive SK-RC-52 or NU-12 xenografts 
were injected with either 89Zr-cG250 or 124I-cG250 and microPET imaging and biodistribution 
studies were performed to assess tumor uptake and image contrast of both radiolabeled mAbs. 
The results of this study show that both radiolabeled mAbs visualized the CAIX-expressing xe-
nografts, but that tumor uptake and tumor-nontumor ratios of 89Zr-cG250 were higher in both 
tumor models (NU-12: 114.7 vs. 38.2, p=0.029; SK-RC-52 48.7 vs. 32.0, p=0.26), indicating 
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that 89Zr-cG250 immuno-PET could be more sensitive than 124I-cG250. 
In Chapter 7, the use of cG250-based fluorescent imaging was studied in nude mice with ccRCC 
xenografts. In vivo fluorescent imaging was performed with fluorophors, which emit light of 
a defined wavelength when excited. Fluorescent imaging is a potentially extremely sensitive 
imaging modality, but its clinical applications are limited due to the relatively low penetration 
depth (< 2 cm) of the emitted light in tissue. Potentially, sensitive intra-operative detection of 
tumor tissue might be feasible. In this study, mice with ccRCC xenografts were injected with 
cG250 conjugated with the fluorescent dye IRdye-800CW and fluorescent images were acquired 
to assess tumor uptake and feasibility of optical imaging in ccRCC. The cG250-IRdye-800CW 
conjugate was labeled with 125I. The biodistribution of the cG250-IRdye-800CW was determined 
and micro-single photon emission computed tomography (SPECT) scans were acquired. The 
IRdye-800CW-conjugated mAb clearly visualized the CAIX-expressing tumors and there was a 
clear correlation between fluorescence and micro-SPECT imaging. Moreover, the biodistribution 
studies showed specific uptake of the cG250-IRdye-800CW conjugate in the tumor xenografts 
(SK-RC-52: 31.5 ± 9.6 %ID/g). This study provided proof of principle that fluorescence imaging 
of ccRCC lesions with cG250-IRdye-800CW is feasible. Fluorescent imaging in ccRCC could be 
applied to intra-operatively detect positive surgical margins during (partial) tumor nephrec-
tomy, tumor affected lymph nodes or occult metastases.
The studies described in this thesis have added to the knowledge of the use of mAb cG250 in 
the imaging and therapy of ccRCC lesions. In the current clinical practice there is not yet a role 
for mAb cG250 in the diagnosis or treatment of ccRCC. Further elucidation of the role of cG250 
might eventually offer a clinical benefit for the patients who have to bear this disease with its 
often dismal prognosis.
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Het doel van de studies zoals beschreven in dit proefschrift was om de diagnostische en the-
rapeutische toepassingen van radioactief gelabeled anti-CAIX monoklonaal antilichaam (mAb) 
cG250 bij heldercellig niercelcarcinoom (ccRCC) te onderzoeken.
In Hoofdstuk 1 is een overzicht van de literatuur gegeven over het gebruik van mAbs in solide 
maligniteiten, met speciale aandacht voor het gebruik van anti-CAIX mAb cG250 in ccRCC. MAb 
cG250 is gericht tegen het carbonische anhydrase isoform IX (CAIX) antigeen, een epitoop 
welke alomtegenwoordig tot expressie komt op ccRCC cellen. Howel vooruitgang is geboekt, 
is radioimmunotherapie in solide maligniteiten niet zo succesvol als in hematologische malig-
niteiten. Er zijn verschillende factoren die de opname van mAbs in solide maligniteiten be-
moeilijken: trage extravasatie van antilichamen, slechte perfusie van tumoren, heterogeniteit 
in antigeen expressie waar het mAb tegen gericht is en de hoge interstitiële vloeistofdruk in 
tumorweefsel. Al deze factoren bemoeilijken de adequate opname van mAbs in tumor cellen.
Het mechanisme van CAIX expressie en het gebruik van CAIX en antilichamen gericht tegen 
CAIX in de prognose, diagnose en therapie van ccRCC werden uitgediept in Hoofdstuk 2. 
Expressie van CAIX wordt voornamelijk gereguleerd door het Von-Hippel Lindau (VHL) eiwit. 
Wanneer VHL door mutaties niet meer wordt geproduceerd in ccRCC, zal meer Hypoxia inducible 
factor (HIF) 1α geproduceerd worden, waardoor als gevolg CAIX alomtegenwoordig tot expres-
sie komt in ccRCC. Hoge CAIX expressie is gecorreleerd met een toegenomen mortaliteit, wat 
CAIX een onafhankelijke prognostische marker maakt in patiënten met ccRCC. Toevoegen van 
CAIX expressie aan RCC nomogrammen laat de prognostische nauwkeurigheid toenemen. Targe-
ten van CAIX met radioactief gelabeled cG250 in patiënten met ccRCC liet uitstekende visuali-
satie zien van ccRCC primaire tumoren en metastasen die CAIX tot expressie brengen met single 
photon emission tomography (SPECT) en positron emission tomography (PET). Afbeelden van 
CAIX met cG250 zou daarmee een interessante diagnostische modaliteit kunnen zijn voor (her)
stagen van ccRCC en zou onnodige operaties kunnen voorkomen in patiënten met massa’s in 
de nier met onbekende etiologie. Radioimmunotherapie met hoge doses radioactief 131I gela-
beled cG250 is onderzocht in verschillende behandelschema’s (eenmalig hoge dosis, multipele 
hoge doses en gefractioneerd), maar de resultaten van deze studies waren ontmoedigend met 
beperkte therapeutische werkzaamheid.
Brouwers et. al. ontdekten dat wanneer radioimmunoscintigrafie met cG250 in patiënten met 
ccRCC met het residualiserende radioactieve label 111In werd verricht er een hogere tumor op-
name bleek dan wanneer het niet-residualiserende radioactieve label 131I werd gebruikt. Daarbij, 
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cG250 radioimmunotherapie in muizen met humane ccRCC xenograften met cG250 gelabeled 
met het residualiserende radionuclide 177Lu verbeterde de overleving significant ten opzichte 
van het niet-residualiserende 131I. Deze bevindingen hebben geleid tot een fase 1 studie waarin 
progressieve gemetastaseerde ccRCC patiënten behandeld werden met oplopende activiteits 
doses 177Lu-cG250. De doelen van deze studie waren de maximaal toelaatbare dosering (MTD) 
en de therapeutische effectiviteit te bepalen van maximaal drie doses 177Lu-cG250 radioimmu-
notherapie. De resultaten van deze studie zijn beschreven in Hoofdstuk 3. De MTD van 177Lu-
cG250 radioimmunotherapie bleek 2405 MBq/m2 te zijn, waarbij de hematologische toxiciteit 
de limiterende factor bleek. Bij 17 van de 23 patiënten die behandeld werden trad stabilisatie 
op van voorheen progressieve ziekte na de eerste behandelcyclus (74%) en één patiënt had 
een partiële remissie. Vier patiënten kregen alle drie radioimmunotherapie toedieningen, waar-
bij twee patiënten stabilisatie van de ziekte hadden die bijna twee en zes jaar duurde. Groei 
van de langste diameter van alle evalueerbare lesies van alle patiënten was verminderd van 
40,4% voor behandeling naar 5,5% na de eerste behandelcyclus (p<0,001), wat aangeeft dat 
177Lu-cG250 radioimmunotherapie voorheen progressief gemetastaseerd ccRCC kon stabiliseren. 
Toedieningen van 177Lu-cG250 radioimmunotherapie waren veilig en werden goed verdragen. De 
resulaten van deze studie hebben geleid tot de start van een fase 2 trial, waarin patiënten met 
progressief gemetastaseerd ccRCC behandeld worden met 177Lu-cG250 radioimmunotherapie 
met de MTD van 2405 MBq/m2, met een maximum van drie behandelcycli.
In Hoofdstuk 4 werden de 111In-cG250 en 177Lu-cG250 scans van de studie beschreven in 
hoofdstuk 3 dosimetrisch geanalyseerd om de opgenomen dosis straling te bepalen na 177Lu-
cG250 radioimmunotherapie. Data van diagnostische 111In-cG250 scans werd gebruikt om de 
verblijfstijden van 177Lu-cG250 en 90y-cG250 in relevante weefsels te schatten. Opgenomen 
doses straling werden berekend voor het hele lichaam, rode beenmerg, normale weefsels en 
tumor metastasen op de therapeutische 177Lu-cG250 scans en op de gesimuleerde 177Lu-cG250 
en gesimuleerde 90y-cG250 data. De dosis op het rode beenmerg werd berekend middels twee 
methoden: een bloed-gebaseerde methode waarbij radioactiviteits metingen op bloed afnames 
die op vaste tijdspunten na injectie werden afgenomen werd verricht en een scan-gebaseerde 
methode waarbij de opname in de schedel regio op de scintigrafische afbeeldingen als surro-
gaat voor de opname in het rode beenmerg werd berekend. Een sterke correlatie werd gevonden 
tussen trombocyten- en leucocyten toxiciteit en de rode beenmerg dosis die berekend was 
met de radioactiviteits metingen in de bloed afnames. Een correlatie werd ook gevonden tus-
sen trombocyten toxiciteit en de scan-gebaseerde rode beenmerg dosis, maar niet tussen de 
leucocyten toxiciteit en de scan-gebaseerde rode beenmerg dosis. Dus, de berekende doses van 
opname van 111In-cG250 konden worden gebruikt om de myelotoxiciteit te voorspellen zoals 
veroorzaakt door behandeling met 177Lu-cG250. Dit zou kunnen leiden tot patiënt specifieke 
doseringen gebaseerd op een toxiciteits risico analyse van 111In-cG250 farmacokinetiek of scin-
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tigrafie voorafgaand aan radioimmunotherapie. Een omgekeerde relatie werd gevonden tussen 
tumor grootte en opgenomen doses straling. Tumor-steriliserende doseringen (>50 Gy) werden 
gevonden in 2 van 40 tumoren, maar 12 van de 40 tumoren bleken >25 Gy opgenomen doses 
te hebben in de eerste behandelcyclus, wat aangeeft dat met opeenvolgende behandelingen 
tumor-steriliserende doses haalbaar zouden kunnen zijn. Een vergelijking tussen 177Lu-cG250 
en 90y-cG250 dosimetrie toonde een hogere tumor-rode beenmerg ratio voor 177Lu-cG250 in 
vergelijking met 90y-cG250 (15,7 vs. 12,0) wanneer de bloed-gebaseerde methode werd ge-
bruikt voor berekening van de rode beenmerg dosis. De langere halfwaardetijd van 177Lu in 
vergelijking met 90y (6,7 vs. 2,7 dagen) is beter verenigbaar met de trage farmacokinetiek van 
cG250 accumulatie in ccRCC, waardoor 177Lu het te verkiezen radionuclide zou zijn voor cG250 
radioimmunotherapie in ccRCC patiënten.
Opname van mAbs in solide tumoren wordt, onder andere, verhinderd door een aberrante tumor 
vasculatuur. De vascular endothelial growth factor (VEGF) komt sterk tot expressie in ccRCC, ook 
onder invloed van de voornoemde toegenomen productie van HIF-1α. Bevacizumab is een mAb 
gericht tegen VEGF-A. In eerdere studies is gebleken dat 111In-gelabeled bevacizumab VEGF-A 
expressie in colorectaal carcinoom kon afbeelden. Neo-angiogenese remmers zoals sorafenib en 
sunitinib zijn geregistreerd voor de behandeling van gemetastaseerd ccRCC. Echter, traditionele 
response metingen van behandeling (conventionele CT scans) zijn mogelijk niet geschikt voor 
neo-angiogenese behandeling, aangezien responses meestal niet tumor-krimp zijn, maar cen-
trale tumor necrose. Deze studie onderzocht het potentieel van 111In-bevacizumab om ccRCC af 
te beelden en het effect van sorafenib behandeling op het afbeelden van ccRCC tumoren met 
111In-bevacizumab. In Hoofdstuk 5 werden 9 RCC patiënten die gepland stonden voor tumor 
nefrectomie geanalyseerd. Patiënten werden gescand na toediening van 111In-bevacizumab en 
daaropvolgend behandeld met sorafenib 2dd400mg voor 4 weken. In de laatste week van de 
behandeling werden opnieuw scans gemaakt na toediening van 111In-bevacizumab. In de con-
trole groep van 5 patiënten werden alleen scans gemaakt na toediening van 111In-bevacizumab 
een week voor de tumor nefrectomie. Alle patiënten ondergingen de tumor nefrectomie en de 
veranderingen in opname van 111In-bevacizumab voor en na sorafenib behandeling werden 
gcorreleerd met de immunohistochemische analyse van VEGF-A expressie en vasculaire markers 
van het chirurgische preparaat. 111In-bevacizumab kon duidelijk ccRCC primaire tumoren en me-
tastasen afbeelden. Neo-adjuvante behandeling met sorafenib resulteerde in een significante 
vermindering van opname van 111In-bevacizumab in de tumor (gemiddelde afname 60,5%, 
p=0,011). Immunohistochemie toonde een onveranderde VEGF-A expressie na sorafenib be-
handeling en een verwoeste tumor vasculatuur. Deze resultaten laten zien dat het effect van 
sorafenib op de tumor vasculatuur zorgt voor de verminderde opname van radiogelabeled mAb 
in de tumor.
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In Hoofdstuk 6 is het meest geschikte radionuclide bepaald voor immuno-PET scans van ccRCC 
in een muizenmodel. Immuno-PET scans in pre-operatieve RCC patiënten met 124I-cG250 is 
goed onderzocht. Omdat 124I een niet-residualiserend radionuclide is, waar de positron emitter 
89Zr wel residualiserend is, was de hypothese van deze studie dat 89Zr-cG250 beter geschikt zou 
zijn dan 124I-cG250 voor immuno-PET van ccRCC. Muizen met CAIX-positieve SK-RC-52 of NU-12 
xenograften werden geïnjecteerd met of 89Zr-cG250 of 124I-cG250. Micro-PET scans en biodistri-
butie studies werden verricht om de tumoropname en contrast van de scans te vergelijken van 
beide radiogelabelde mAbs. De resultaten van deze studies laten zien dat beide radiogelabelde 
mAbs de CAIX-positieve tumoren konden visualiseren, maar dat de tumor opname en tumor-
niet tumor ratios van 89Zr-cG250 hoger waren in beide tumor modellen (NU-12: 114,7 vs. 38,2, 
p=0,029; SK-RC-52: 48,7 vs. 32,0,p=0,26), wat aangeeft dat immuno-PET met 89Zr-cG250 meer 
sensitief zou kunnen zijn dan met 124I-cG250.
In Hoofdstuk 7 werd het gebruik van fluorescent gelabeled cG250 scans bestudeerd in naakte 
muizen met ccRCC xenografts. In vivo fluorescerende scans werd verricht met fluorophors, welke 
licht op een bepaalde golflengte uitzenden wanneer ze aangeslagen worden. Fluorescent scan-
nen is een potentieel extreem gevoelige modaliteit, maar de klinische toepasbaarheid wordt 
beperkt door de relatief lage penetratie diepte (<2 cm) van het uitgezonden licht in weefsel. 
Potentieel zou ultrasensitieve detectie van tumor weefsel mogelijk zijn. In deze studie werden 
muizen met ccRCC xenograften geïnjecteerd met cG250 geconjugeerd met de fluorescente dye 
IRdye-800CW en fluorescente scans werden gemaakt om de tumor opname en haalbaarheid 
van optical imaging in ccRCC te bepalen. Het cG250-IRdye-800CW conjugaat was gelabeled 
met 125I. De biodistributie van het cG250-IRdye-800CW werd bepaald en micro-single photon 
emission computed tomography (SPECT) scans werden vervaardigd. Het cG250-IRdye-800CW 
conjugaat kon duidelijk de xenograften die CAIX tot expressie brengen visualiseren op de scans 
en er was een sterke correlatie tussen fluorescentie en de micro-SPECT scans. Daarbij lieten de 
biodistributie studies zien dat er specifieke opname was van het cG250-IRdye-800CW conju-
gaat in de tumor xenografts (SK-RC-52: 31,5 ± 9,6 %ID/g). Deze studie geeft het bewijs dat 
fluoresente imaging van ccRCC lesies mogelijk is met gebruik van cG250-IRdye-800CW. Fluo-
rescente imaging zou kunnen worden toegepast om intra-operatief positieve resectievlakken 
te diagnosticeren tijdens (partiële) tumor nefrectomie, door tumor aangetaste lymfeklieren te 
onderscheiden of voor het ontdekken van occulte metastasen.
De studies beschreven in dit proefschrift dragen bij aan de kennis van het gebruik van mAb 
cG250 in de diagnostiek en therapie van ccRCC lesies. In de huidige klinische praktijk is er nog 
geen rol voor mAb cG250 in de diagnose of behandeling van ccRCC. Het verder onderzoeken van 
de functie en significantie van cG250 zou uiteindelijk een voordeel op kunnen leveren voor de 
patiënten die deze ziekte moeten dragen met een vaak sombere prognose.
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GENERal DISCuSSION aND FuTuRE PROSPECTS
In this thesis, results of preclinical and clinical trials are described which aimed to further 
investigate the potential of monoclonal antibody (mAb) cG250 in the diagnosis and treatment 
of renal cell carcinoma (RCC).
Radioimmunotherapy prospects
Although great progress has been made in the treatment of metastatic RCC patients in the past 
years with tyrosine kinase inhibitors (TKI) such as sunitinib and sorafenib, the disease still is 
lethal for all patients. Progression-free and overall survival rates have increased significantly, 
but at the cost of side-effects that are high in frequency as well as in severity 1,2. This leads to 
a decrease in quality of life in many patients. The results of the activity dose escalation study 
in 23 RCC patients indicated that the maximum tolerated dose of radiolabeled 177Lu-cG250 
radioimmunotherapy in metastatic RCC patients was 65 mCi/m2 (chapter 3), with hematologic 
toxicity being dose-limiting. Moreover, clinical efficacy of the radioimmunotherapy was noted 
as it halted disease progression in most patients that received a therapeutic dose. This result is 
in contrast with previous radioimmunotherapy trials in metastatic RCC using cG250 labeled with 
the non-residualising radiolabel 131I in which no substantial antitumoral activity was noted 3. 
The observation that radioimmunotherapy with 177Lu-cG250 might stop or decrease metastatic 
RCC growth is promising, albeit this was seen in a small cohort of patients treated with vari-
ous doses of 177Lu-cG250 and needs verification. In a phase 2 study currently metastatic RCC 
patients are treated with a maximum of three cycles of 177Lu-cG250 radioimmunotherapy to de-
termine antitumoral activity. Severe (grade 3 or 4 CTC) side effects of 177Lu-cG250 radioimmuno-
therapy were only hematological. Patients did not suffer from severe clinical side effects: only 
mild and passing nausea and fatigue were observed the first weeks after 177Lu-cG250 injection. 
Residence times of the scout 111In-cG250 dose were similar to those of the therapeutic 177Lu-
cG250 dose. Therefore the absorbed doses and toxicity of the red bone marrow, the dose limi-
ting factor in radioimmunotherapy, could be predicted using the images acquired after injection 
of 111In-cG250. 111In-cG250 scans were used to predict tumor absorbed doses of 177Lu-cG250 and 
90y-cG250 radioimmunotherapy and 177Lu-cG250 revealed higher tumor-to-red-marrow dose ra-
tios than 90y-cG250, making 177Lu the more suitable radionuclide for radioimmunotherapy in RCC 
(chapter 4). Our observation that higher radiation doses were guided to smaller tumor lesions is 
in line with the observations of Brouwers et. al. 4. This provides a rationale to treat RCC patients 
with radioimmunotherapy in the early stages of metastatic disease, possibly even before TKI 
treatment is started which is accompanied by many side effects and a possible decrease in qua-
lity of life. Further studies will, however, have to show that 177Lu-cG250 radioimmunotherapy 
does not prevent TKI treatment in patients due to sustained hematotoxicity. One could consider 
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to treat patients with radioimmunotherapy at a lower activity dose, since antitumoral effects 
were also seen at doses < 65 mCi/m2. 
One future strategy to improve radioimmunotherapy efficacy and reduce hematotoxicity could 
be pretargeting. In pretargeted radioimmunotherapy (PRIT), administration of the mAb is se-
parated from the injection of the radionuclide. The unlabeled mAb  is first injected and  binds 
to the tumor and clears from circulation and normal organs. The radionuclide is administered in 
a second injection as a rapidly clearing agent with high affinity for the previously administered 
mAb. Affinity of the rapidly clearing radioactive agent binding to the mAb may be achieved 
through avidin-biotin interaction or with bispecific mAbs (bsmAbs). This has been evaluated 
in colorectal cancer (CRC) bearing mice using a peptide targeting the carinoembryonic antigen 
which is ubiquitously expressed in CRC 5. This study showed that PRIT using 177Lu-labeled pep-
tides potentially is an effective anti-tumor treatment modality with limited (hemato)toxicity. 
Moreover, in 47 progressive metastatic medullary thyroid carcinoma patients PRIT showed high 
response rates with manageable hematologic toxicity 6. For cG250, a bsmAb (cG250 X DTIn-1) 
was produced and pretargeting experiments in nude mice with RCC xenografts targeted with 
111In-labeled bivalent peptide showed excellent tumor targeting 7.
The use of alpha particle emitting radionuclides has the advantage of high cytotoxic potency, 
combined with a low range, which might reduce radiation effects to normal tissues that are not 
targeted by the antibody.  However, most alpha-emitters have a half-life of less than one hour, 
which is not compatible with mAbs targeting tumors. Combining the high cytotoxicity of the 
alpha emitting radionuclides with pretargeting could overcome the slow accrual of intact mAb 
in tumors and deliver high radiation doses to tumor lesions. Radioimmunotherapy with tumor 
targeting peptides labeled with the alpha-emitter Bi-213 (t1/2 = 45 min) has been studied 
in mice with intraperitoneal melanoma metastases, showing increased survival and mild renal 
toxicity 8.
Positron emission tomography (PET) is a technique which is increasingly used due to the high 
spatial resolution and accurate quantitative analysis of the images. PET imaging of RCC lesions 
with 124I-cG250 is well characterized in patients scheduled for nephrectomy 9. In immuno-PET 
using mAb cG250, higher tumor uptake and more sensitive imaging can be achieved when 
cG250 is labeled with 89Zr instead of 124I (chapter 6). Therefore, (pre-operative) characterization 
of RCC lesions using cG250-PET might best be done with 89Zr-cG250 instead of 124I-cG250. A 
clinical comparative study is warranted to test this hypothesis. 
Bone marrow toxicity following 177Lu-cG250 radioimmunotherapy could be predicted from the 
111In-cG250 images, but also based on activity measurements in blood samples after injection 
of 111In-cG250. This could allow for individualized dosing in radioimmunotherapy, and subse-
quently a possible reduction of hematologic toxicity. Arguably, more specific dosimetric ana-
lyses can be performed on 111In-cG250 imaging with single photon emission computed tomo-
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graphy (SPECT) 10. Since 89Zr is a residualising radionuclide, dosimetric analyses on 89Zr-cG250 
scout PET imaging preceding 177Lu-cG250 radioimmunotherapy might yield even more accurate 
bone marrow toxicity predictions than 111In-cG250 SPECT. Consequently, this might even further 
improve the individualized 177Lu-cG250 radioimmunotherapy dosing schedule.
Antibody accumulation in tumors
One of the major limitations of radioimmunotherapy is inefficient delivery of the radiolabeled 
mAb to the tumor. Jain et. al. 11, 12 have described the barriers that limit accumulation of 
antibodies in tumors in detail. To enhance the uptake of the radiolabeled mAb in the tumor, 
barriers within the tumor (vasculature) could be altered. We explored whether 111In-labeled 
mAb bevacizumab would target the VEGF expressed in RCC lesions. Furthermore, we investiga-
ted whether treatment of RCC with TKI sorafenib would alter RCC vasculature in a way that it 
could enhance tumor uptake of 111In-bevacizumab. A significant decrease in tumor uptake of 
111In-bevacizumab uptake 4 weeks after sorafenib treatment of RCC patients was observed. Im-
munohistochemistry of the surgically removed specimens revealed vessel destruction, and no 
changes in expression of the target antigens VEGF and CAIX (chapter 5). These results were also 
observed in patients treated one week with sorafenib who were imaged with 111In-cG250. Still, 
combination treatments of radioimmunotherapy with TKI remains an interesting concept, since 
TKI treatment does not cause tumor cell death, but merely destruction of tumor blood vessels. 
Our studies indicate that careful timing of the administration of both treatments is required. 
Either RIT should precede TKI treatment or the minimum time interval between TKI treatment 
and optimal antibody tumor uptake should be determined.
Optical imaging
Optical imaging of RCC lesions is feasible with cG250 conjugated with fluorescent IR-Dye800CW 
as demonstrated in mice with subcutaneous RCC lesions (chapter 7). This provides a rationale 
for exploring the possibilities of intra-operative detection of RCC masses outside the primary 
tumor such as tumor-affected lymph nodes or distant metastases. This approach was proven 
successful in ovarian cancer surgery 13. A great advantage of this technique could be the highly 
sensitive detection of residual tumor lesions without the use of radioactive tracers.
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logie Dr. Carla van Herpen bedanken voor de inspirerende overlegmomenten. Helaas is in het 
begin van mijn promotietraject Prof. Dr. De Mulder overleden, ondanks de korte samenwerking 
heeft hij een blijvende indruk op mij achter gelaten door zijn doorzettingsvermogen en scher-
pe analyses. William Leenders van de afdeling pathologie wil ik danken voor het bekijken van 
de coupes van de neo-adjuvante studie en de mogelijkheden die je op het lab hebt geschapen 
voor zowel de neo-adjuvante studie als het optical imaging project.
Stijn Muselaers, jij hebt het stokje van mij overgenomen op het G250-project. Heel veel succes 
met de studies en de opleiding urologie.
De studenten die mee hebben gewerkt aan delen van het onderzoek. Karin, jij hebt me ontzet-
tend geholpen met de dosimetrische analyse en het vervolmaken van het manuscript. Door 
jouw inbreng heeft het artikel meer diepte gekregen,dank voor je bijzondere inzet! Duby, de 
eerste stappen in de optical imaging op onze afdeling heb jij samen met Huub gezet.
In het Catharina ziekenhuis Eindhoven wil ik Dr. Grard Nieuwenhuijzen bedanken voor de mo-
gelijkheden om aan mijn proefschrift te werken in de hectische periode die de vooropleiding 
algemene chirurgie toch is.
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In het Atrium medisch centrum Heerlen wil ik eerst en vooral Dr. Karl Delaere bedanken. In 
de transitieperiode van de chirurgie naar de urologie heeft u mij aan de hand genomen en 
opnieuw duidelijk gemaakt wat de urologie zo mooi maakt. Dank voor uw vertrouwen en dat 
u mij heeft laten zien wat de kracht van de bescheidenheid is. Uiteraard wil ik ook de andere 
stafleden danken voor hun bereidheid en inzet mij te begeleiden in mijn pad van assistent 
naar aanstaand collega. Mijn mede-assistenten wil ik bedanken voor een zeer gezellige tijd 
en prettige werksfeer in het Heerlense: Bart, Floris, Maarten, Jessica, Melanie, Mark, Geert, 
Leonie, Sam, Rens en Matthijs.
Mijn paranimfen Matthijs en Pieter-Jan. Matthijs, dank voor je onvoorwaardelijke steun bij het 
schrijven van mijn ‘stukjes’ en ik ben er trots op dat jij als mijn broer achter mij staat als ik 
dit werk mag verdedigen. Pieter-Jan, vriendschap kan soms vloeibaar zijn, maar bij ons is dat 
gelukkig niet gebleken. Door de jaren heen zijn wij voor mijn gevoel alleen maar dichter bij 
elkaar gekomen, al was de afstand soms groot. Ik ben blij dat je nu weer het geluk gevonden 
hebt en hoop dat onze vriendschap zich zal blijven verdiepen. Heb in ieder geval nu al zin in 
de vrijdagmiddagborrels afgewisseld in Utrecht en Den Bosch!
 
Ik wil mijn familie bedanken; mam, pap, yvonne, Ernst, Kim, Charlotte, Kendra en Jan-Willem. 
Dank jullie allemaal voor de continue steun, onverdeelde interesse en de soms o zo noodza-
kelijke ruggensteun om dit project tot een goed einde te brengen. Zoals iedere familie heeft 
ook de onze donkere dagen gekend, maar gelukkig hebben we altijd steun bij elkaar kunnen 
vinden.
René en Dricus, onze vakantie vorig jaar in Andalusië samen met Pieter-Jan was in mijn ogen 
niet alleen om onze 30e verjaardag te vieren, het was vooral een uiting van onze fantastische 
vriendschap. Ik vind het geweldig dat wij dit soort dingen kunnen blijven doen en ik vrees al 
voor de reis die we gaan maken als we 60 worden!
Lieve Karin, dank voor je enorme geloof in mij. Als consultant wil je graag orde in de chaos 
scheppen, maar helaas waren je spreadsheets en timeframes aan mij niet besteed (“I did it 
my way”). Desalniettemin bleef je me onvoorwaardelijk steunen en op een positieve manier 
aansporen. Als ik heel eerlijk ben is dat een van de grootste redenen dat dit boekje hier über-
haupt voor u ligt.
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